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Abbreviations  
APC = Antigen-presenting cell  
APL = Altered peptide ligand   
BBB = Blood brain barrier  
BP = Biological process 
CC = Cellular component 
CDF = Chip definition file 
CIS = Clinically isolated syndrome 
CNS = Central nervous system 
CSF = Cerebrospinal fluid 
EAE = Experimental autoimmune encephalomyelitis 
EDSS = Expanded disability status scale 
EDTA = Ethylenediaminetetraacetic acid 
FACS = Fluorescence-activated cell sorting 
FDR = False discovery rate 
GA = Glatiramer acetate 
GEO = Gene expression omnibus 
GO = Gene Ontology 
HSP = Heat shock protein 
IFN = Interferon 
IL = Interleukin 
i.m. = Intramuscular injection 
MACS = Magnetic-activated cell sorting 
MAID = MA plot-based signal intensity-dependent fold-change criterion 
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MBP = Myelin basic protein 
MF = Molecular function 
MHC = Major histocompatibility complex  
mRNA = Messenger ribonucleic acid 
miRNA = Micro ribonucleic acid 
MRI = Magnetic resonance imaging 
MS = Multiple sclerosis 
ncRNA = Non-coding ribonucleic acid 
NGS = Next generation sequencing 
NK cell = Natural killer cell 
PBMC = Peripheral blood mononuclear cells 
PCR = Polymerase chain reaction 
pre-miRNA = Precursor-miRNA 
pri-miRNA = Primary-miRNA 
PWM = Position weight matrix 
RIN = RNA integrity number 
RISC = RNA-induced silencing complex 
RRMS = Relapsing-remitting multiple sclerosis 
s.c. = Subcutaneous 
SD = Standard deviation 
SNP = Single nucleotide polymorphism  
TCR = T-cell receptor 
TF = Transcription factor 
TFBS = Transcription factor binding site 
Treg cell = T regulatory cell
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1. Introduction 
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central 
nervous system (CNS). MS is thought to be a result of the body’s immune system crossing 
the blood brain barrier (BBB) into the CNS where it attacks the myelin sheath, a protective 
insulation surrounding nerve cells. The demyelination of the axons leads to decreased 
conduction velocity of action potentials or in the worst case a complete stop of the signal. 
MS is characterized by inflammatory axonal demyelination of neurons which can be 
detected as MS lesions which occur predominantly in the white matter region of the brain 
and spinal cord [1, 2]. These lesions can be analyzed by magnetic resonance imaging 
(MRI). Formation of new lesions results in physical disabilities and decline in cognitive 
functions.  
The onset of MS disease typically occurs at 20 to 50 years of age [3]. MS affects more than 
2.5 million people worldwide. Geographically MS is highly prevalent in northern and 
southern hemispheres. Gender plays a role in the occurrence of MS, incidence is higher 
in women compared to men with a ratio of at least 3:1 [4]. 
There are several factors which could be involved in the pathogenesis of MS. 
Environmental factors such as infection by Epstein-Barr virus [5] and low levels of vitamin 
D [6] were proposed to trigger the pathogenesis of MS. Genetics is also considered as a 
key factor for MS pathogenesis. For example, mutations in the HLA-DRB1 gene are 
compromising the immune systems response to differentiate between self-proteins and 
foreign proteins [7]. The genotype HLA-DRB1*15:01 increases the risk of MS more than 
3-fold [8]. In another study mutations in the IL7R gene resulted in changes in growth, 
proliferation and survival of immune cells [9]. In the immunological aspect Th2 cells, 
regulatory CD4+ T cells and NK cells among others are thought to be responsible for the 
relapsing-remitting and chronic progressive nature of the disease [10]. 
Diagnosis of MS is done clinically by neurological examinations and para-clinically by MRI, 
CSF analysis (spinal tap) and evoked potentials. MS can be diagnosed using McDonald 
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criteria [11] and the disability is usually scored with the expanded disability status scale 
(EDSS) [12].  
There are four main types of MS [13] which are characterized by the progression of the 
disease: relapsing-remitting MS (RRMS) is characterized by relapses (attacks) followed by 
remission (recovery), secondary-progressive MS (SPMS) happens following an initial 
RRMS period and a phase in which the disability worsens constantly regardless of any new 
relapse episode taking place or not, primary-progressive MS (PPMS) is characterized by a 
steady worsening of neurological functions from the beginning of the disease onset and 
there are no relapses. Before the diagnosis of RRMS there is often a condition called the 
clinically isolated syndrome (CIS). CIS can be a precursor condition of clinically definite 
MS. It is caused by inflammation or demyelination of nerve tissue and it is typically the 
first neurological episode occurring in a person. 
There are several disease modifying drugs in the market for the treatment of MS (table 
1). First line medications for MS are IFN-beta-1a either in an intramuscular once a week 
dosing or in a subcutaneous three times a week dosing, IFN-beta-1b s.c. every other day 
subcutaneously or GA (daily subcutaneously). In SPMS mitoxantrone intravenous 
infusions are sometimes prescribed. Recently there were new drugs approved for the 
treatment of MS [14]. 
Transcriptome profiling is the study of total RNA molecules within a particular biological 
system. Genetic information is primarily stored in DNA which can be copied by replication 
during cell division. Genes are segments of DNA which code for a particular product which 
can be just a transcript (ncRNA) or a transcript that is further translated into a protein 
(mRNA). There are around 20000 genes in a human genome [15]. RNA is transcribed from 
a template strand of DNA by the RNA polymerase enzyme and the transcription process 
is the first step in gene expression. Messenger RNA can be decoded by the ribosome into 
long amino acid chains called proteins. A transcript may also encode for non-coding RNA 
such as microRNA (miRNA), ribosomal RNA (rRNA) or transfer RNA (tRNA). Figure 1 shows 
the central dogma of molecular biology where RNA is transcribed from the DNA and later 
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translated into a protein. microRNAs are small RNA which are involved in the regulation 
of genes by mRNA cleavage or by translational repression [16]. 
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Table 1: Recommended multiple sclerosis disease modifying treatments. IFN-beta or glatiramer 
acetate (GA) are first-line treatments for relapsing-remitting multiple sclerosis (RRMS) and 
clinically isolated syndrome (CIS), and fingolimod, natalizumab and mitoxantrone along with 
cyclophosphamide are used as escalation therapies for RRMS. For secondary-progressive multiple 
sclerosis (SPMS) mitoxantrone along with cyclophosphamid are used as treatments. (Adapted 
from the guidelines and recommendations of the Deutsche Gesellschaft für Neurologie. Reference: 
URL: www.dmsg.de/dokumentearchiv/dgnkknms_msll_20120412_final.pdf) 
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Figure 1: Adapted central dogma of molecular biology. The sequence information flows from DNA 
to RNA to protein. DNA is copied as RNA in a process called transcription and RNA is translated 
into proteins. MicroRNAs are involved in the regulation of gene expression. 
In recent years there were several studies related to the gene expression profiling of 
various human diseases [17, 18, 19]. These studies were possible because of the 
development of various high-throughput platforms such as DNA microarrays [20] and 
TaqMan Array cards [21]. DNA microarrays allow to simultaneously measure the genome-
wide changes of thousands of genes. In the same way TaqMan Array cards are used to 
quantify hundreds of miRNAs and mRNAs based on the more sensitive polymerase chain 
reaction (PCR) a method to analyze a short sequence of DNA or RNA quantitatively. In the 
studies reported in this dissertation both of these platforms were used to study the gene 
expression profile of MS patients.  
IFN-beta and GA treatments bring down the number of relapses in MS but their 
mechanism of action and the effects of the treatments at the molecular level are yet to 
be fully understood. The previously known effects of IFN-beta and GA therapy on the 
immune system are explained in section 1.1 and 1.2. The studies reported in this thesis 
revealed various changes which happen at the gene expression level of monocytes and 
peripheral blood mononuclear cells (PBMC) from patient blood during GA or IFN-beta-1b 
s.c. treatment. MS patients who were about to start GA or IFN-beta-1b s.c. therapy were 
recruited and blood samples were collected at various time points in a longitudinal 
fashion. Monocytes or PBMC were isolated and transcripts (mRNA and miRNA) were 
isolated. Using DNA microarrays and real-time PCR the transcripts were analyzed 
quantitatively. The differentially expressed genes identified were investigated for their 
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functions and gene interaction networks were conceived. Figure 2 gives an overview of 
the studies reported in this thesis.  
 
Figure 2: Study design. Overview of the study design which is common to the GA and the IFN-beta-
1b study. MS patients who were about to start a disease modifying therapy with GA or IFN-beta-
1b were studied. Blood samples were collected and using different gene expression profiling 
platforms such as TaqMan real-time PCR and Affymetrix GeneChips the expression profiles of 
mRNAs and miRNAs were acquired. The data were analyzed comparing the expression before and 
during therapy. The differentially expressed genes were filtered and used in the construction of 
gene interaction networks.  
1.1 Glatiramer acetate  
Glatiramer acetate (Copaxone® or Copolymer 1) is a peptide drug used in the first-line 
treatment of MS. There are four different amino acids which are the building blocks of 
GA. They are glutamic acid, lysine, alanine and tyrosine (G-L-A-T) in a molar ratio of 
1.5:3.6:4.6:1.0. These amino acids are synthesized into random peptide sequences which 
are 40-100 residues long [22]. The peptides in GA were initially intended to trigger 
experimental autoimmune encephalomyelitis (EAE) by imitating myelin basic protein 
(MBP) but instead GA inhibited EAE [23]. EAE is an animal model for brain inflammation 
and it is also used to study T-cell mediated autoimmune diseases [24]. GA has become a 
regular therapy for MS patients due to its beneficial clinical effects and its safety profile 
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[25]. Despite many studies trying to understand the mechanisms of action of GA the 
molecular mechanism still remains unclear. 
GA is believed to act as an altered peptide ligand (APL). An APL is a peptide variant which 
possesses properties similar to a particular antigen but when bound to T-cell receptors 
(TCR) it provokes a different response. During GA therapy, the partial activation of T-cells 
specific for MBP and other myelin antigens can distract the T-cell response, and this may 
contribute to the clinical effects of GA [26]. There are many studies which have shown 
that GA can bring a shift in T-helper cells by changing the cell population from Th1 to Th2 
cells and this shift towards GA-reactive Th2 may be a main mechanism of action [27]. Th2 
cells are anti-inflammatory in nature and they are capable of migrating across the blood 
brain barrier where they suppress inflammatory factors. This is called local bystander 
suppression. This process is thought to actively damper the activation of auto-reactive 
immune cells [28, 29]. Despite our understanding the precise mechanism of action of GA 
remains unclear. 
The influence of GA on antigen presenting cells (APC) has been studied as well. APC, such 
as dendritic cells and macrophages, differentiate from monocytes [30]. These monocytes 
are believed to be a key population playing a role in the immune-modulatory effects of 
GA therapy [31]. One of the most rational mechanism of action of GA is its ability to bind 
to major histocompatibility complex (MHC) molecules and this means that it competes 
with myelin antigens in order to be presented on APC. GA can act as an antagonist of 
MBP/MHC at MBP-specific T cell receptors [32]. Weber et al. showed that monocytes 
when treated with GA switch from a pro-inflammatory to an anti-inflammatory type, and 
this change is characterized by the down-regulation of pro-inflammatory cytokines (e.g. 
IL-12) and the up-regulation of anti-inflammatory cytokines (e.g. IL-10) [26, 33]. 
Interestingly Monocytes produce 5- to 10-times more IL-12 and IL-18, in progressive 
multiple sclerosis [34]. In various monocyte studies the GA treatment resulted in an 
increase in anti-inflammatory type II monocytes. Type II monocytes are also characterized 
by increased secretion of transforming growth factor (TGF)-beta, and decreased 
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production of tumor necrosis factor (TNF). The suppressor functions of these monocytes 
were shown to contribute to Th2 deviation of naive T-cells in the CNS of MS patients [26, 
33]. It was also shown that GA can change the expression of monocytes by increasing the 
expression of IL1RA while decreasing the production of IL-1β [35]. Changes in monocytes 
can be due to direct effects of GA or can be indirectly facilitated by cytokines produced 
by GA-specific Th2 cells as there may be active feedback loops connecting human T-cell 
and APC responses [26, 27].  
There are more studies needed to understand the mechanism of action of GA. There are 
not many studies in the past which explored the effect of GA on the gene expression of 
monocytes. The in vivo gene regulatory effects of GA on monocytes have so far not been 
examined in a genome-wide and longitudinal manner. 
 1.2 Interferon-beta  
Interferons belong to a family of cytokines produced in the human body during the innate 
immune response against viral infections (pathogens) [36]. Interferon-beta is effective in 
the suppression of the symptoms of MS [15, 37]. Injectable recombinant IFN-beta is used 
as first-line treatment for RRMS, CIS and SPMS with relapses. IFN-beta treatment has 
been shown to be effective in bringing down the number of relapses and to reduce the 
formation of new inflammatory lesions in the brain. There are different types of IFN-beta 
therapies in the market. They differ in dosage, mode and frequency of administration, but 
they are very similar in therapy effectiveness [38, 39].  
The exact mechanism of action of interferon-beta proteins is still not fully understood. 
One proposed mechanism of action is that IFN-beta therapy decreases the expression of 
major histocompatibility complex (MHC) class II molecules on APC [40] as well as co-
stimulatory molecules such as CD80 and CD28 on lymphocytes and APC which directly 
affects the activation of T-cells by decreasing their auto-reactive behavior thus inhibiting 
T-cell proliferation. Interferon-beta also changes the delicate balance of cytokines. IFN-
beta treatment suppresses the pro-inflammatory Th1 and Th17 cells and their expression 
of IL-2, IL-12, IL-17 and interferon-γ while promoting the production of anti-inflammatory 
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Th2 cytokines (IL-10 and TGF-β). Interferon-beta can inhibit the expression of the 
adhesion molecule VLA-4 on T-cells and the release of matrix-metallo-proteinases (MMP) 
by T-cells which stops the migration of activated immune cells crossing the BBB from the 
blood stream [41]. 
IFN-beta has been shown to clearly affect the gene expression of various blood cells [41, 
42, 43]. More than a hundred genes have been consistently found to be differentially 
expressed during treatment [44]. The transcript levels of most of these genes are up-
regulated within a few hours after IFN-beta injection, and they return to pre-treatment 
or normal levels after a few days [45]. The IFN-beta-responsive genes are involved in the 
beneficial effects of the treatment and they express it by immunomodulatory, anti-
proliferative and anti-pathogenic processes. However, there was so far no study that 
investigated the expression of miRNAs in the course of IFN-beta-1b s.c. therapy. As a part 
of this dissertation microarray technology was used to analyze the gene expression 
dynamics in the peripheral blood of MS patients in response to IFN-beta therapy. In this 
study the expression profiles of mRNAs and miRNAs were for the first time simultaneously 
measured. It is important to study the transcriptome profile before and during the 
treatment in order to better understand the delicate changes brought by the treatment. 
The study presented in manuscript 2 focused on differentially expressed miRNAs and their 
involvement in the mechanism of action of IFN-beta-1b s.c therapy. 
1.3 MicroRNA in multiple sclerosis 
MicroRNA are small non-coding RNA molecules about 22 nucleotides in length. Their main 
role is to control the expression of genes by translational repression or by target mRNA 
cleavage. A single miRNA can regulate hundreds of miRNA. The miRNA regulation of genes 
depends on sequence specificity [46]. The biogenesis of a miRNA starts with a RNA 
polymerase II enzyme that transcribes the primary RNA (pri-miRNA) from the miRNA 
genes in the genome. The pri-miRNA is then matured by the enzymatic activity of 
ribonuclease III (RNase III) which results in about 70 nucleotides long precursor miRNAs 
(pre-miRNA). Pre-miRNAs are then exported into the cytoplasm and by the action of the 
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enzyme Dicer and other protein complexes the pre-miRNA is further shortened to about 
22 nucleotides which when loaded to an RNA-induced silencing complex (RISC) become 
active. The complex then binds to the 3’ untranslated region of a target mRNA. In 
consequence, the target mRNA is either cleaved directly by the RISC or translationally 
repressed.  
So far there are only relatively few miRNA-mRNA interactions which have been 
experimentally validated. It is thus necessary to computationally predict putative target 
genes for miRNAs [47, 48, 49]. miRNAs contain a seed region located at the 5’ end of the 
strand. Mostly the 2nd to 8th nucleotides are called the seed region and this is the region 
which recognizes the target sequence. In most of the prediction algorithms the seed 
region forms the core idea along with the thermodynamics of the microRNA-mRNA 
interaction.  
miRNAs are often found in clusters in the genome, as they are often found in close vicinity 
[50]. There are about 2500 unique mature microRNAs (miRBase 20 release) reported for 
humans. There are several miRNA target gene prediction databases available. The 
miRWalk database [51] allows to compare the predictions of 10 different algorithms. 
Experimentally verified interactions from the literature can be found in other databases 
such as miRTarBase [52] .The miR2Disease database helps in finding out miRNAs which 
are involved in MS and other diseases (http://www.mir2disease.org/). In the recent years 
there has been a tremendous development in miRNA databases and miRNA expression 
profiling platforms [53]. 
MicroRNA in MS and EAE is a relatively new field, a more complete picture is presented 
in manuscript 3 and manuscript 4. However it is interesting to note that there were only 
two small studies so far which reported about MS therapy effects on miRNA expression. 
A study by Waschbisch et al. [54] on 5 selected mature miRNAs found that GA treatment 
normalizes dysregulated miRNA expression in RRMS and in another study by Sievers et al. 
[55], differentially expressed miRNAs in B cells of patients treated with natalizumab were 
found. In the IFN-beta study reported in this thesis (manuscript 2) TaqMan microfluidic 
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cards as well as miRNA microarrays were used in the analysis. The microRNAs which were 
found to be differentially expressed upon IFN-beta treatment were further analyzed for 
target interaction networks. 
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2. Aims and objectives  
The studies reported in this thesis are inter-related and they focus on a common goal to 
find out how first-line disease-modifying therapies prescribed for MS influence the blood 
transcriptome (in vivo). GA and IFN-beta were the two drug candidates analyzed. The 
expression profiles of mRNAs and miRNAs were measured. As gene expression profiling 
platforms, microarrays and TaqMan microfluidic cards were used. The data obtained from 
these experiments were analyzed for differentially expressed genes and miRNAs during 
therapy. The studies were longitudinal in design and had different time points depending 
on the therapy GA or IFN-beta. The mRNA and the miRNA expression data were acquired 
and the up- and down-regulation in relation to pre-treatment levels was analyzed. The 
up- and down-regulated mRNAs and miRNAs were then used in the construction of gene 
interaction networks. Three different interaction networks were constructed. The 
purpose of these studies was to better understand the mechanism of action of GA and 
IFN-beta-1b s.c. and to find biological markers of therapy response. 
Study 1: Glatiramer acetate treatment effects on gene expression in monocytes of 
multiple sclerosis patients. 
Background: This study is the first genome-wide RNA profiling of monocytes under GA 
therapy. Monocytes are part of the innate immune system. Changes in the gene 
expression of monocytes could directly affect the pathophysiology of MS. Monocytes are 
known to shift their cytokine profiles from pro-inflammatory to anti-inflammatory when 
treated with GA. Monocytes secrete less TNF-alpha and IL-12 but more IL-10 and TGF-β 
on GA treatment. This longitudinal study was designed to investigate the differentially 
expressed genes within the first 2 months into GA treatment in monocytes from the blood 
of 8 RRMS patients from the Department of Neurology, University of Rostock. 
Aim: To find out the effects of GA treatment on monocytes at the level of transcriptome. 
The aim was to find out the role of monocytes in the therapeutic outcome of GA and to 
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better understand its mechanism of action and to validate previous findings of other 
research groups on specific genes. 
Study 2: MicroRNA expression changes during interferon-beta treatment in the 
peripheral blood of multiple sclerosis patients. 
Background: This is the first study to report on miRNA expression during IFN-beta-1b s.c. 
therapy. Injections of recombinant IFN-beta-1b s.c. are a first-line option in the treatment 
of RRMS. IFN-beta-1b s.c. has been shown to reduce the number of relapses and to 
suppress the accumulation of new inflammatory lesions in the brain. There were several 
studies in the past which showed that there is a clear modulation of IFN-regulated genes 
during treatment, but there were no studies which analyzed miRNA-mRNA interactions 
in the presence of IFN-beta-1b s.c. treatment in MS patients. 
Aim: To identify microRNAs and mRNAs which are differentially expressed in blood when 
MS patients are treated with IFN-beta-1b s.c. and to find out the most relevant miRNA-
mRNA interactions and their involvement in the pathophysiology of MS.  
Study 3: Integration of microRNA databases to study microRNAs associated with 
multiple sclerosis. 
Background: MicroRNAs are small molecules which are known to have a broad influence 
in the regulation of gene expression. In many diseases they have been discussed as 
potential biomarker candidates. For the majority of microRNAs the target genes are yet 
to be validated but there are databases which predict target sequences. This study 
integrates different databases to find out the MS-relevant miRNA targets. 
Aim: The aim was to establish a work-flow that integrates the information of different 
databases and to find out miRNA-mRNA target interactions using online target prediction 
databases. MS-associated miRNAs were used in the analysis to find out their molecular 
interaction network. 
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Study 4: MicroRNAs in multiple sclerosis and experimental autoimmune 
encephalomyelitis. 
Background: MicroRNA’s role in the MS disease is an emerging field. MicroRNAs are 
known to play a central role in the pathogenesis of the disease. This is one of the earliest 
articles which reviewed the interesting connection between miRNAs and MS. 
Aim: To find out MS-relevant miRNAs which were reported in the literature and review 
their involvement in MS and EAE. To reflect the current state of the art in the field of 
miRNA in MS. To review the findings of studies using blood cells or brain tissues to find 
differentially expressed miRNAs in MS.
  Materials and methods 
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3. Materials and methods 
3.1 Study population and blood sample collection 
Two studies dealing with MS patients were performed: a study on IFN-beta and a study 
on GA. Eight patients diagnosed with RRMS were recruited for the GA study (manuscript 
1) and six patients (CIS n=2 and RRMS n=4) were recruited for the IFN-beta study reported 
in manuscript 2. These patients were diagnosed according to the 2010 revised McDonald 
criteria [11]. 
For the GA study, patients started treatment with GA in 20 mg doses given daily as 
subcutaneous injection. For the IFN-beta-1b s.c. study, the patients started with the 
Betaferon® titration pack, and gradually reached a full dose of 250 µg. Blood samples 
were used in these studies as these drugs are known to mainly target immune related 
cells. Blood samples for GA study were collected for each patient at 5 different time 
points: before the first injection of GA (baseline) and after 1 day, 1 week, 1 month and 2 
months. Blood was collected by venipuncture with ethylenediaminetetraacetic acid 
(EDTA). In the IFN-beta-1b s.c. study, 4 different time points were investigated: baseline, 
after two days, after four days and after 1 month. The rationale behind these time points 
was that they give a snapshot on the initial changes which occur at the start (early phase) 
of the treatment. Clinical follow-up data containing EDSS scores and the number of 
relapses were collected and recorded. The studies were approved by the ethics 
committee of the University of Rostock and performed according to the Declaration of 
Helsinki. All patients gave written informed consent to be included in the study. 
3.2 Cell isolation, RNA and miRNA preparation and gene expression profiling 
For the GA study, monocytes were isolated from the blood samples using erythrocyte lysis 
buffer (Qiagen), followed by magnetic-activated cell sorting (MACS). For the IFN-beta-1b 
s.c. study, PBMC were isolated using the Ficoll gradient method. In the IFN-beta-1b s.c. 
study, total RNA enriched with small RNA was isolated using the mirVana miRNA isolation 
  Materials and methods 
 
17 
  
kit (life technologies, USA). RNA from monocytes was isolated using RNeasy columns and 
the RNA quality and quantity was measured. In both studies, the microarray experiments 
for mRNA quantification were performed with an Affymetrix platform. HG-U133 Plus 2.0 
GeneChips were used to quantify the expression of about 19,000 genes. The microRNA 
expression was quantified using TaqMan Array Human MicroRNA cards. These cards are 
based on real time PCR. They can quantify the expression of 651 mature microRNAs. For 
validation of the miRNA data, samples of n=3 MS patients at two time points (baseline 
and after one month) which resulted in six samples were used. The RNA of these 6 
samples was labeled and hybridized onto Affymetrix GeneChip miRNA 2.0 arrays. To verify 
the results in an independent cohort of 12 MS patients, microRNAs were also measured 
using TaqMan single-tube assays. The hsa-miR-191-5p housekeeping miRNA was used for 
normalization. 
3.3 Data analysis and databases 
The microarray data pre-processing and quality control was done with the Affymetrix 
GeneChip operating software and MAS5.0 statistical algorithms (Microarray Analysis Suite 
5.0). Since the design of the microarrays the annotation of genes has changed. There are 
probes on the microarrays which detect no transcript and probes which correspond to 
multiple transcripts. To remove such probes from the analyses a custom chip definition 
file (CDF) was used, which was based on the GeneAnnot database [56]. Every probe set in 
the custom CDF matches a single gene. Normalization of the data was performed by a 
loess fit to the data using the R package “affy”. 
Two analyses were performed to filter genes which are differentially expressed in the 
data: I) paired t-tests comparing the expression at baseline with the expression at the 
time points during therapy were calculated. II) In the second analysis the data was 
analyzed with the MAID filtering method, which calculates MA plot-based signal intensity-
dependent fold-changes (MAID-scores) for each time point comparison [57]. To find out 
significantly up-regulated or down-regulated genes compared to baseline, both MAID-
score and paired t-test outputs were combined. 
  Materials and methods 
 
18 
  
In the miRNA interaction study described in manuscript 3 (chapter 8.3), MS-relevant 
miRNAs were collected from the miR2Disease database [58]. miRBase [59], the central 
database for pre-miRNAs and mature microRNAs, was used to collect sequence 
information about the miRNAs and also to find out the genomic location of the miRNAs. 
The target mRNAs were predicted using the miRWalk database [51]. miRWalk database 
was used for the study because the database has its own target prediction algorithm along 
with nine other algorithms from other target prediction databases. miRTarBase was used 
to acquire experimentally validated miRNA target interactions [52]. miRNA regulating 
transcription factors were acquired from the miRGen database [60]. smiRNAdb is a 
database containing expression profile information of miRNAs in various cell types and 
tissue samples [61]. 
3.4 Gene Ontology analysis 
A Gene Ontology (GO) term enrichment analysis was performed to analyze the function 
of the genes filtered in the GA study. The analysis was based on the association of 
functional annotations for each gene in the GO database [62]. The R package GOstats was 
used to test GO terms for overrepresentation. All the genes which were measured with 
the HG-U133 Plus 2.0 microarray were used in the analysis as ‘gene universe’. 
3.5 Molecular network analysis 
The Pathway Studio software version 7.1 from Ariadne Genomics was used in the network 
construction presented in manuscript 1. The gene interactions were automatically 
obtained from the literature by text mining. The interactions were then exported and fed 
into Cytoscape, which is an open source software for visualization [63]. The resulting 
interactions were represented in various shapes to indicate the regulatory effects such as 
positive, inhibitory and binding interactions. 
To construct regulatory networks between miRNAs and genes (manuscript 2 and 
manuscript 3), the miRNAs were subjected to interaction analysis using various miRNA 
databases. Computational target predictions were found using miRWalk database [51] 
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and for experimentally validated miRNA targets miRTarBase was used. miRWalk database 
integrates 10 different prediction algorithms. Only interactions which were predicted 
consistently by several of the algorithms were further used. This helped to reduce the 
high number of putative and maybe false positive targets. These interactions were 
visualized again using the Cytoscape software. 
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4. Results 
This thesis consist of two main studies and two reviews which focused on expression 
profiles of genes and miRNAs, and their interactions in MS and during therapy. One major 
objective was to find out the effects of two disease modifying drugs: I) GA therapy and 
how does it affect monocytes at the gene expression level, and II) IFN-beta-1b therapy 
and how it affects PBMC at the miRNA and mRNA level. The gene expression data of 
monocytes and PBMC were acquired before and during the treatment of GA or IFN-beta-
1b. Analyses of the expression data helped to better understand the mechanisms of 
action of GA and IFN-beta-1b. The studies were longitudinal and recorded the individual 
gene expression changes across time. The results reported in this synopsis can be 
summed up into three categories: filtering of genes, visualization of mRNA/miRNA 
dynamics and interaction network analysis. 
4.1 Differential expressed genes and microRNAs 
In the GA study (n=8 RRMS patients) (manuscript 1), there were five different blood 
sampling time points. The monocyte transcript levels were always compared with the pre-
treatment levels (baseline). The Affymetrix microarrays measured 18.862 different genes. 
When the baseline levels were compared with those at day one, 438 genes were filtered 
with the MAID analysis criterion (|MAID-score|>2) and 1124 genes were filtered with the 
paired t-test criterion (p-value<0.05). In the combined analysis 171 genes were filtered of 
which 101 genes were up-regulated and 70 genes were down-regulated. Altogether four 
time points were compared with the pre-treatment levels using t-test and MAID-scores 
resulting in different gene lists and when aggregated there were a total of 463 different 
genes identified to be differentially expressed during the first 2 months of GA treatment 
(figure 3). 
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Figure 3: GA therapy - Filtering of genes. Using Affymetrix microarrays the transcript levels of 
18.862 genes were analyzed in monocytes. GA was prescribed 20 mg once daily at study onset. 
Five different time points were analyzed, before the start of GA treatment (baseline) and after one 
day, one week, one month and two months of GA treatment. t-test p-values and MAID-scores were 
used to determine differentially expressed genes. The expression levels at baseline were compared 
with the expression levels during GA therapy. The number of up-regulated genes is indicated by 
the red arrow and the number of down-regulated genes is indicated by the green arrow. Adapted 
from manuscript 1 [64]. 
In figure 4 represents the mean mRNA expression dynamics of 23 genes from the GA 
study. From the 463 genes filtered in total by the previous analysis, these 23 genes were 
found to be differentially expressed in at least two consecutive time point comparisons. 
Out of the 23 genes there were 18 genes which were up-regulated and 5 genes which 
were down-regulated. 
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Figure 4: mRNA dynamics of selected differentially expressed genes during GA therapy. Out of 
the 463 filtered genes these 23 genes were differentially expressed at least in two consecutive time 
point comparisons. There are 18 up-regulated and 5 down-regulated genes. The gene expression 
dynamics are shown in relation to the time points. The MAID-score, a fold change variant that is 
calculated from the data of all patients in the GA study, is represented on the y-axis and the time 
points are represented on the x-axis. Adapted from manuscript 1 [64]. 
In the IFN-beta-1b s.c. study the PBMC gene expression levels during IFN-beta-1b s.c. 
treatment were compared with baseline. In figure 4A the numbers of differentially 
expressed mRNAs are presented in the table along with a bar plot. In figure 4B the 
numbers of differentially expressed miRNAs are presented along with a bar plot. The row 
“Total” gives the union set over all the three time point comparisons. In total, there were 
95 genes found to be differentially expressed in response to IFN-beta-1b s.c. treatment. 
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Out of them n=75 genes were found to be up-regulated. The strongest changes in the 
expression of genes were observed at one month versus baseline. The filtering further 
identified more down-regulated miRNAs (n=13) than up-regulated miRNAs (n=7) during 
the IFN-beta- treatment. The maximum changes in miRNA expression occurred after one 
month of therapy (figure 5). 
 
 Figure 5: IFN-beta-1b s.c. therapy - miRNA and mRNA filtering. PBMC samples were used for the 
analysis. The IFN-beta-1b treatment effects on PBMC were analyzed. (A) & (B) show the number 
of IFN-beta-1b responsive genes and miRNAs, respectively. (A) Shows the number of mRNAs which 
were found to be differentially expressed across the time points. In (B) the number of miRNAs 
which were differentially expressed in relation to the time points are given. There were more 
mRNAs which were up-regulated in response to IFN-beta-1b treatment in contrast to a relatively 
higher number of miRNAs which were found to be down-regulated. Adapted from manuscript 2 
[65]. 
In the IFN-beta-1b s.c. study the miRNAs expression profiles were analyzed and the most 
significant finding is presented in figure 6. The expression dynamics of hsa-miR-29c-3p in 
the first month of the IFN-beta treatment are visualized. The down-regulation of hsa-miR-
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29c-3p is consistent across three different analysis. Initially six patients were analyzed 
with TaqMan miRNA cards, and this revealed the down-regulation of this miRNA in PBMC. 
Samples of three patients out of the 6 patients were re-analyzed using Affymetrix miRNAs 
arrays and the results were consistent with the findings from the TaqMan miRNA cards. 
In the last analysis the down-regulation of hsa-miR-29c-3p was confirmed in an 
independent validation cohort of 12 patients and their PBMC samples were analyzed 
using TaqMan single-tube assays.  
 
 
Figure 6: hsa-miR-29c-3p expression dynamics during IFN-beta-1b s.c. therapy. Down-regulation 
of hsa-miR-29c-3p in PBMC in response to IFN-beta-1b s.c. treatment is shown across three 
different techniques (A - TaqMan miRNA cards, B - Affymetrix miRNA arrays and C - TaqMan single 
tube assays). The Affymetrix data are in log2 scale and the TaqMan data are in linear scale due to 
a different data pre-processing. P=paired t-test p-values are given in each graph. Each colored line 
represents a patient. Adapted from manuscript 2 [65]. 
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4.2 Gene interaction network analysis 
The shortlisted genes from the GA study were used as input for the network analysis. The 
network was constructed using Pathway Studio software [66]. The software constructs 
the network based on text-mining information. The output resulted in 41 genes with 59 
interactions. The interactions between the genes were visualized as a network. The 
interactions consisted of 43 positive regulatory interactions, 14 inhibitory interactions 
and 2 binding interactions (figure 7). 
 
Figure 7: Interaction network of differentially expressed genes during GA therapy. The 
differentially expressed genes (n=463) which were filtered in 4 time point comparisons were used 
as input for the Pathway Studio software. The software found 41 genes (=nodes) which had 59 
interactions (=edges). The other genes had no interaction with the other differentially expressed 
genes. Different types of interactions (=edges) are shown differently. There are seven nodes, 
indicated blue in color, which are involved in the regulation of many other genes in the network. 
→ = positive effect (n = 43), ┤= negative effect (n = 14), ─ = binding (n = 2). Adapted from 
manuscript 1 [64].  
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The manuscript 3 focused on miRNAs that were found to be dysregulated in the blood of 
MS patients in four studies [67, 68, 69, 70]. The molecular interaction network was 
constructed using MS-associated miRNA, target genes and transcription factors (TF) 
acquired from various databases. TF-miRNA interactions were obtained from the miRGen 
2.0 database [60]. Validated and predicted miRNA-mRNA interactions were obtained 
from miRTarBase [52] and miRWalk [51] databases. In the network hsa-miR-20a-5p and 
hsa-miR-20b-5p are very closely related to each other and were predicted to regulate 
many common target genes. They appear close to hsa-miR-17-5p, whose targets were 
obtained from miRTarBase only and which belongs to the same miRNA cluster as hsa-miR-
20a-5p. The network revealed several feedback loops in the network, e.g. SOX9 was seen 
both as transcriptional regulator and as a target gene of hsa-miR-145-5p (figure 8).  
 
 
Figure 8: MS associated miRNA, target gene and transcription factor interaction network. 
Cytoscape interaction network of MS-associated miRNAs (n=14) and their target genes (n=1498) 
and regulating TFs (n=39). TF – miRNA interactions were retrieved from miRGen 2.0 database. 
Validated and predicted mRNA – miRNA interactions were found using miRTarBase and miRWalk 
databases. The network visualizes the complexity of molecular interactions associated with 
miRNAs that were described in the literature to be higher or lower expressed in the blood of 
patients with MS. Adapted from manuscript 3 [71]. 
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5. Discussion  
MS is a chronic inflammatory autoimmune disease of the CNS. The studies reported in 
this thesis focused on the transcriptome profiling of MS patients’ blood and the gene 
expression changes during therapy. High-throughput profiling platforms such as 
Affymetrix microarrays and very sensitive methods such as TaqMan real-time PCR were 
used in these studies. The transcriptome analysis comprised mRNA expression and miRNA 
expression. The GA study and the IFN-beta-1b study were longitudinal consisting of 
different time points at which the blood samples were collected. In the GA study 
monocytes isolated from the blood samples were analyzed and in the IFN-beta-1b study 
PBMC samples were used. Differentially expressed mRNAs and miRNAs were filtered as 
up- or down-regulated. They were then used in the construction of molecular interaction 
networks.  
MS is a complex disease and still there is no cure for MS [72]. There are several disease 
modifying drugs (table 1) used in the treatment of MS. Diagnosis of MS is not always 
straightforward as it is generally an elimination process. Diagnosis of MS is time 
consuming and other CNS disorders must be ruled out. The studies reported in this thesis 
focused on understanding more about the underlying changes within the immune cells as 
a result of the treatment with GA or IFN-beta-1b therapy. The mechanism of action of 
both of the drugs is not fully understood. In the studies monocytes and PBMC populations 
were analyzed longitudinally before and during GA or IFN-beta-1b treatment. 
In the GA study, 463 genes were filtered as differentially expressed across the five 
different time points (before GA therapy as well as one day, one week, one month and 
two months under GA treatment). Gene Ontology (GO) analysis showed the 
overrepresented GO terms and they included ‘lymphocyte proliferation’ and ‘regulation 
of T-cell proliferation’, explained in detail in manuscript 1. The GO findings are consistent 
with earlier studies that showed that GA lowers the lymphocyte proliferation by 
modulation of monocytes and monocyte-derived dendritic cells, hence reducing the 
number of auto-reactive T-cells [73, 74, 75]. 
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The GA study reported here was compared with the study by Achiron et al. which was 
another microarray study analyzing the gene expression in PBMC during GA treatment 
[76]. In the Achiron et al. study only two time points were compared, before and after 3 
months of GA treatment [76]. In this thesis the GA treatment effects were studied at five 
time points and this helps to understand the variation in mRNA dynamics in a higher 
resolution which was not previously possible. Using Affymetrix microarrays, Achiron et al. 
found 480 genes to be differentially expressed in response to GA treatment in PBMC. 
When comparing the gene lists of both of the studies there were only five genes (BAT1, 
ELOVL5, ETV7, MT1E and PCBD1) in common. Therefore the GA study could not validate 
the results by Achiron et al. as there are very few gene overlapping between these two 
independent studies. An explanation can be that GA possibly acts selectively on other 
subsets of circulating cells. A possible hypothesis could be that GA might mainly alter the 
functional properties of (auto-reactive) T-cells, and this could be the reason behind a 
slightly stronger influence on the gene expression of PBMC than of monocytes from GA-
treated patients.  
In another study by Weber et al., it was shown that monocytes when treated with GA shift 
to anti-inflammatory type II monocytes [33]. They have shown in a mouse model that 
there is an increased secretion of IL-10 and TGF-beta and decreased levels of IL-12 and 
TNF-alpha. In the study described in manuscript 1, there were few cytokines like CXCL9 
and CXCL10, which showed increased expression the day after the start of GA therapy. 
CXCL10 was also previously shown to be induced in PBMC when treated with GA [77]. 
However, the cytokines IL-10 and IL-12 were stable in expression and did not change upon 
treatment in vivo, thus not supporting a significant shift in the cytokine profile of 
monocytes. The GA study could not find a stable pattern of differentially expressed genes 
which could support the notion of an increase of type II monocytes in the 2 months long 
study. 
It is quite clear that GA treatment could influence the gene expression profile in 
monocytes but the transcriptome changes were not consistent across the time points. 
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Out of the 463 genes there were only 23 genes which were differentially expressed in at 
least two consecutive time point comparisons, but nevertheless these 23 genes can be 
regarded as good candidates for molecular markers of GA activity. These candidate genes 
need further studies to understand their role in the mechanism of GA. When looking at 
the overall effect of GA on the gene expression profile it is clear that the drug has only 
moderate influences on monocytes. 
GA’s influence on the gene expression level is not yet clearly understood. There were very 
few studies in the past which have reported on differentially expressed genes during GA 
therapy. In the GA study a clear snapshot of the gene expression dynamics across five 
different time points before and after the start of GA therapy was generated. The study 
was able to report moderate changes in expression when compared with the pre-
treatment levels. The gene expression was altered but there was no gene consistently 
modulated across all the time points. However the 23 genes which were differentially 
expressed in at least two time point comparisons are potential molecular marker 
candidates which need to be studied in more detail. 
In the IFN-beta-1b s.c. study, which was a longitudinal genome-wide study examining the 
in vivo effects of IFN-beta-1b on PBMC, mRNA and miRNA expression profiles were 
analyzed simultaneously. Information from various databases was integrated to examine 
how miRNAs affect the expression levels of their target mRNAs. The study was able to 
show that the mRNA results were quite consistent with results published before. Out of 
the 95 differentially expressed genes filtered in this study (figure 5), in the Goertsches et 
al. study 63 differentially expressed genes were also reported [78] and in the Hecker et 
al. study 49 of the 95 genes were already identified as transcriptionally modulated in 
response to IFN-beta-1a s.c. [42]. Out of the 95 genes reported in the IFN-beta-1b s.c. 
study 75 were found up-regulated. In contrast, in the miRNA data, the filtering method 
could find more down-regulated than up-regulated miRNAs during therapy. There were 
20 miRNAs filtered as differentially expressed miRNAs and 7 were up-regulated. In the 
   Discussion 
 
30 
  
analysis four miRNA (hsa-miR-29a-3p, hsa-miR-29c-3p, hsa-miR-193a-3p and hsa-miR-
532-5p) were confirmed to be down-regulated.  
The expression of the mir-193 family members hsa-miR-193a-3p and hsa-miR-193a-5p 
was repressed during the therapy. A study by Lindberg et al. showed increased expression 
of hsa-miR-193a-5p in CD4+ T cells of RRMS patients when compared to healthy controls 
[79]. Otaegui et al. described that hsa-miR-193a-3p is related to the remission stage of 
MS [80]. hsa-mir-193a controls the apoptotic processes by helping CASP3 activation 
stimulated by TNFSF10 signaling [81]. TNFSF10 (=TRAIL) is a known IFN-beta-induced gene 
and it was transcriptionally up-regulated in the patients’ PBMC. The regulation of mir-193 
miRNAs thus could play an important role in the molecular mechanisms of action of IFN-
beta therapy. 
let-7 family members (hsa-let-7a-5p and hsa-let-7b-5p) were found to be expressed at 
higher levels during treatment in the IFN-beta-1b s.c. study. In another study it was shown 
in primary macrophages that hsa-let-7b-5p is up-regulated in response to IFN-beta in vitro 
[82]. In another study miRNAs of the let-7 family were shown to activate TLR7 signaling in 
microglia and macrophages which induces neurodegeneration [83]. Gandhi et al. [84] in 
their study reported variations in expression levels of hsa-let-7a-5p in the blood plasma 
of patients with secondary progressive MS when compared with patients with RRMS. In 
CD4+ T cells, let-7 miRNA reduce the expression of IL-10, a cytokine with anti-
inflammatory properties [82].  
The IFN-beta-1b s.c. study was an interesting integration of different molecular layers that 
are orchestrated to a tapestry of genes. The study integrated mRNA and miRNA 
expression profiles before and during IFN-beta-1b s.c. treatment across different time 
points. This was the first time such a study has been performed. The study definitely 
improved the understanding of the molecular effects of IFN-beta-1b s.c. treatment in MS 
patients.  
   Discussion 
 
31 
  
In the third study, MS-related miRNA-mRNA interactions were studied. The regulatory 
network between mRNAs and MS-associated miRNAs was constructed using information 
from different databases. In this study 16 miRNAs were found in the miR2Disease 
database as higher or lower expressed in blood cells of MS patients. CDKN1A (p21) was 
the gene with the maximum number of interactions in the network. CDKN1A interacts 
with five miRNAs which are associated with MS. For instance the miRNAs hsa-miR-20a-5p 
and hsa-miR-20b-5p are known to interact with CDKN1A according to miRTarBase and 
miRWalk databases. The function of CDKN1A is to block the induction of the S-phase in T-
cells. Thus any faulty regulation of this gene can result in autoimmune processes [85]. 
Another study by de Santis et al. [86] showed that CDKN1A expression can also be 
regulated by miRNA hsa-miR-25-3p and hsa-miR-106b-5p, thereby controlling the TGF-
beta pathway and influencing the development of regulatory T-cells in MS patients. In the 
network the RUNX1 gene is interacting with four miRNAs. It is involved in various aspects 
of T-cells including development and function. It is a central factor in the differentiation 
of Th17 cells with a dual effect on IL17 transcription [87]. 
In the network four miRNAs target TF E2F1. E2F1 helps to regulate the start for antigen-
stimulated activation of T-cells and also plays a role in the negative selection in the thymus 
[88]. FOXO1 has five interactions and FOXO3 has three interactions in the network. FOXO1 
and FOXO3 belong to the fork head family of TFs. The function of FOXO1 is to suppress 
the activation, proliferation and development of T-cells. Down-regulation of FOXO1 by 
hsa-miR-182-5p was described to be necessary for T-cell clonal expansion [89]. Deletion 
of FOXO1 along with FOXO3 in mice was shown to result in inflammatory diseases and 
decreased Treg cell differentiation [90]. 
The mechanisms of GA and IFN-beta are not fully understood. The GA and IFN-beta-1b 
studies reported here gave new insights to better understand the mechanisms of action 
of these drugs. The studies reported in this thesis have several interesting findings, for 
instance the down-regulation of hsa-miR-29c-3p in response to IFN-beta therapy. 
Secondly, hsa-let-7a-5p and hsa-miR-16-5p were found highly expressed in peripheral 
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blood and brain and their precise relevance to MS needs to be studied further. Thirdly, 
the 16 MS-relevant miRNAs and their 1498 target genes along with their 39 TFs definitely 
delivered a wider understanding of the possible interactions taking place at the molecular 
level. Fourthly, in the GA study the 23 genes which were differentially expressed across 
two time points may represent useful biomarkers of the biological response to GA. Most 
of the findings reported here are novel and will help us to better understand MS 
pathophysiology and MS treatment.
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6. Summary 
MS is an inflammatory disease of the central nervous system. There are many types of 
disease modifying drugs available for MS but none of them can cure MS. The medications 
are taken for the rest of the life. Despite that our understanding about MS is still unclear. 
Genome-wide transcriptome studies are vital to understand the changes happening at 
the molecular level during treatment. Due to the advancement of technology it is now 
possible to precisely measure the expression levels of thousands of genes simultaneously. 
The studies reported in this thesis analyzed the changes which happen at the 
transcriptome level during the course of treatment. Glatiramer acetate and interferon-
beta-1b s.c. were the drugs analyzed in two independent studies. The studies reported 
revealed several differentially expressed transcipts which included both mRNAs and 
miRNAs. The differentially expressed genes and miRNAs can be considered as biomarker 
candidates for therapy monitoring which can also help to better understand the 
mechanism of action of GA and IFN-beta-1b s.c. 
GA is a peptide drug used in the treatment of RRMS. Its mechanism of action is still not 
clearly understood. The study in this thesis gave a snapshot of changes which happened 
during the treatment in monocytes at the gene expression level. Affymetrix GeneChips 
were used to analyze the gene expression of 18.862 genes in the blood monocyte sub-
population. Monocytes from eight MS patients were isolated. Total RNA was then isolated 
from those samples. GA was prescribed 20mg once daily. The study was longitudinal in 
design with five different blood sampling time points, baseline – before the start of the 
treatment, after one day, after one week, after one month and after two months. There 
were more than 400 genes which were filtered as differentially expressed genes when 
compared with their pre-treatment levels. These genes were not reported before in any 
genome-wide study on GA therapy Out of them only 23 genes appeared in at least two 
consecutive time point comparisons. The differentially expressed genes were analyzed 
further for interactions and a gene interaction network was constructed using Pathway 
Studio software. The network revealed interactions between the GA-responsive 
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differentially expressed genes VCAM1, CXCL9, CXCL10, POMC, OXT, PTPRC, CD38 and 34 
other genes. This interaction network can help to better understand the gene regulatory 
changes during GA treatment. The network interactions need to be further studied with 
wet lab experiments to understand the cascade of events taking place within the cell 
during GA therapy.  
The IFN-beta-1b study design was longitudinal with four different time points (baseline, 
after 2 days, after 4 days and after 1 month). PBMC were isolated from the patient blood 
and total RNA was isolated from them. Using Affymetrix microarrays and TaqMan 
microfluidic cards miRNA and mRNA gene expression were measured. miRWalk and 
miRTarBase databases were used to find out the interactions between the differentially 
expressed mRNAs and miRNAs. The interaction predicting database used different types 
of algorithms to find the most likely miRNA target genes. In the filtering of IFN-beta-1b-
responsive miRNAs and mRNAs there were 95 mRNAs of which 75 were up-regulated and 
20 were down-regulated. Additionally, there were 20 miRNAs which were filtered. Out of 
them 7 were up-regulated and 13 were down-regulated. The study found that there were 
more mRNA which were up-regulated and contrastingly there were more miRNAs which 
were down-regulated. The miRNA hsa-miR-29c-3p was confirmed to be significantly 
down-regulated in response to IFN-beta-1b treatment. Further investigation of the 
miRNA-mRNA interactions with in vivo miRNA target assays such as the luciferase assay 
are needed.  
The manuscript 3 presented different databases in the context of miRNA, their contents 
and utility. The target predicting databases use different types of algorithms to predict 
miRNA targets. miRWalk database was extensively used in the study for target prediction 
and the main reason was that it combines information from 10 target prediction 
databases. The miRNA targets reported in the study were at least predicted by 7 different 
databases consistently. The review explains the information which can be collected from 
different miRNA databases and how to integrate the heterogeneous information to 
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investigate functions and interactions of miRNAs. This may serve as a guideline for similar 
studies on different issues or diseases.  
The studies reported in this thesis brought a wealth of new information to the table. There 
are more studies needed to improve our understanding on the mechanisms of action of 
these drugs and to improve them. The findings reported in this thesis will hopefully help 
in the quest to find a better treatment for MS.
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expression in monocytes of multiple sclerosis
patients
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Abstract
Background: Glatiramer acetate (GA) is a mixture of synthetic peptides used in the treatment of patients with
relapsing-remitting multiple sclerosis (RRMS). The aim of this study was to investigate the effects of GA therapy on
the gene expression of monocytes.
Methods: Monocytes were isolated from the peripheral blood of eight RRMS patients. The blood was obtained
longitudinally before the start of GA therapy as well as after one day, one week, one month and two months.
Gene expression was measured at the mRNA level by microarrays.
Results: More than 400 genes were identified as up-regulated or down-regulated in the course of therapy,
and we analyzed their biological functions and regulatory interactions. Many of those genes are known to regulate
lymphocyte activation and proliferation, but only a subset of genes was repeatedly differentially expressed at
different time points during treatment.
Conclusions: Overall, the observed gene regulatory effects of GA on monocytes were modest and not stable over
time. However, our study revealed several genes that are worthy of investigation in future studies on the molecular
mechanisms of GA therapy.
Keywords: Glatiramer acetate, Relapsing-remitting multiple sclerosis, Monocytes, Gene expression profiling,
Microarray analysis
Background
Multiple sclerosis (MS) is a chronic immune-mediated
disease of the central nervous system (CNS). The auto-
reactive behavior of the immune system in MS patients
is associated with inflammatory lesions in the CNS and
axonal demyelination. There is currently no cure for
MS, but there are several therapies available as disease-
modifying agents. The relapsing-remitting type of MS
(RRMS) is mainly treated with immunomodulating
drugs like interferon-beta (IFN-β) and glatiramer acetate
(GA) [1,2].
GA (copolymer 1) is a first-line treatment option for
RRMS. Different clinical trials have shown that GA
treatment decreases the incidence of relapses and sig-
nificantly reduces the number of gadolinium-enhancing
lesions in magnetic resonance imaging (MRI) [3-6]. GA
is not a defined chemical substance, but a standardized
mixture of synthetic peptides. These peptides are made
up of four different amino acids, glutamic acid, lysine,
alanine and tyrosine (G-L-A-T), in a molar ratio of
1.5:3.6:4.6:1.0, assembled in a random order into poly-
peptide chains with a length of 40 to 100 residues [7].
This mixture of peptides was initially intended to mimic
myelin basic protein (MBP) and to induce experimental
autoimmune encephalomyelitis (EAE), the animal model
of MS [8]. However, surprisingly, GA inhibited EAE in
rodents and monkeys [9]. Today, GA has been well-
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established for MS therapy for more than a decade due
to its beneficial clinical effects and its favorable safety
profile.
According to pharmacokinetic studies, GA is quickly
absorbed after subcutaneous administration, and it un-
dergoes rapid degradation to amino acids and shorter
peptides. Only 10% of the peptides remain at the site of
injection after one hour [10]. A fraction of GA presumably
enters the lymphatic circulation and reaches the regional
lymph nodes where it modulates immune responses.
Of note, patients treated with GA have the tendency to
develop antibodies against it. However, the biological
meaning of anti-GA antibodies remains controversial
and it is unclear whether they may have a neutralizing
or a beneficial effect in MS patients [11-14].
Different molecular mechanisms of action of GA have
been proposed [7,15-18]. One postulated mechanism is
that GA peptides act as altered peptide ligands (APL).
An APL is a peptide, usually closely related to an agonist
peptide in amino acid sequence, that induces a different
function or partial response of T-cells specific for the
agonist peptide as a result of the modified interaction
with the T-cell receptor (TCR). During GA therapy, the
partial activation of T-cells specific for MBP and other
myelin antigens can induce peripheral tolerance, and this
may contribute to the clinical effects of GA by preventing
the attack of the myelin sheath around the nerves. Indeed,
cross-reactivity of GA-specific T-cells with myelin antigens
has been demonstrated, and there is evidence that
prolonged exposure to GA results in anergy or depletion
of GA-reactive cells that are possibly relevant in the
pathogenesis of MS [19-23]. On the other hand, several
studies have shown that GA induces a T helper cell type 1
(Th1) to Th2 shift in T-cells. Th1 and Th2 each produce
a different combination of pro- and anti-inflammatory
cytokines, respectively. The increase of GA-reactive Th2
cells during treatment is regarded as a central mechanism
of action of GA [24-27]. These anti-inflammatory Th2-like
cells were found to mediate regulatory functions as
they can migrate into the brain and act suppressively at
the sites of inflammation (local bystander suppression).
This leads to a reduced activation and proliferation of
auto-reactive immune cells, even if they recognize un-
related antigens and do not cross-react with GA [11].
Antigen-presenting cells (APC) are also believed to play
a role in the immunomodulatory effects of GA therapy.
The professional APC are dendritic cells and macro-
phages, which differentiate from circulating monocytes
[28]. The interplay between APC and T-cells is funda-
mental in adaptive immune responses as well as in the
pathophysiology of MS [29]. One suggested mechanism of
GA is that it binds to major histocompatibility complex
(MHC) molecules and thus competes with myelin anti-
gens for their presentation on APC to T-cells. Specifically,
GA can act as an antagonist of MBP/MHC at MBP-
specific TCR and it is able to displace MBP from the bind-
ing site on MHC class II molecules [30,31]. On the other
hand, GA was shown to change the properties of APC in
such a way that they stimulate Th2-like responses. These
APC are called type II APC. The effect of the drug on
APC seems to depend on the cell type [11,32]. Weber
et al. showed that GA inhibits monocyte reactivity and
induces type II monocytes, which promote both Th2
differentiation and expansion of T regulatory cells (Treg).
They observed that after GA administration in EAE,
the pattern of cytokine production by monocytes switched
towards an anti-inflammatory profile, characterized by
down-regulation of pro-inflammatory cytokines (for ex-
ample, IL12) and up-regulation of anti-inflammatory
cytokines (for example, IL10) [33,34]. An increased IL10
production of monocytes has already been observed
72 hours post GA therapy initiation in a recent study by
Ayers et al. [35]. Other studies confirmed that there is an
increase in anti-inflammatory type II monocytes during
GA therapy, and that the suppressor functions of these
monocytes contribute to Th2 deviation of naive T-cells of
MS patients [36-38]. Additionally, GA was shown to affect
monocytes by increasing the expression of IL1RA while
diminishing the production of IL1-β [39,40]. Recently,
Caragnano et al. also observed a trend for IL1-β down-
regulation in stimulated monocytes from GA-treated MS
patients, and this was paralleled by lower levels of P2RX7,
a receptor regulating cytokine production and apoptosis
[41]. However, whether GA acts directly on monocytes
in vivo, or whether the effects on monocytes are mediated
by cytokines produced by GA-specific Th2 cells, is unclear
as there is a dynamic feedback loop between human T-cell
and APC responses [11,36].
However, GA not only modulates CD4+ T helper cell
responses and binds to MHC class II molecules on APC.
It has also been shown that GA incites an HLA class I-
restricted, cytotoxic suppressor CD8+ T-cell response
[42]. This may be mediated by heat shock proteins
(HSPs) that bind extracellular antigens and mediate
their cellular uptake. HSP-antigen complexes are then
directed toward either the conventional class II pathway
or the MHC class I pathway through cross-presentation
[43,44]. In the similar way, GA peptides may bind to
HSPs, and thus may be presented on MHC class I mole-
cules resulting in an altered activation of T-cell subsets.
This potentially leads to cytotoxic T-cells, which can kill
CD4+ T-cells in a GA-specific manner [42]. In addition to
its immunomodulatory effects, direct neuroprotective and
even remyelinating properties have been ascribed to GA
as well [45-49]. For instance, GA may foster repair after
neurologic damage by stimulating the expression of
neurotrophic factors like BDNF by various immune
and CNS resident cells [50].
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Over the last years, several research groups performed
longitudinal gene expression profiling studies with micro-
arrays to better understand the mechanisms of action
of MS therapies. However, while the broad and rapid
gene regulatory effects of IFN-β treatment in blood
cells have been investigated extensively [51], there is
only one such study for GA treatment: Achiron et al.
measured the gene expression in peripheral blood
mononuclear cells (PBMC) from 14 RRMS patients be-
fore and three months after initiation of GA therapy
[52]. In their analysis, they identified 480 genes to be
differentially expressed at the transcript level. They
concluded that changes in the expression of immuno-
modulatory genes during GA therapy are important to
reduce the activity of the disease [52].
The present study focuses on the effects of daily sub-
cutaneous GA injections on the mRNA expression
profile of monocytes in the peripheral blood. We were
interested in monocytes because GA has been described
as modulating these cells to promote Th2-like responses
[11,31], but the in vivo effects have so far not been
examined in a genome-wide and longitudinal manner.
We obtained monocytes from RRMS patients immediately
before as well as at four different time points after the
start of GA therapy. The gene expression analysis was
performed using microarrays. Genes that were found to
be differentially expressed in response to GA therapy were
then analyzed for biological functions and molecular
interactions to derive new hypotheses on the molecular
mechanisms of action of GA. This is the first study that
investigates the transcriptome dynamics over the course
of the therapy in a cell type-specific manner.
Methods
Blood sample collection
Eight Caucasian patients with diagnosed RRMS according
to the revised McDonald criteria [53] were recruited
for this study. The patients started a treatment with GA
(Copaxone, Teva Pharmaceutical Industries Ltd., Petah
Tikva, Israel) in 20 mg doses given daily as a subcutaneous
injection. Five of the patients were not treated with any
immunomodulatory or immunosuppressive drug prior
to the onset of this study. Two patients (MS3 and MS5)
received subcutaneous IFN-β, and one patient (MS8)
received mitoxantrone (the last injection was four months
ago) previously (Table 1). All patients were given routine
care following the consensus treatment guidelines and
recommendations of the German Society of Neurology
(DGN). Blood samples were obtained from each patient
at five different time points: before the first injection of
GA (baseline) and after one day (that is, before the second
injection) as well as after one week, one month and two
months. Collection of blood was done by venipuncture
with ethylenediaminetetraacetic acid (EDTA) as anti-
coagulant. An approximate volume of 15 ml whole
blood was collected for each patient and each time
point. In the clinical follow-up, the patients were assessed
neurologically, monitored for relapses, and rated using the
expanded disability status scale (EDSS) and cranial MRI.
The study was approved by the ethics committee of the
University of Rostock and carried out according to the
Declaration of Helsinki. All patients gave written informed
consent to be included in the study.
Monocyte isolation, RNA preparation and gene
expression profiling
Monocytes were isolated from the blood samples using
erythrocyte lysis buffer (Qiagen, Hilden, Germany), fol-
lowed by magnetic-activated cell sorting (MACS). The
CD14+ cells were magnetically labeled using CD14
MicroBeads and collected as positively selected cell
fraction using the autoMACS Separator (Miltenyi Biotec,
Teterow, Germany). Total RNA was then isolated from
the monocytes using RNeasy columns (Qiagen, Hilden,
Germany). RNA concentrations were measured using a
NanoDrop 1000 spectrophotometer (Thermo Fisher Scien-
Table 1 Demographic data and clinical data of the eight patients
Patient Gender Age at
study onset
Disease
duration
Previous
treatment
EDSS at
baseline
EDSS after
12 months
Relapses during first
12 months
cMRI at
follow-up
MS1 Female 41 0 None 1.5 1.5 0 -
MS2 Female 50 10 None 1.5 1.5 1 New lesion
MS3 Female 37 33 IFN-beta sc. 1.0 1.5 0 stable
MS4 Female 38 9 None 1.0 1.5 0 New lesion
MS5 Female 38 89 IFN-beta sc. 3.5 2.0 1 stable
MS6 Female 47 1 None 1.5 1.5 0 New lesion
MS7 Male 35 16 None 1.0 1.0 0 New lesion
MS8 Male 25 55 Mitoxantrone 2.0 2.5 1 New lesion
The table shows gender, age, the previous treatment, and the EDSS scores at therapy initiation (baseline) and after 12 months. The duration from the diagnosis of
definite MS to the start of GA therapy in months (disease duration) is also given. The gender ratio was 6:2 (female: male) and the average age at study onset was
38.9 ± 7.6 years (mean ± SD). Three patients had a relapse during the first 12 months after GA treatment initiation. Five patients showed a new brain lesion in the
follow-up compared to pre-treatment. cMRI: cranial magnetic resonance imaging, EDSS: expanded disability status scale, sc.: subcutaneous, SD: standard deviation.
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tific, Wilmington, DE, USA) and their integrity was
assessed with an Agilent 2100 Bioanalyzer using RNA
6000 Pico LabChips. The microarray experiments were
performed with an Affymetrix platform. HG-U133 Plus
2.0 GeneChips were used for this analysis. From each
sample preparation, total RNA amounts ranging from
100 ng to 200 ng were used as starting material. RNA
was converted to cDNA and later into biotinylated
cRNA using the MessageAmp II-Biotin Enhanced Kit
(Ambion, Foster City, CA, USA). The cRNA molecules
were fragmented and 15 μg of cRNA were hybridized
onto the GeneChips for 16 hours at 45°C. The GeneChips
were later washed and stained in the Affymetrix Fluidics
Station 450 and scanned with a GeneChip Scanner
3000 7G system. All these procedures were performed
according to the manufacturer protocols (Affymetrix,
Santa Clara, CA, USA).
Microarray data pre-processing
Initial data pre-processing and quality control was done
using the Affymetrix GeneChip operating software (GCOS
1.4) and MAS5.0 statistical algorithms (Microarray
Analysis Suite 5.0) (Affymetrix, Santa Clara, CA, USA).
Since the annotation of genes has changed since the
development of the microarrays, there are oligonucleotide
probes on the chips, which match to no transcript, and
probes, which match to multiple transcripts. Therefore,
to exclude such probes from the analysis, we used a
custom chip definition file (CDF), which was based on
the GeneAnnot database version 1.9 (http://www.xlab.
unimo.it/GA_CDF/, CDF version 2.1.0) [54]. Each probe
set in the custom CDF matches a single gene. Data
normalization was done by a loess fit to the data with
span = 0.05 using the R package ‘affy’.
Filtering of differentially expressed genes
To filter differentially expressed genes from the data, we
applied two criteria. First, we computed paired t-tests
comparing for each gene the expression at baseline with
the expression at one day, one week, one month and
two months. In the second analysis, we evaluated the
data with the MAID filtering method, which calculates
MA plot-based signal intensity-dependent fold-changes
(MAID-scores) for each time point comparison [55].
To filter genes that are significantly up-regulated or
down-regulated relative to baseline, we combined the
MAID-score outcomes with the paired t-test outcomes.
Genes with |MAID-score| > 2 and t-test P-value < 0.05
were filtered as differentially expressed.
Functional analysis of differentially expressed genes
To investigate the functions of the filtered genes, we
performed a Gene Ontology (GO) term enrichment
analysis, which was based on the association of functional
annotations for each gene in the GO database. GOstats
[56], a Bioconductor software package, was the application
used to test GO terms for overrepresentation. GOstats
computes a probability based on a hypergeometric distri-
bution, which assesses whether the number of filtered
genes associated with the term is larger than expected by
chance. As a reference, that is, the gene universe, we used
all genes that were measured with the HG-U133 Plus 2.0
microarrays (n = 18,862).
Text mining-based gene interaction network analysis
A gene interaction network was constructed for the
filtered genes using the Pathway Studio software version
7.1 from Ariadne Genomics (Rockville, MD, USA) [57].
This software allowed the extraction of gene interactions
that were automatically obtained from the literature by
text mining. The information about interactions between
the genes was exported from the Pathway Studio software
as a table, which contains nodes (genes) and edges
(interactions) as the building blocks of the gene network.
Cytoscape, which is an open source software [58], was
used to visualize the network. The edges were represented
in various shapes to display the type of the interaction
(positive, inhibitory and binding).
Results
Patient and sample information
Eight patients were included in this study (six females
and two males). The patients were 38.9 ± 7.6 years of age
(mean ± standard deviation) and had a mean EDSS of 1.6
(1.0 to 3.5) after a mean disease duration of 26.6 (0 to 89)
months (Table 1). All patients started GA treatment at
standard dose. During the follow-up period of 12 months,
three patients had one relapse each and the other five
patients had no relapse. There was only a moderate
increase in disability when comparing the EDSS at study
onset (baseline) with the EDSS after a follow-up of one
year (Table 1). One patient discontinued the therapy in
this period of time: MS5 had a severe relapse soon after
study onset and, therefore, switched to natalizumab
therapy (Tysabri, Biogen Idec, Weston, MA, USA) after
three months. Cranial MRI scans were done for seven
of the eight patients before the start of GA therapy as well
as after a mean follow-up of 17.6 ± 9.5 months. Despite
the therapy, five patients each had one new lesion.
From each blood sample, monocytes were isolated by
MACS separation. For quality control, we analyzed the
mRNA levels of genes, which are known to be specific-
ally expressed by different blood cell types [59]. This re-
vealed high CD14+ monocyte purities (Additional file 1:
Figure S1). The RNA that was isolated from the mono-
cytes was in general of high quality with an average
RNA integrity number (RIN) of 9.6. The quality of RNA
was poor for three samples (MS3/1 month, MS6/1 week,
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MS7/1 week) and so they were excluded from further
analyses.
Differentially expressed genes
The pre-processing of the Affymetrix microarray data
resulted in transcript levels for 18,862 different genes
and 37 different samples. The data are available in the
Gene Expression Omnibus (GEO) database with the
accession number ‘GSE42763’. The filtering of genes
differentially expressed in response to GA therapy resulted
in a gene list for each time point comparison. In total, 171
genes met the filtering criteria for one day, 116 genes
for one week, 124 genes for one month and 101 genes
for two months versus baseline (Figure 1, Additional
file 2: Table S1). These four gene lists, when aggregated,
resulted in 463 different genes (293 up-regulated and
170 down-regulated genes). We observed no accumulation
of gene regulatory effects in the course of the therapy
since similar numbers of genes were filtered at early
(within the first week) and later time points (after one
and two months). Moreover, unexpectedly, we found no
stable signature of GA-responsive genes since only 45 of
the 463 genes were repeatedly identified as differentially
expressed, and there was no gene modulated in expression
at all time points during therapy.
To further narrow down the list of genes, we selected
only those genes that were expressed at significantly
higher or lower levels compared to baseline at two or
more consecutive time points. This resulted in a subset
of 23 out of the 463 genes. Of these 23 genes, 5 genes
were down-regulated (CD34, RPA4, HMGB1L4, BAZ2B
and RARS) and 18 genes were up-regulated (for example,
ATOX1, BLOC1S1, LIMD2, POLR2I and RPA3). The
average mRNA expression dynamics of these genes during
GA therapy are shown in Figure 2.
Functional annotation of the genes
A Gene Ontology (GO) term enrichment analysis was
performed to determine the functions, which are char-
acteristic for the genes filtered as differentially expressed
in response to GA therapy (n = 463). The GO terms are
classified into three major categories: biological process
(BP), cellular component (CC) and molecular function
(MF). In our analysis, we shortlisted the top 20 overrep-
resented GO terms according to the P-value (Table 2).
Several genes appeared under multiple GO terms.
The GO terms, which had the most gene members in
the list of filtered genes, were ‘extracellular region’
(GO:0005576, P-value = 2.27E-07) and ‘immune system
process’ (GO:0002376, P-value = 1.19E-04). The GO
term ‘extracellular region’ contains genes whose protein
products are secreted from cells, for example, cell com-
munication molecules, and it was associated to 76 of
the 463 genes. Out of them, 45 genes were up-regulated,
for example, POMC, MMP17, LTB, XCL1 and APOL3,
and 31 genes were down-regulated, for example, CD163,
ADAMTS5, TNFSF14, CTSZ and PAM. The GO term
‘immune system process’ contained 48 of the genes. Out
of them, 35 genes were up-regulated, for example, CD38,
CXCL9, CXCL10, IL18 and ICAM2, and 13 genes were
down regulated, for example, PTPRC, NCK2, C4BPA,
Figure 1 Longitudinal study design and gene filtering results. Blood was sampled from eight patients at five different time points: before
the start of GA treatment as well as after one day, one week, one month and two months. The expression of 18,862 genes was measured in
monocytes with Affymetrix microarrays, and transcript levels during therapy were compared to the pre-treatment levels. t-test P-values and
MAID-scores were used to determine differentially expressed genes. For instance, when comparing the baseline levels with the expression levels
after one day, 438 genes survived the MAID analysis criterion (|MAID-score| > 2) and 1,124 genes survived the paired t-test criterion (P-value < 0.05). In
combination, this resulted in 171 filtered genes: 101 were up-regulated (red arrow) and 70 were down-regulated (green arrow). For each time point
comparison, a similar number of genes were filtered. However, the overlap of these four gene lists was relatively small (n = 45). When taken together,
463 different genes were identified to be differentially expressed within the first two months of GA therapy.
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GLMN and ITGAV. There were 22 genes that belonged to
both of these GO terms.
There were several overrepresented GO terms, which
are relevant to monocytes, for instance ‘mononuclear cell
proliferation’ (GO:0032943, P-value = 5.76E-04), ‘regu-
lation of mononuclear cell proliferation’ (GO:0032944,
P-value = 5.44E-04) and ‘leukocyte proliferation’ (GO:00
70661, P-value = 6.92E-04). These GO terms form a
hierarchy where a GO term is part of a broader GO
term, hence these GO terms share most of the genes.
Genes found modulated in expression during GA treatment
and belonging to all of these three terms are, for example,
CD38, GLMN, IGHM, IL18, NCK2 and PTPRC. Other
notable overrepresented GO terms were ‘regulation of
lymphocyte activation’ and ‘cytokine activity’.
Gene interaction network
The unified list of 463 genes was used as input for the
Pathway Studio software to gather pair-wise interactions
between them. The output resulted in 41 genes (= nodes)
with 59 interactions (= edges). The interactions were
visualized as a network (Figure 3). The edges vary
according to their interaction type. There were 43 positive
regulatory interactions, 14 inhibitory interactions and 2
binding interactions. The network revealed different
interaction clusters. Seven of the genes, CXCL10, CXCL9,
VCAM1, POMC, OXT, PTPRC and CD38, possess the
majority of the interactions with the other genes in the
network: except PTPRC, they all appeared as up-regulated
during GA therapy.
POMC, a polypeptide hormone precursor, had 12
interactions and is therefore the most connected gene
in the network. For instance, VCAM1, OXT, IL18 and
ADCY6 (which were up-regulated) and IGFBP1 (which
was down-regulated) are influenced by POMC according
to the literature-based interaction network. The second
cluster is based on VCAM1, a vascular cell adhesion
protein, which had 11 interactions. It is regulated by
IL18, POMC, ITGAV, CYP2C19, CXCL10, CXCL9,
TRAF2, NOTCH4 and TIE1. Of these, ITGAV was
down-regulated and all the other genes were up-regulated
in response to GA treatment. The third cluster is formed
by OXT, which regulates CD38, SLA5A5, GHRH and
POMC. The fourth cluster is based on two up-regulated
chemokines, CXCL9 and CXCL10, which together had 14
interactions. They have a feedback loop between them,
and CXCL10 is further regulated by IL18, IL27 and XCL1,
which were all up-regulated after the first week of GA
therapy. The network also shows that PTPRC (= CD45) is
linked with PTPRCAP, CD34, CD38, IL21 and VCAM1.
Figure 2 Dynamics of 23 genes consistently modulated in expression during glatiramer acetate (GA) therapy. A subset of the 463 filtered
genes appeared repeatedly as differentially expressed in consecutive time point comparisons. The graph shows the mean mRNA expression
dynamics of 23 genes that were repeatedly found expressed at significantly higher or lower levels across at least two different time points
compared to the pre-treatment levels. There were 18 up-regulated genes and 5 down-regulated genes (CD34, RPA4, HMGB1L4, RARS and BAZ2B).
The MAID-score, a fold-change variant that is calculated from the data of all patients, is represented on the y-axis and the time points are
represented on the x-axis.
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CD38 had six interactions: CD38 inhibits CD34, is reg-
ulated by IL21, and has feedback loops with OXT and
PTPRC (Figure 3).
Discussion
This study focused on the in vivo effects of GA therapy
on the gene expression of monocytes, which are the
precursors of macrophages and dendritic cells. The
monocytes were obtained from the blood of RRMS
patients and we compared the transcript levels before
and after the start of GA therapy. For each patient, the
gene expression was measured at five time points up to
two months into therapy. In these data, we identified
463 genes as up-regulated or down-regulated during
therapy compared to pre-treatment levels. More than a
hundred genes were filtered at early (after one day) and
later (after two months) time points post treatment ini-
tiation. However, relatively few genes were repeatedly
found to be differentially expressed in the course of
time. This indicated that the gene regulatory effects of
GA on monocytes are rather modest and no stable gene
expression signature could be seen. Nevertheless, the
mRNA changes of some genes might tell us something
about GA’s molecular mechanisms of action.
Compared to our study, in the gene expression study
by Achiron et al., only two time points were compared:
before and after three months of GA treatment [52].
Therefore, the variability in the mRNA dynamics early
during therapy possibly has been underestimated so far.
Moreover, Achiron et al. studied the gene expression
changes in PBMC of RRMS patients, whereas we studied
monocytes. Using Affymetrix microarrays, they found
480 genes to be differentially expressed in response to
GA administration, with the main effects being related
to antigen-activated apoptosis, inflammation, adhesion,
and MHC class I antigen presentation [52]. As in our
study, there were more up-regulated than down-regulated
genes. However, when comparing their gene list (n = 480)
with ours (n = 463), only five genes (BAT1, ELOVL5,
ETV7, MT1E and PCBD1) were in common. One explan-
ation for that might be that GA possibly acts primarily on
other subsets of circulating cells, for example, by altering
the functional properties of (autoreactive) T-cells. There-
fore, different gene regulatory effects might be seen in
PBMC than in monocytes from GA-treated patients.
On the other hand, a recent cross-sectional study by
Ottoboni et al. found no significant differences in the
PBMC RNA profiles of untreated and GA-treated patients
Table 2 Analysis of gene functions
Term GO accession ExpCount Count Odds ratio P-value
Extracellular region GO:0005576 (CC) 42 76 2.06 2.27E-07
Cytokine activity GO:0005125 (MF) 4 15 4.18 1.12E-05
Receptor binding GO:0005102 (MF) 21 41 2.19 1.85E-05
Extracellular region part GO:0044421 (CC) 22 42 2.06 5.17E-05
Immune response GO:0006955 (BP) 17 35 2.19 6.74E-05
Extracellular space GO:0005615 (CC) 17 34 2.17 9.00E-05
Immune system process GO:0002376 (BP) 28 48 1.90 1.19E-04
Regulation of lymphocyte activation GO:0051249 (BP) 5 14 3.30 2.19E-04
Defense response GO:0006952 (BP) 18 33 2.01 4.38E-04
Regulation of lymphocyte proliferation GO:0050670 (BP) 2 9 4.27 5.07E-04
Lymphocyte proliferation GO:0046651 (BP) 3 10 3.89 5.08E-04
T-cell proliferation GO:0042098 (BP) 2 8 4.75 5.37E-04
Regulation of mononuclear cell proliferation GO:0032944 (BP) 2 9 4.23 5.44E-04
Cytokine receptor binding GO:0005126 (MF) 4 12 3.33 5.48E-04
Mononuclear cell proliferation GO:0032943 (BP) 3 10 3.82 5.76E-04
Regulation of leukocyte activation GO:0002694 (BP) 5 14 2.97 5.90E-04
Regulation of leukocyte proliferation GO:0070663 (BP) 2 9 4.14 6.26E-04
Leukocyte proliferation GO:0070661 (BP) 3 10 3.72 6.92E-04
Regulation of cell activation GO:0050865 (BP) 5 14 2.82 9.40E-04
Regulation of T-cell proliferation GO:0042129 (BP) 2 7 4.93 9.56E-04
The top 20 Gene Ontology (GO) terms that were significantly overrepresented for the list of filtered genes (n = 463 genes) are shown in the table sorted by
P-value. For example, in the second row, ‘cytokine activity’ is listed as an overrepresented GO term. ‘GO:0005125’ is the corresponding GO database accession.
The third and fourth column give the expected number (‘ExpCount’, 4 genes) and the actual number (‘Count’, 15 genes) of genes in the filtering result that are
associated with ‘cytokine activity’. This led to an odds ratio of 4.18 and a P-value of 1.12E-05. The GO terms are classified into three major groups: biological
process (BP), cellular component (CC) and molecular function (MF).
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[60]. In their study, they took into account the multiple
testing by computing false discovery rates (FDR) [61].
In our data set, if we set the threshold for statistical
significance at FDR < 0.05, also no gene remained as
differentially expressed during GA therapy. Instead, we
chose less conservative filtering criteria to detect even
moderate shifts in the gene expression of monocytes,
but, in consequence, also some weakly modulated and less
expressed genes survived the filtering for GA-responsive
genes (Additional file 2: Table S1). A subset of 23 genes
was repeatedly identified to be up-regulated or down-
regulated at different time points during therapy (Figure 2).
These 23 genes might represent good candidates of
molecular markers of GA activity. However, for con-
firmation, a larger independent study with more sensitive
measurement techniques such as real-time PCR is needed.
As another limitation of our study, we did not measure
the transcript levels in the long-term after the first two
months of treatment. Possibly, the full modulation of
immunological processes by GA may require more
time. It was also beyond the scope of the present study
to examine whether the individual gene expression profiles
are associated with the clinical data (for example, relapse
rate, EDSS and MRI).
We performed a GO term enrichment analysis for
the list of 463 filtered genes to classify them according
to their functions and the biological processes they are
involved in (Table 2). Overrepresented GO terms included
‘lymphocyte proliferation’ and ‘regulation of T-cell prolif-
eration’. These findings are consistent with earlier studies
that showed that GA suppresses lymphocyte proliferation
through modulation of monocytes and monocyte-derived
dendritic cells, thereby reducing the number of autoreactive
T-cells [38,62,63]. Members of these GO terms are, for
example, cytokines such as IL18 and TNFSF14. Addition-
ally, we searched for interactions between the genes and
retrieved 59 interactions. Of note, these interactions were
obtained by literature mining. Therefore, the gene network
(Figure 3) shows direct as well as indirect regulatory
effects on the transcript and protein level. Seven genes
had several interactions (CXCL9, CXCL10, VCAM1,
POMC, OXT, PTPRC and CD38).
Figure 3 Interaction network of genes differentially expressed in response to glatiramer acetate (GA). A gene interaction network was
retrieved for the 463 filtered genes using the Pathway Studio software. The software delivered a network of 41 genes (= nodes) with 59
interactions (= edges) between them. The other genes with no interaction are not shown in the figure. Edges are represented in different ways
in the network. An arrow (→) means positive effect (n = 43), a ‘T’ (┤) means negative effect (inhibition, n = 14) and a line (─) means binding
(n = 2). The seven nodes, which are highlighted in dark green, are involved in the regulation of many other genes and thus may play an
important role in the molecular mechanisms of action of GA. The network is available as a Cytoscape session file from the authors upon request.
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The network contained different cytokines, for example,
CXCL9 and CXCL10 whose expression was increased one
day after the start of GA therapy. These two chemokines
bind to the CXCR3 receptor and are involved in the
recruitment of immune cells to sites of inflammation,
principally acting on activated CD4+ Th1 cells, CD8+
T-cells and natural killer (NK) cells [64,65]. A previous
study already showed that the transcription of CXCL10
is induced in PBMC after GA administration [66]. Both
CXCL9 and CXCL10 were also described to be modulated
in expression in blood during treatment with IFN-β
[67]. Therefore, both drugs seem to affect the chemokine
gradient between brain lesions and the peripheral immune
compartment. The cytokine group further included in-
terleukins (IL18, IL21, IL25 and IL27), which were all
found to be up-regulated in our data set. Of those, IL18
and IL27 play important roles in the differentiation and
expansion of naive CD4+ T-cells [68,69]. Moreover,
TNFSF14, a member of the TNF cytokine family, was
down-regulated one day after the first GA injection.
TNFSF14 is known to function as a costimulatory factor
regulating the activation of T-cells [70]. A single nucleo-
tide polymorphism within an intron of the TNFSF14
gene is associated with MS susceptibility [71,72]. Another
related member of the TNF family, LTB (lymphotoxin-β),
was also filtered as differentially expressed. Both LTB
and TNFSF14 bind to the LTBR receptor, and they provide
communication links in innate and adaptive immune
responses [73,74]. However, the transcriptional modula-
tion of these cytokines was not stable over time and it thus
remains unclear how these immunoregulatory effects may
exactly contribute to the mechanisms of action of GA.
The interaction network of filtered genes also contains
several cell adhesion receptors, for example, ITGAV,
ICAM2 and VCAM1. ITGAV encodes the integrin αV,
an integral membrane protein that can interact with a
variety of extracellular matrix ligands. Integrins orches-
trate monocyte differentiation into macrophages, and
they play a role in macrophage adhesion, migration and
tissue infiltration [75]. Moreover, ITGAV is known to
mediate proinflammatory cytokine synthesis in human
monocytes [76]. It was expressed at lower levels after
the first injection of GA, which may reflect the previously
described shift in the gene expression of monocytes
towards an anti-inflammatory profile [34,39].
Other genes in the network are implicated in quite
different biological processes, for example, RARS, WARS,
PTPRC, PTPRCAP and MIRN21. RARS and WARS
encode the arginyl- and tryptophanyl-tRNA synthetase,
respectively. They catalyze the amino acid attachment
to cognate tRNAs during protein synthesis. However,
besides their role in protein translation, biologically
active fragments of WARS were also discovered to be
involved in angiogenesis signaling pathways [77]. PTPRC is
a transmembrane glycoprotein associated with PTPRCAP.
Both genes were found modulated in expression after
one month of treatment compared to baseline. PTPRC
functions as a regulator of cytokine receptor signaling
and influences cellular processes such as cell proliferation
[78]. Upon activation of monocytes, proteolytic processing
of PTPRC results in a protein fragment, which is released
and acts as an inhibitor of T-cell proliferation [79]. The
microRNA gene MIRN21 was expressed at higher levels
after two months compared to pre-treatment levels.
MicroRNAs are involved in the post-transcriptional
regulation of gene expression. The transcript MIRN21
harbors the mature microRNA hsa-miR-21, which has
been shown to be up-regulated in active MS lesions
[80] and to be higher expressed in PBMC of RRMS
patients versus controls [81]. MicroRNAs in MS and
therapy are worthy of being explored in more detail
[82,83]. So far, there is only one study that has specifically
investigated whether GA therapy affects the levels of
mature microRNAs, but this study was limited to five
selected microRNAs [84].
Other studies demonstrated that GA treatment leads
to a change in the properties of monocytes from pro-
inflammatory type I monocytes to anti-inflammatory type
II monocytes [34]. However, although some cytokines
were differentially expressed during GA therapy, the
mRNA levels of TNF-α, TGF-β, IL10, IL12, IL1-β and
IL1RA were not affected in our data set. Therefore, we
could not observe a clear cytokine shift in monocytes
in response to GA. One reason for that might be that
in our study monocytes were isolated from peripheral
blood samples of MS patients, whereas, in contrast, in
the study by Weber et al. the monocytes were separated
from the spleen of mice with EAE [34]. Moreover, our
study was restricted to mRNA transcripts and we did not
measure the amounts of the encoded proteins and their
splice variants, whereas other groups analyzed the protein
levels of monocytes in culture after in vitro stimulation
[35,36,38]. Burger et al. studied the effects of GA on the
transcription of two genes (IL1-β and IL1RA) in mono-
cytes [39,40]. However, their results might not be reflected
in our data since they used monocytes from blood donors
and stimulated these cells in vitro with GA. In our study,
we could neither identify a stable signature of differentially
expressed genes nor a solid evidence of an increase of type
II monocytes within the first two months of therapy. This
finding cannot be explained by just the relatively small
number of recruited patients. Therefore, we conclude that
the in vivo effects of GA on monocytes in the peripheral
blood are rather modest and variable. It is likely that most
of the effects occur at the injection sites or in the draining
lymph nodes where (MBP-specific) T-cells as well as
monocytes and professional APC are confronted with GA
peptides. Additionally, since GA is a mixture of randomly
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synthesized peptides, the molecular effects might be
somewhat different from injection to injection. All this
makes it quite a challenge to study the drug’s molecular
mechanisms of action. Further studies are needed to
better understand how GA modulates the immune system,
also because new drugs similar to GA are currently tested
for RRMS (for example, ATX-MS-1467, Apitope Technol-
ogy Ltd., Bristol, UK).
Conclusions
There is a lack of transcriptome studies on the effects of
GA in MS patients. Here, we presented the first genome-
wide and cell type-specific analysis of the mRNA dynamics
during GA therapy. Using microarrays, we longitudinally
measured the gene expression of monocytes for a small
patient group at five different time points. We identified
463 genes as differentially expressed within the first two
months of GA treatment, the majority being associated
with immunological processes (for example, cytokines).
However, the changes in gene expression were not
sustained over time, and most genes were seen up-
regulated or down-regulated only once. Therefore, GA
seems to have only little gene regulatory effects on
monocytes. Our study nevertheless delivered some genes
that are worth investigating in future studies regarding the
molecular mechanisms of GA therapy in the peripheral
blood of MS patients.
Additional files
Additional file 1: Figure S1. Analysis of the purity of the isolated
monocytes. (A) We visualized the measured transcript levels of five
selected genes, which are specifically expressed in different blood cell
types, namely CD14 (monocytes), CD3D (T-cells), MS4A1 (for example,
B-cells), KLRD1 (for example, NK cells) and HBD (erythrocytes). CD14 was
expressed at very high levels (> 18,000) in all 37 samples of the
microarray data set, whereas the other genes were expressed at very low
levels (< 400). This demonstrates high purity of the monocytes isolated
by MACS. (B) We used the Affymetrix microarray data by Novershtern
et al. [59] to compare the mRNA levels of these genes in distinct human
hematopoietic cell populations, for example, CD4+ and CD8+ T-cells,
B-cells and monocytes. The preprocessed data were downloaded from
the GEO database (accession number ‘GSE24759’). The bar charts show
the mean ± standard error of the expression values of the respective
probe sets (given in brackets) in 14 different cell types. A limited purity of
the isolated monocytes would be noticeable in figure A, because CD3D,
MS4A1, KLRD1 and HBD are highly expressed in other cells of the blood.
Additional file 2: Table S1. Filtered differentially expressed genes.
This Excel file contains four gene lists, which provide the genes that
were identified as differentially expressed after one day (t1), one week
(t2), one month (t3) or two months (t4) of GA therapy when compared
to baseline levels (t0). For each gene, identifiers for the databases
GeneCards, Entrez and HGNC (gene symbols) are provided together with
their official full names. Additionally, the mean gene expression levels
(averaged over the patients) and the respective standard deviations (SD)
are given for all compared time points as well as the computed t-test
P-values and MAID-scores. The column ‘Regulation’ denotes, if the gene
was found up-regulated or down-regulated in response to GA relative
to baseline.
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Abstract: MicroRNAs (miRNAs) are small non-coding RNA molecules acting as  
post-transcriptional regulators of gene expression. They are involved in many biological 
processes, and their dysregulation is implicated in various diseases, including multiple 
sclerosis (MS). Interferon-beta (IFN-beta) is widely used as a first-line immunomodulatory 
treatment of MS patients. Here, we present the first longitudinal study on the miRNA 
expression changes in response to IFN-beta therapy. Peripheral blood mononuclear cells 
(PBMC) were obtained before treatment initiation as well as after two days, four days, and 
one month, from patients with clinically isolated syndrome (CIS) and patients with 
relapsing-remitting MS (RRMS). We measured the expression of 651 mature miRNAs and 
about 19,000 mRNAs in parallel using real-time PCR arrays and Affymetrix microarrays. 
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We observed that the up-regulation of IFN-beta-responsive genes is accompanied by a 
down-regulation of several miRNAs, including members of the mir-29 family. These 
differentially expressed miRNAs were found to be associated with apoptotic processes and 
IFN feedback loops. A network of miRNA-mRNA target interactions was constructed by 
integrating the information from different databases. Our results suggest that miRNA-mediated 
regulation plays an important role in the mechanisms of action of IFN-beta, not only in the 
treatment of MS but also in normal immune responses. miRNA expression levels in the 
blood may serve as a biomarker of the biological effects of IFN-beta therapy that may 
predict individual disease activity and progression. 
Keywords: interferon-beta; multiple sclerosis; peripheral blood; microRNA; gene expression 
 
1. Introduction 
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), which is 
characterized by multiple discrete areas of inflammatory demyelination, axonal degeneration, and glial 
scarring. The resulting loss of neurons and axons leads to diverse neurological symptoms, progressive 
disability, and a significant decrease in quality of life. The disease usually begins in early adulthood, 
and is more common in females. Different types of MS are distinguished: In about 85% of patients, the 
disease starts with a single demyelinating episode (clinically isolated syndrome, CIS) and progresses to 
a relapsing-remitting course (RRMS) with acute exacerbations and periods of remission [1–4]. 
A number of disease-modifying therapies for MS are available, and they are especially effective 
when applied in the early stages of the disease [4,5]. Injections of recombinant interferon-beta  
(IFN-beta) are considered a first-line option in the treatment of RRMS. IFN-beta has been shown to 
reduce the number of relapses and to suppress the accumulation of new inflammatory lesions in the 
brain. Three different preparations of IFN-beta are in clinical use. They differ in dose, route, and 
frequency of IFN-beta administration, but they are comparable regarding clinical efficacy [6]. 
IFN-beta has broad effects on the gene regulation of blood cells [7–11]. This has been shown by 
several studies that used microarray technology to analyze the gene expression dynamics in the 
peripheral blood of MS patients in response to IFN-beta therapy. In this way, more than a hundred 
genes have consistently been found differentially expressed during treatment [10]. The transcript levels 
of most of these genes are up-regulated within a few hours after IFN-beta injection, and they return to 
pre-treatment levels after a few days [12,13]. These IFN-beta-responsive genes are believed to  
mediate the beneficial effects of the treatment through immunomodulatory, antiproliferative, and 
antipathogenic processes [7–9]. 
While the therapeutic effects on the regulation of mRNAs have been extensively investigated, 
studies on the regulation of microRNAs (miRNAs) are lacking. miRNAs are a distinct class of small 
(~22 nt) non-coding RNA molecules [14]. They originate from precursor RNAs (pre-miRNAs) found 
in longer primary transcripts (pri-miRNAs), which often also contain the exons of an mRNA. Mature 
miRNAs act as post-transcriptional regulators. They repress gene expression via base-pairing with 
complementary sequences within the 3' untranslated regions (UTRs) of target mRNAs. This interaction 
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results in gene silencing by translational repression or target degradation. A miRNA can have hundreds 
of different mRNA targets, and a target might be regulated by a combination of multiple miRNAs [15]. 
The human genome encodes over 1000 miRNAs [16,17]. miRNAs are thus likely involved in most 
biological processes, and they play essential roles in the immune system and in the correct function of 
the CNS [18,19]. 
Dysregulated expression of miRNAs is associated with pathological conditions, including 
neurological diseases. Human MS studies showed altered miRNA expression in peripheral blood 
samples, lymphocyte subpopulations, and active CNS lesions from MS patients [20–22]. Studies with 
the animal model of MS, experimental autoimmune encephalomyelitis (EAE), also support the 
involvement of miRNAs in this disease [23,24]. These findings provided important insights into the 
pathophysiology of MS and opened a new avenue in biomarker research. If miRNA levels in the blood 
or brain of MS patients correlate with disease stage and progression of disability, they may also 
support early diagnosis and effective treatment in future [25]. 
In order to better understand the molecular mechanisms of action of IFN-beta therapy, it is 
important to investigate the miRNA expression dynamics during therapy. The regulation of miRNAs 
may contribute to the immunomodulatory and clinical effects of the treatment. Moreover, miRNAs 
might be markers for characterizing the biological response to IFN-beta. miRNA biomarkers for 
treatment monitoring could be useful in the individual management of disease activity. However, so 
far, there is only one study on the expression of miRNAs in MS patients during IFN-beta therapy: 
Waschbisch et al. obtained peripheral blood mononuclear cells (PBMC) from patients with RRMS, 
and analyzed the expression of five selected miRNAs by real-time PCR [26]. They compared the 
miRNA levels between treatment-naive patients (n = 36), IFN-beta-treated patients (n = 18), and 
patients treated with glatiramer acetate (GA, n = 20). As a result, none of the five miRNAs was 
differentially expressed in IFN-beta-treated patients, but hsa-miR-146a-5p and hsa-miR-142-3p were 
expressed at significantly lower levels in GA-treated patients [26]. Other researchers used microarrays 
to study the expression of hundreds of miRNAs in IFN-stimulated cells. In this way, O’Connell et al. 
observed that hsa-miR-155-5p is induced in primary murine macrophages after exposure to IFN-beta 
for 6 h [27]. Pedersen et al. studied the regulation of miRNAs in Huh7 cells and primary hepatocytes, 
which were stimulated with different concentrations of IFN-beta for up to 48 h [28]. They observed 
increased and reduced miRNA expression in response to IFN-beta, and showed that some of the  
IFN-beta-induced miRNAs mediate antiviral effects against hepatitis C virus. This provides an 
example of miRNAs as components of the innate immune response. 
In this study, we used microarrays to investigate in parallel the expression dynamics of mRNAs and 
miRNAs in PBMC of patients with CIS or RRMS in response to therapy with subcutaneous (sc.)  
IFN-beta. The blood samples were obtained longitudinally from six patients at four time points in the 
early phase of therapy, namely before the first (baseline), second, and third IFN-beta injection as well 
as after one month of treatment. We then screened for significant changes in miRNA and mRNA 
expression, and identified several miRNAs as differentially expressed during therapy. Information of 
different databases was then integrated [22,29] to examine whether the expression of these miRNAs is 
cell type-specific and correlates with the levels of their target mRNAs. Predicted and experimentally 
verified miRNA-mRNA interactions were compiled to construct a network of IFN-beta-responsive 
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genes and miRNAs. To our knowledge, this is the first genome-wide miRNA profiling study on the  
in vivo effects of IFN-beta treatment in MS. 
2. Results and Discussion 
2.1. Study Population 
Six female patients of Western European descent, and diagnosed with CIS (n = 2) or RRMS  
(n = 4), were recruited for this study (Pat1-6, mean age 37.5 years, Table 1). The patients were 
treatment-naive and started an immunomodulatory therapy with IFN-beta-1b (Betaferon, Bayer 
HealthCare) administered subcutaneously every other day. In the first weeks, the Betaferon titration 
pack was used, hence the patients started with a low dose (62.5 µg for the first three injections) that 
was gradually increased to the full dose (250 µg) after three weeks. All patients were continuously 
treated with IFN-beta-1b for at least one year. During follow-up, they were monitored for relapses and 
rated using the Expanded Disability Status Scale (EDSS). The individual disease activity during 
therapy was relatively low: Four of the patients (Pat1-4) were relapse-free and showed no disability 
progression within the first year of treatment (Table 1). The two patients with CIS (Pat1 and Pat5) did 
not convert to clinically definite MS in this period of time. 
Table 1. Clinical data and demographic data of the patients. 
Patient Type Age Disease duration EDSS (baseline) EDSS (1 year) Relapses (1 year) 
Pat1 CIS 28 1 1.0 1.0 0 
Pat2 RRMS 38 2 1.5 1.5 0 
Pat3 RRMS 22 1 1.5 1.0 0 
Pat4 RRMS 50 12 2.5 2.5 0 
Pat5 CIS 60 2 1.5 2.5 0 
Pat6 RRMS 27 2 2.0 1.0 2 
Six female patients were recruited for the main cohort of this study. They were diagnosed with  
relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) suggestive of MS. The age at study 
onset (in years) and the duration from the diagnosis to the start of IFN-beta-1b sc. therapy (in months) are 
shown. Additionally, the EDSS scores before treatment initiation (baseline) and after one year, as well as the 
number of relapses during the first year of clinical follow-up are given in the table. 
Note that the patient group included only women. A differential hormonal regulation of immune 
system genes in blood cells has been described for different phases of the menstrual cycle [30]. Such 
differences in gene expression may have led to increased variance in the data. However, prior mRNA 
profiling studies observed no significant gender-specific differences in the gene expression signature in 
response to IFN-beta therapy [8,31], and this seems to be the case regarding the expression of miRNAs 
as well (see Section 2.5). 
2.2. Parallel Measurement of mRNAs and MicroRNAs in Blood Cells 
Patient blood samples were drawn immediately before first IFN-beta injection as well as two days, 
four days, and one month post therapy initiation. Total RNA of Ficoll-isolated PBMC from each 
sample was extracted to measure the levels of mRNAs and miRNAs with different platforms. We used 
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TaqMan Array Human MicroRNA cards (Applied Biosystems, Foster City, CA, USA) to quantify the 
expression of 651 mature miRNAs and Affymetrix HG-U133 Plus 2.0 microarrays (Affymetrix, Santa 
Clara, CA, USA) to quantify the expression of about 19,000 mRNAs. In this way, we obtained in 
parallel the mRNA and miRNA expression profiles from six patients (Pat1-6) within the first month of 
IFN-beta treatment. 
The data were preprocessed as described in Section 3.6. Relatively low variation in the 
transcriptome profiles indicated high data quality, comparable to our previous microarray time course 
data sets [8,31,32]. In the miRNA data, systematic and stochastic variation was higher. For the 
TaqMan miRNA B-cards of Pat5, the raw threshold cycle (Ct) values were generally higher 
(Supplementary File 1) due to an unknown measurement bias. In the PBMC samples of the other  
five patients, approximately 400 miRNAs could be detected (Ct < 38) with the TaqMan miRNA arrays 
(Table 2). The raw TaqMan data were transformed to the linear scale, and coefficients of variation 
(CV) were calculated to assess the effects of data normalization. The normalization decreased the 
average CV over all 768 measured assays from 0.953 to 0.894. The CV for the housekeeping miRNA 
hsa-miR-191-5p [33] was 0.183. In comparison, assays for the non-coding RNAs U6, U44 and U48 
had CVs of >0.35. The CV for the housekeeping mRNA GAPDH was 0.071. 
Table 2. Numbers of microRNAs detected in the samples with the TaqMan cards set. 
Patient Baseline ~48 h ~96 h 1 month 
Pat1 380 374 364 373 
Pat2 375 407 392 362 
Pat3 427 400 408 407 
Pat4 390 387 388 389 
Pat5 285 258 266 262 
Pat6 431 451 446 391 
Approximately 400 miRNAs were found to be expressed (raw Ct value < 38) per sample. The numbers are 
lower for the PBMC samples of patient Pat5, where generally lower miRNA amounts were measured with 
the B-cards for all four time points (Supplementary File 1). 
2.3. Analysis of mRNA Expression Dynamics 
We filtered for mRNAs showing strong expression changes in response to IFN-beta therapy by 
comparing the baseline expression levels with the expression levels at the three time points during 
treatment. The MAID filtering method [34] was used to analyze the mRNA dynamics. As a result, 14, 
34, and 66 genes were found to be expressed at higher or lower levels after two days, four days, and 
one month, respectively. In total, 95 genes were identified as up-regulated (n = 75) or down-regulated 
(n = 20) in the early course of the therapy (Supplementary File 2). The gene expression changes in the 
first month of subcutaneous IFN-beta-1b treatment are visualized in the heat map in Figure 1. 
A permutation test (see Section 3.7) revealed that the number of 95 differentially expressed genes is 
significantly higher than would be expected by chance. In randomly permuted data sets, 29.6 genes on 
average were filtered. The number of filtered genes was below 95 in 98.8% of the permutations, which 
implies an empirical p-value of <0.05, demonstrating that most of the mRNA expression changes that 
we found are indeed due to the therapy. 
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Figure 1. Heat map visualization of the mRNA expression changes in response to  
IFN-beta. Shown are the baseline and one month transcript levels of the 95 genes that were 
identified as differentially expressed during IFN-beta therapy. The patient samples are 
represented in the columns, the genes are represented in the rows, and the gene expression 
levels were centered and scaled in row direction (z-scores). The clustering analysis clearly 
separated the PBMC samples obtained at baseline and after one month of therapy. The row 
labels of the heat map (i.e., the respective genes) are given in Supplementary File 2. The 
upper half of the heat map contains most of the IFN-beta-induced genes. 
 
Despite the relatively small patient cohort (n = 6), the mRNA results were quite consistent with the 
literature. In another study, we already analyzed the PBMC gene expression profiles of a larger group 
of MS patients (n = 25) treated with IFN-beta-1b sc. [31]. In total, 63 of the 95 differentially expressed 
genes were also filtered in the previous study. Recently, we completed a similar microarray study on 
the effects of IFN-beta-1a sc. [8], in which 49 of the 95 genes were already identified as 
transcriptionally modulated (Supplementary File 2). Moreover, more up-regulated than down-regulated 
genes were filtered, which also confirms previous findings [10]. After the first IFN-beta injections, 
fewer genes were altered in expression than after one month (cf. Goertsches et al., 2010 [31]). This can 
be explained by the fact that the patients started the first week of the therapy with a quarter of the full 
dose (Betaferon titration pack). Most of the filtered genes are part of an up-regulated type I IFN 
signature. For instance, IFI6, IFI44L, and SIGLEC1 are known type I IFN-induced genes, which were 
up-regulated at all time points during therapy in comparison to baseline. In contrast, FCER1A was 
consistently down-regulated in response to therapy as has been described previously as well [8,31,32]. 
Regarding the functions of these genes, the reader is referred to the literature [7-9]. 
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2.4. Analysis of MicroRNA Expression Dynamics 
As for the mRNA data, the MAID filtering method [34] was used to identify miRNAs that are 
differentially expressed in PBMC within the first month of IFN-beta treatment. When we compared the 
expression levels at the three time points during therapy with the expression levels at baseline,  
20 different miRNAs were filtered. Of these, seven miRNAs appeared as up-regulated and 13 miRNAs 
appeared as down-regulated in response to the therapy (Figure 2, Table 3 and Supplementary File 3). 
According to the permutation test, this is significantly more than expected by chance: In only 0.6% of 
the randomly permuted data sets, 20 (or more) miRNAs were filtered, and only 7.7 miRNAs were 
filtered on average. 
Figure 2. Summary of the filtering of IFN-beta-responsive mRNAs and microRNAs. 
PBMC expression levels during therapy were compared to pre-treatment levels. The 
number (#) of differentially expressed mRNAs and miRNAs is depicted in the tables and 
bar plots. The row “Total” gives the union set over all three time point comparisons.  
(A) In the mRNA data, 95 genes were found to be modulated in expression in response to 
IFN-beta-1b treatment. As expected, most of them were up-regulated (n = 75) and known 
type I IFN-induced genes, and the strongest changes were observed at one month versus 
baseline; (B) In the miRNA data, the filtering method identified more down-regulated than 
up-regulated miRNAs during therapy, again with the strongest effects seen after one month. 
 
Two of the 20 miRNAs (hsa-miR-149-5p and hsa-miR-708-5p) were filtered at two different time 
points. For the remaining miRNAs, the expression changes were not very stable in the course of 
therapy. This may be due to the small number of patients and the fact that the accuracy of miRNA 
measurements is in general limited. Therefore, our list of 20 miRNAs represents candidates that have 
to be validated in a larger patient cohort using, e.g., single real-time PCR assays. 
Most of the miRNAs (n = 14) were filtered as up-regulated or down-regulated one month after  
IFN-beta-1b sc. treatment initiation. This corresponds to the results of the gene expression profiling, 
where the strongest changes in mRNA levels were also observed after one month (Figure 2). Previous 
studies demonstrated that the majority of IFN-beta-responsive genes can be seen at this time  
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point [8,31]. Therefore, we hypothesize that, similarly, the number of miRNAs that are modulated in 
expression is not much higher after long-term treatment. Instead, the development of neutralizing 
antibodies (NAb) to IFN-beta might impair the biological response to the drug in some patients [35]. 
However, further studies are needed to investigate the long-term regulation of miRNAs and the 
potential effects of NAb. 
Table 3. Details of microRNAs differentially expressed during IFN-beta therapy. 
Mature miRNA Sequence Expression 
change 
Family pre-miRNA pri-miRNA Location 
hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU up-regulated let-7 MIRLET7A1  chr9 (q22.32) 
MIRLET7A2 MIR100HG chr11 (q24.1) 
MIRLET7A3 MIRLET7BHG chr22 (q13.31) 
hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU up-regulated let-7 MIRLET7B MIRLET7BHG chr22 (q13.31) 
hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG up-regulated mir-15 MIR16-1 DLEU2 chr13 (q14.2) 
MIR16-2 SMC4 chr3 (q25.33) 
hsa-miR-27a-5p AGGGCUUAGCUGCUUGUGAGCA down-regulated mir-27 MIR27A   chr19 (p13.13) 
hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA down-regulated mir-29 MIR29A   chr7 (q32.3) 
hsa-miR-29b-1-5p GCUGGUUUCAUAUGGUGGUUUAGA down-regulated mir-29 MIR29B1   chr7 (q32.3) 
hsa-miR-29c-3p UAGCACCAUUUGAAAUCGGUUA down-regulated mir-29 MIR29C   chr1 (q32.2) 
hsa-miR-95 UUCAACGGGUAUUUAUUGAGCA down-regulated mir-95 MIR95 ABLIM2 chr4 (p16.1) 
hsa-miR-149-5p UCUGGCUCCGUGUCUUCACUCCC down-regulated mir-149 MIR149 GPC1 chr2 (q37.3) 
hsa-miR-181c-3p AACCAUCGACCGUUGAGUGGAC down-regulated mir-181 MIR181C   chr19 (p13.13) 
hsa-miR-193a-3p AACUGGCCUACAAAGUCCCAGU down-regulated mir-193 MIR193A   chr17 (q11.2) 
hsa-miR-193a-5p UGGGUCUUUGCGGGCGAGAUGA down-regulated mir-193 MIR193A   chr17 (q11.2) 
hsa-miR-342-5p AGGGGUGCUAUCUGUGAUUGA up-regulated mir-342 MIR342 EVL chr14 (q32.2) 
hsa-miR-346 UGUCUGCCCGCAUGCCUGCCUCU up-regulated mir-346 MIR346 GRID1 chr10 (q23.2) 
hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU down-regulated mir-423 MIR423 NSRP1 chr17 (q11.2) 
hsa-miR-518b CAAAGCGCUCCCCUUUAGAGGU up-regulated mir-515 MIR518B   chr19 (q13.42) 
hsa-miR-532-5p CAUGCCUUGAGUGUAGGACCGU down-regulated mir-188 MIR532 CLCN5 chrX (p11.23) 
hsa-miR-708-5p AAGGAGCUUACAAUCUAGCUGGG down-regulated mir-708 MIR708 TENM4 chr11 (q14.1) 
hsa-miR-760 CGGCUCUGGGUCUGUGGGGA up-regulated mir-760 MIR760   chr1 (p22.1) 
hsa-miR-874 CUGCCCUGGCCCGAGGGACCGA down-regulated mir-874 MIR874 KLHL3 chr5 (q31.2) 
The table lists the 20 miRNAs found to be expressed at higher or lower levels in the PBMC of patients with CIS or MS in response to 
IFN-beta therapy. The base sequence, the gene regulatory effect of the treatment (“Expression change”), the miRNA family, the HGNC 
symbols of the precursor and primary miRNAs, as well as the genomic location are shown. Two of the mature miRNAs (hsa-let-7a-5p 
and hsa-miR-16-5p) are processed from more than one precursor miRNA. For 11 miRNAs the pri-miRNA transcript has been annotated. 
None of these pri-miRNAs appeared in the mRNA filtering result. Precursor miRNAs of hsa-let-7a-5p and hsa-let-7b-5p, and of  
hsa-miR-29a-3p and hsa-miR-29b-1-5p are clustered, i.e., they share their transcription locus. 
Apparently, there are more down-regulated than up-regulated miRNAs during therapy, which is the 
opposite of the mRNA results. This suggests that the induction of IFN-beta-responsive genes is 
paralleled by a preferential down-regulation of miRNAs, which is plausible given that miRNAs act as 
gene silencers. Therefore, we analyzed whether the miRNAs indeed participate in the regulation of the 
mRNA transcripts (see Section 2.7). 
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2.5. Validation of IFN-beta-Induced MicroRNA Expression Changes 
We used Affymetrix miRNA microarrays to replicate the miRNA measurements of the PBMC 
samples from three patients (Pat1-3) before the start of IFN-beta therapy as well as after one month 
(see Section 3.4). These microarrays had a lower measurement range than the TaqMan miRNA arrays, 
though the comparability of the data was acceptable (Spearman’s rho = 0.823). The statistical analysis 
of this additional data set is limited by the small number of patients. However, when we compared the 
mean miRNA expression levels before and one month after treatment initiation, 13 of the 20 filtered 
miRNAs showed the same trend of up-regulation or down-regulation (Supplementary File 3).  
At the significance threshold alpha = 0.10, four miRNAs (hsa-miR-29a-3p, hsa-miR-29c-3p,  
hsa-miR-193a-3p, and hsa-miR-532-5p) were confirmed to be down-regulated during treatment. 
For further validation, we selected five of the 20 filtered miRNAs to quantify their expression in 
PBMC of an independent cohort of 12 patients using TaqMan single-tube assays (Supplementary File 
4 and Supplementary File 5). These 12 patients (8 RRMS/4 CIS, 7 females/5 males, mean age  
36.2 years) also started a therapy with IFN-beta-1b sc. The PBMC were obtained again in a 
longitudinal manner before the first drug injection and after one month of treatment. In this data set, 
hsa-miR-29a-3p and hsa-miR-29c-3p could be confirmed as differentially expressed in response to 
IFN-beta therapy (t-test p-values < 0.001). hsa-miR-29c-3p was expressed at lower levels during 
therapy in comparison to pre-treatment levels in all 12 patients, hence independent of disease stage 
(CIS or RRMS), age, and gender (Figure 3). Additionally, hsa-miR-532-5p was confirmed to be  
down-regulated (p-value = 0.048). hsa-miR-16-5p and hsa-miR-149-5p showed the same trend of 
expression change as in the other data sets (TaqMan miRNA arrays and Affymetrix miRNA arrays), 
but this was not statistically significant (p-values > 0.10, Supplementary File 3). 
2.6. Functions of the MicroRNAs in the Context of Multiple Sclerosis 
The filtered miRNAs (Table 3) affect diverse cellular functions and pathways, and some of them 
have been implicated in MS. In our data set, hsa-let-7a-5p and hsa-let-7b-5p, which belong to the let-7 
family, were expressed at higher levels during therapy. Lehmann et al. showed that let-7 family 
members can activate TLR7 signaling in macrophages and microglia, thereby inducing 
neurodegeneration [36]. In CD4+ T cells, let-7 miRNAs reduce the expression of IL10, a cytokine with 
anti-inflammatory properties [37]. The up-regulation of hsa-let-7b-5p by IFN-beta has already been 
demonstrated in vitro in primary macrophages [38]. Interestingly, hsa-let-7b-5p is in turn capable of 
binding the endogenous IFN-beta transcript, forming a negative feedback loop for the regulation of 
IFN-beta protein [38]. Recently, Gandhi et al. found altered hsa-let-7a-5p levels in the blood plasma of 
patients with the secondary-progressive form of MS, but not of patients with RRMS [39]. 
The observed up-regulation of hsa-miR-16-5p in response to IFN-beta therapy may restore the 
aberrant expression of this miRNA in the disease. Two studies observed reduced levels of  
hsa-miR-16-5p in the blood of RRMS patients. One study compared the expression in PBMC and 
CD4+ T cells from untreated patients and healthy donors [40]. The other study showed that  
hsa-miR-16-5p is down-regulated in B cells as well [41]. 
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Figure 3. Down-regulation of hsa-miR-29c-3p in response to IFN-beta therapy. The  
hsa-miR-29c-3p expression dynamics within the first month of IFN-beta treatment are 
presented. (A) TaqMan miRNA cards revealed reduced levels of this miRNA in the PBMC 
of 6 patients (Pat1-6, the main cohort); (B) Affymetrix miRNA arrays were then used to 
replicate the measurement for three of these patients (Pat1-3); (C) Finally, the down-regulation 
of hsa-miR-29c-3p was confirmed in an independent group of 12 patients (the validation 
cohort) using TaqMan single-tube assays. The Affymetrix analysis was based on 
hybridization of miRNA molecules to probes (probe set “hsa-miR-29c_st”), whereas the 
TaqMan analyses were based on real-time PCR. The TaqMan data are in linear scale, and 
the Affymetrix data are in log2 scale due to a different data preprocessing. 
 
Three miRNAs of the mir-29 family were down-regulated one month after the start of therapy, and 
this was confirmed for two of them in an independent validation cohort of 12 patients (Figure 3).  
hsa-miR-29a-3p and hsa-miR-29c-3p were both expressed at relatively high levels (Supplementary File 3), 
and their mature sequences differ only in one base (Table 3). Therefore, it is likely that they play 
similar roles as post-transcriptional regulators. hsa-miR-29a-3p and hsa-miR-29b-1-5p belong to the 
same genomic cluster. Smith et al. demonstrated that IFN-gamma enhances the transcription of this 
miR-29ab1 cluster, which acts in a negative feedback loop by regulating TBET and IFN-gamma [42]. 
Additionally, they showed decreased hsa-miR-29b-3p levels upon T cell activation in MS patients. 
This suggests a dysregulation of the feedback loop, which may bias T helper type 1 cell differentiation 
and may contribute to chronic inflammation [42]. Other studies also provided evidence that the members 
of the mir-29 family control innate and adaptive immune responses by targeting IFN-gamma [43,44]. 
The therapeutic down-modulation of mir-29 miRNAs might be mediated by NF-kappaB. The 
activation of NF-kappaB signaling, via ligation of Toll-like receptors, was shown to inhibit miR-29ab1 
expression [45]. Functionally, mir-29 promotes apoptosis, whereas repression of mir-29 levels is 
protective [45]. hsa-miR-29a-3p has been further shown to regulate myelin gene expression by 
Schwann cells [46]. 
hsa-miR-181c-3p was filtered as down-regulated during IFN-beta therapy. Several studies described 
the other strand of its pre-miRNA to be dysregulated in MS. Lower levels of hsa-miR-181c-5p were 
measured in PBMC [47] and in MS lesions [48] of patients in comparison to controls. On the other 
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hand, hsa-miR-181c-5p seems to be overabundant in the cerebrospinal fluid of patients with MS [49]. 
However, the biological processes that are influenced by the hsa-mir-181c miRNAs and their role in 
MS therapy remain largely unknown. 
The expression of the mir-193 family members hsa-miR-193a-3p and hsa-miR-193a-5p was 
repressed during the therapy (Table 3). A study by Lindberg et al. demonstrated increased expression 
of hsa-miR-193a-5p in CD4+ T cells of RRMS patients compared to healthy subjects [50]. Otaegui et al. 
confirmed the potential relevance of this miRNA duplex in MS. Based on a co-expression network 
analysis, they postulated that hsa-miR-193a-3p is related to the remission stage of MS [51]. Moreover, 
the precursor molecule hsa-mir-193a was found to modulate apoptotic processes by promoting CASP3 
activation induced by TNFSF10 signaling [52]. TNFSF10 (=TRAIL), in turn, is a known IFN-beta-induced 
gene and was transcriptionally up-regulated in the patients’ PBMC (Supplementary File 2). The 
concomitant regulation of mir-193 miRNAs may thus contribute to the molecular mechanisms of 
action of IFN-beta. 
Another miRNA caught our attention: hsa-miR-223-3p appeared to be the highest expressed 
miRNA in most PBMC samples (mean raw Ct value = 13.6). In a microarray study by Keller et al., 
elevated levels of this miRNA were measured in the peripheral blood of RRMS patients as compared 
with healthy controls [53]. A significantly increased expression of hsa-miR-223-3p was later 
confirmed in PBMC from RRMS patients using real-time PCR [54]. Functionally, hsa-miR-223-3p 
modulates inflammatory responses by modulating the NF-kappaB pathway [55]. 
The remaining miRNAs identified in our study have so far not been mentioned in the context of 
MS, and their functions are poorly understood. miRNAs that have been repeatedly described  
to be differentially expressed in MS, e.g., hsa-miR-142-3p, hsa-miR-146a-5p, hsa-miR-155-5p and  
hsa-miR-326 [22], were not contained in the filtering result, thus the therapy did not normalize their 
abnormal expression (cf. Waschbisch et al. [26]). Further studies are needed to decipher the 
immunological pathways involved, and to better understand the role of miRNA-dependent regulatory 
mechanisms in the immunopathogenesis of MS. 
2.7. Interactions between Filtered MicroRNAs and mRNAs 
Interactions between the 20 filtered miRNAs and the 95 filtered mRNAs were derived from two 
databases providing potential target genes of miRNAs. The miRWalk database [56] was used to obtain 
miRNA-mRNA interactions consistently predicted by multiple computational algorithms. This resulted 
in 74 potential interactions for 15 of the 20 filtered miRNAs. The miRTarBase database [57] was used 
to extract interactions with experimental evidence in the literature. This resulted in two verified 
interactions: hsa-miR-16-5p was identified as a post-transcriptional regulator of HERC6 in both 
databases. Moreover, there is an experimentally determined interaction between hsa-let-7b and IFIT5. 
IFIT5 is a known IFN-beta-induced gene. A recent study by Abbas et al. characterized IFIT5 as an 
innate immune effector molecule acting as a sensor of viral single-stranded RNAs [58]. This confers 
antiviral defense by inhibiting viral replication. However, IFIT5 also recognizes cellular RNAs, 
including tRNAs [59]. The full network of miRNA-mRNA target interactions is visualized in Figure 4. 
The most connected regulators in the network were hsa-miR-16-5p and hsa-miR-532-5p with  
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nine IFN-beta-responsive target genes each. hsa-miR-29a-3p and hsa-miR-29c-3p, which are closely 
related to each other, had eight predicted gene targets in common due to their similar mature sequences. 
Figure 4. Verified and predicted interactions between IFN-beta-responsive microRNAs 
and mRNAs. The network of miRNA-target interactions between differentially expressed 
miRNAs and mRNAs was built using the databases miRWalk and miRTarBase. miRWalk 
reported results of 10 different prediction algorithms, and we only considered mRNA 
targets being computationally predicted by at least five of the 10 algorithms. miRTarBase 
provided experimentally validated miRNA-target interactions. In total, 15 of the filtered 
miRNAs were linked to 34 of the filtered genes by 74 predicted and two validated 
interactions. hsa-miR-29a-3p and hsa-miR-29c-3p (in the center-right) belong to the same 
miRNA family and are predicted to regulate eight target genes in common. The network is 
available as a Cytoscape session file (Supplementary File 6). 
 
Down-regulated SH3BGRL2 and up-regulated XAF1 are simultaneously targeted by several (n > 5) 
miRNAs (miRNA target hubs [60]). Both genes have already been identified as differentially 
expressed in our previous studies on the effects of IFN-beta therapy [8,31] (Supplementary File 2). 
XAF1 is a critical mediator of IFN-beta-induced apoptosis. Its expression correlates with the cellular 
sensitivity to the pro-apoptotic actions of TNFSF10 [7,61]. However, while this supports the notion that 
miRNAs contribute to the mechanisms of action of IFN-beta, it should be noted that the majority of 
interactions in the network is predicted. For instance, the miRNA-mRNA interaction between  
hsa-miR-16-5p and SESN1 is predicted by nine out of 10 algorithms implemented in the miRWalk 
database, but has not yet been experimentally demonstrated. Another limitation is that we did not 
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analyze whether the miRNAs bind their target mRNAs at multiple sites. Such a cooperative regulation 
through repetitive elements in the 3' UTR can increase repression efficacy [62]. Additional studies are 
needed to validate the miRNA targets, e.g., by luciferase assays. 
Opposing effects exist in the network since several mRNAs are targeted by down-regulated and  
up-regulated miRNAs (Figure 4). Moreover, the network does not include the effects of the 
transcription factors (TF), which are activated through the IFN-beta signaling pathway and which are 
known to regulate the expression of most of the genes [31,63]. Therefore, it is difficult to disentangle 
the effects of miRNA expression changes on the mRNA levels measured during therapy. Further 
studies are thus required, e.g., specific miRNA transfection experiments examining the impact on 
potential target genes at both the mRNA and protein level. 
Our network analysis was limited to the set of filtered genes, and the many other potential target 
genes of the filtered miRNAs were out of scope. Moreover, we did not investigate whether the 
miRNAs target viral RNAs, which is also worth to be explored in detail [28]. Despite these limitations, 
we conclude that miRNA-mediated regulation plays an important role in the pleiotropic effects of  
IFN-beta in normal immune responses as well as in the treatment of MS. 
2.8. Cell Type-Specific Expression of IFN-beta-Responsive MicroRNAs 
We analyzed whether the miRNA expression changes during therapy affect the gene expression in 
different cell populations involved in the disease. This was done by comparing the cell type-specific 
expression of the miRNAs using information from the smirnaDB database [64] (Figure 5). Of the 
filtered miRNAs, hsa-miR-16-5p is highly expressed among diverse blood cells, in particular 
monocytes and CD4+ T cell lines, whereas hsa-miR-149-5p is only detected in brain (Figure 5). 
Accordingly, in our time course data set, hsa-miR-16-5p was expressed at very high levels, and  
hsa-miR-149-5p was expressed at relatively low levels (Supplementary File 3). Several miRNAs, 
however, were not detected in some cell populations (clone count = 0) due to the limited sensitivity of 
the measurement technique used to generate these data [65]. More sensitive methods could be used  
to further analyze the cell type-specific roles of selected miRNAs in MS and therapy, e.g.,  
hsa-miR-29a-3p and hsa-miR-29c-3p, which were expressed in B cells. 
2.9. Final Remarks and Perspectives 
The cellular regulation of the miRNAs is still not well understood. Many type I IFN-responsive 
genes harbor in their promoter region a specific sequence motif, the IFN-stimulated response element 
(ISRE), which is bound by IFN-activated TFs [7]. However, when we searched miRGen 2.0, a 
database of TF binding sites for miRNA transcripts [66], there was only one miRNA (hsa-mir-203a) 
that was predicted to have an ISRE located near the transcription start site. It is conceivable that some 
of the filtered miRNAs are regulated at the RNA processing level rather than at the transcriptional 
level. Several post-transcriptional mechanisms can affect mature miRNA biogenesis and stability [67]. 
Recent studies provided evidence that miRNAs can be suppressed by circular RNAs, which act as 
natural miRNA sponges [68]. On the other hand, the localization of the miRNAs might be altered, e.g., 
by microparticle shedding [69]. Additional research is needed to elucidate how the activity of miRNAs 
might be modulated during therapy. 
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Figure 5. Expression of 17 filtered miRNAs in different cell populations. The heat map 
visualizes the levels of IFN-beta-responsive miRNAs in 19 blood cell populations and  
four brain tissues. The data were downloaded from the smirnaDB database [64], which did 
not contain three of the 20 filtered miRNAs (hsa-miR-27a-5p, hsa-miR-29b-1-5p and  
hsa-miR-181c-3p). hsa-let-7a-5p and hsa-miR-16-5p are highly expressed in peripheral 
blood and brain. hsa-let-7b-5p and hsa-miR-149-5p are preferentially expressed in brain 
tissues. Several of the miRNAs (e.g., hsa-miR-346) were not detected in certain cell types [65]. 
 
Currently, there is a clear lack of studies investigating the changes in miRNA expression during MS 
therapy. Apart from the study by Waschbisch et al. [26] (see Section 1), there is only another study by 
Sievers et al., who found differentially expressed miRNAs in B cells of patients treated with 
natalizumab [41]. Future miRNA profiling analyses should use a longitudinal design and address both 
the short-term and the long-term effects of the available treatments. Such studies may also help to 
understand why some patients continue to have clinical relapses, disability progression or active 
lesions despite therapy. Defining the individual response to treatment is difficult, but miRNAs may 
have the potential to be used as prognostic biomarkers, thereby facilitating improved patient care. The 
identification of miRNA biomarkers should be supported by functional studies on how miRNAs affect 
complex biological processes by targeting multiple genes in different cell types. 
3. Experimental Section 
3.1. Samples 
Fifteen milliliters peripheral venous EDTA blood samples were taken from six patients (Table 1) 
immediately before first (baseline), second, and third IFN-beta injection as well as after one month. 
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For validation, further blood samples were taken from an independent cohort of 12 patients 
(Supplementary File 4) before and one month after the start of IFN-beta-1b sc. therapy. The samples 
were always processed within one hour. PBMC were separated by isopycnic centrifugation in Ficoll 
density gradients, and total RNA enriched with small RNAs was isolated using the mirVana miRNA 
isolation kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturers’ protocols. The study 
was approved by the University of Rostock’s ethics committee and carried out according to the 
Declaration of Helsinki. Written informed consent was obtained from all patients before study onset. 
3.2. Gene Expression Profiling Using Microarrays 
To quantify the mRNA levels, total RNA from each of the 24 PBMC samples of the main study 
cohort was labeled and hybridized to Affymetrix microarrays. Biotinylated cRNA were prepared 
according to the standard Affymetrix 3' IVT protocol from 200 ng total RNA (Expression Analysis 
Technical Manual; Affymetrix, Santa Clara, CA, USA). Following fragmentation, 15 µg of cRNA 
were hybridized for 16 h at 45 °C on Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays. 
The microarrays were washed and stained in the Affymetrix Fluidics Station 450, and scanned using 
the Affymetrix GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA, USA). 
3.3. MicroRNA Expression Analysis Using Real-Time PCR 
To quantify the miRNA expression levels, we used the TaqMan Array Human MicroRNA A + B 
Cards Set v2.0 (Applied Biosystems, Foster City, CA, USA), which consists of two 384-well plates 
with TaqMan assay reagents. These plates contain 720 assays to measure 651 different human 
miRNAs. Moreover, there are 30 assays for positive controls, 2 assays for negative controls, and 16 
assays were discarded as they link to dead miRNA entries in the miRBase database (release 17) [17]. 
Total RNA (120 ng) from each sample (n = 24) was reverse transcribed to cDNA using Megaplex RT 
Primers in combination with Megaplex PreAmp Primers (Life Technologies, Carlsbad, CA, USA). The 
real-time PCR measurements were then performed with predesigned primers and TaqMan probes with 
45 cycles according to the manufacturer’s instructions in a 7900HT Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). Raw Ct values were computed using the SDS 2.3 and 
RQ Manager 1.2 software (Applied Biosystems, Foster City, CA, USA), and undetermined data were 
set to Ct = 45. 
3.4. Validation MicroRNA Analysis Using Microarrays 
For validation, we replicated the miRNA expression measurements of the PBMC from three 
patients (Pat1-3) at two time points (before the first IFN-beta injection as well as after one month). 
Total RNA of these six samples was labeled and hybridized to Affymetrix GeneChip miRNA 2.0 
arrays. Biotinylated RNA was prepared using the FlashTag Biotin HSR RNA labeling kit according to 
the standard Affymetrix protocol from 600 ng total RNA (Expression Analysis Technical Manual; 
Affymetrix). Following fragmentation, the biotin-labeled RNA was hybridized for 16 h at 45 °C on 
Affymetrix miRNA 2.0 arrays. The microarrays were washed and stained in the Affymetrix Fluidics 
Station 450, and scanned using the Affymetrix GeneChip Scanner 3000. 
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3.5. Validation MicroRNA Analysis Using Real-Time PCR 
To verify the results in an independent cohort of patients, we measured 5 of the 20 filtered miRNAs 
in PBMC samples from 12 additional patients (Supplementary File 5). The blood samples were 
obtained before and after one month of IFN-beta-1b treatment. The miRNAs were selected based on a 
combination of different criteria, e.g., change of expression after one month according to both  
the TaqMan miRNA array data and the Affymetrix miRNA microarray data. The validation  
experiment was performed using TaqMan single-tube assays for hsa-miR-16-5p (Assay ID 000391),  
hsa-miR-29a-3p (Assay ID 002112), hsa-miR-29c-3p (Assay ID 000587), hsa-miR-149-5p (Assay ID 
002255), and hsa-miR-532-5p (Assay ID 001518). Additionally, the housekeeping miRNA  
hsa-miR-191-5p (Assay ID 002299) was measured for normalization [33]. For each assay, 10 ng of 
total RNA from each sample (n = 24) were used to convert an individual miRNA to cDNA using an 
RT primer specific for the miRNA of interest (Applied Biosystems). The real-time PCR quantitation 
was performed in triplicates with predesigned primers and TaqMan probes according to the TaqMan 
MicroRNA Assay protocol with 45 cycles in a 7900HT Sequence Detection System (Applied 
Biosystems). An equivalent of 0.5 ng total RNA was used to obtain a single data point. Raw Ct values 
were computed using the SDS 2.3 and RQ Manager 1.2 software (Applied Biosystems). 
3.6. Expression Data Preprocessing 
In the case of the Affymetrix U133 Plus 2.0 gene expression microarrays, the raw probe-level 
signals were converted to expression values (signal intensities) using the MAS5.0 algorithm and 
custom GeneAnnot-based chip definition files (version 2.2.0) [70]. Data normalization was performed 
by loess normalization using the R package “affy”. Each Affymetrix GeneChip yielded mRNA levels 
of 19,204 human genes. 
In case of the TaqMan miRNA cards, we first set the detection limit at Ct = 38 [71], and converted 
the raw Ct values to the linear scale using the equation 2
−Ct
 × 10
−9
. After this step, a Ct value of  
38 corresponds to an expression signal of 0.004, and a Ct value of 20 corresponds to an expression 
signal of 953. Systematic differences in the time course data were then corrected by loess 
normalization. This was done separately for each patient (n = 6) and each card (A and B). Finally, to 
reduce variation in the expression signals between the patients, we scaled the data of card A and of 
card B so that the respective 95% quantile was the same for each patient. 
In case of the Affymetrix miRNA microarrays, the raw signals were converted to expression values 
using the RMA algorithm with quantile normalization. For each chip, this resulted in log-transformed 
expression levels for 20,706 probe sets interrogating small non-coding RNA transcripts. For each of 
the 20 filtered miRNAs (Table 3), there was one designated probe set. 
In case of the TaqMan single-tube real-time PCR miRNA assays, we set the detection limit at  
Ct = 38 [71], calculated the mean Ct value of each triplicate, converted the raw Ct values to the linear 
scale using the equation 2
−Ct
, normalized the results to the expression values of the housekeeping 
miRNA hsa-miR-191-5p [33], and scaled these ratios by a factor of 1000 for convenience. 
The non-normalized and the normalized expression data of the six patients receiving IFN-beta 
therapy are available in the Gene Expression Omnibus (GEO) database via the SuperSeries record 
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GSE46293. This GEO entry links to all data from the Affymetrix U133 Plus 2.0 microarrays, the 
TaqMan MicroRNA Cards Sets v2.0, and the Affymetrix miRNA 2.0 microarrays. 
3.7. Filtering of Differentially Expressed mRNAs and MicroRNAs 
We filtered the Affymetrix U133 Plus 2.0 and TaqMan miRNA cards data sets for  
IFN-beta-responsive genes and miRNAs by comparing the PBMC expression levels immediately 
before treatment initiation (baseline) with the expression levels two days, four days, and one month 
after the start of IFN-beta therapy. Up-regulation and down-regulation of genes and miRNAs were 
quantified using signal intensity-dependent fold-changes (MAID-scores) as described in our previous  
studies [8,34] (see also http://www.hki-jena.de/index.php/0/2/490). MAID-scores represent adjusted 
fold-changes, where a higher fold-change (i.e., relative change in expression) is required for genes 
expressed at low levels than for genes expressed at high levels. This is realized by an exponential 
function (MAID regression curve) that is fitted to the signal intensity-dependent variation in the data. 
For each time point comparison and each type of array, we computed the MAID-score for all patients 
and for all measured genes and miRNAs. We then selected the genes and miRNAs being up-regulated 
(MAID-score above the cutoff C) or being down-regulated (MAID-score < −C) in at least four of the  
six patients. We chose C = 2 for the gene expression data set, and C = 1 for the miRNA expression 
data set. For the latter, a lower MAID-score cutoff was chosen because the larger variation in the 
miRNA data already leads to a higher MAID regression curve. 
To provide an estimate of the number of genes and miRNAs passing the MAID filtering by chance, 
a permutation test was performed. The data sets were permuted 1000 times by randomly rearranging 
the temporal sequence of the data of each patient. The same filtering criteria as described above were 
then applied to each permutation. 
As an alternative filtering criterion, we statistically compared the PBMC expression levels of 
mRNAs and miRNAs before and during treatment using paired t-tests (Supplementary File 2 and 
Supplementary File 3). However, considering the relatively small number of patients in our study, the 
MAID filtering method is thought to be more robust to the variation in the data. 
3.8. Visualization of the mRNA Expression Data 
A heat map was used to visualize the expression changes of the 95 filtered mRNAs (Figure 1). The 
heat map displays the respective data of all 6 patients before the start of therapy and after one month. 
To reorder the rows and columns of the data matrix, hierarchical clustering was performed with the 
single linkage method and Pearson’s correlation coefficient as a measure of similarity. For 
visualization purposes, the expression values (signal intensities) were centered and scaled row-wise 
(resulting in z-scores) with the standard R heat map function. 
3.9. Evaluation of the MicroRNA Validation Data 
Spearman’s rank correlation coefficient (rho) was calculated to evaluate whether the TaqMan 
miRNA array data correlate with the Affymetrix miRNA microarray data (120 data pairs: 20 miRNAs, 
three patients, and two time points). Paired t-tests were computed for assessing the difference in 
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expression after one month of IFN-beta-1b sc. therapy versus baseline in the preprocessed and 
normalized data of the Affymetrix microarrays (Pat1-3) and of the TaqMan single-tube assays (n = 12 
additional patients). 
3.10. Interaction Network Analysis 
We studied the regulatory interactions between the miRNAs and their target mRNAs by integrating 
the information from two different databases. Experimentally verified and computationally predicted 
target genes of the 20 IFN-beta-responsive miRNAs were extracted from the databases miRTarBase 
(version 3.5) [57] and miRWalk (April 2013) [56], respectively. miRWalk contained predictions for all 
20 filtered miRNAs, and miRTarBase contained interactions for 9 of the 20 miRNAs. For the 
prediction of targets with miRWalk, we applied the option of the web server to run the calculations 
with 10 different prediction algorithms on 3' UTRs of all human genes, and then gathered only the 
miRNA-mRNA interactions that were predicted by at least 5 of the 10 algorithms. Finally, interactions 
being associated with the 95 filtered genes were visualized as a network using the Cytoscape software 
(version 2.8.0) [72]. 
3.11. MicroRNA Expression in Different Cell Populations 
To investigate the expression of the filtered miRNAs in different peripheral blood cell types and 
brain regions, we used the smirnaDB database, which provides expression levels of 692 human 
miRNAs for 170 cell populations and tissues [64]. This miRNA expression atlas is based on sequence 
analysis of small RNA clone libraries [65]. The relative cloning frequencies of miRNAs represent a 
measure of miRNA expression. However, in this data set, many miRNAs were identified at very low 
clone counts (cf. Landgraf et al. [65]). The data for 19 blood cell types (including three CD4+ T cell 
lines) and four brain tissues were downloaded from smirnaDB and visualized as a heat map in the R 
software environment. 
4. Conclusions  
To our knowledge, this is the first longitudinal genome-wide study examining the in vivo effects of 
IFN-beta treatment on miRNA expression in blood cells of patients with CIS or RRMS. The strongest 
changes in mRNA and miRNA expression were detected one month after the start of IFN-beta-1b sc. 
treatment. We observed that the induction of IFN-beta-responsive genes is paralleled by a preferential 
down-regulation of miRNAs. This suggests that the regulation of miRNAs contributes to the molecular 
mechanisms of action of IFN-beta in protective immune responses as well as in MS therapy. We 
confirmed the down-regulation of hsa-miR-29a-3p, hsa-miR-29c-3p, and hsa-miR-532-5p in an 
independent cohort of patients. We further analyzed the interactions between differentially expressed 
miRNAs and mRNAs. The largest number of predicted interactions to IFN-responsive genes was 
found for hsa-miR-532-5p and hsa-miR-16-5p. Up-regulated hsa-miR-16-5p was expressed at very 
high levels in different cell types of the blood, in particular monocytes. However, unraveling the 
complex gene regulatory interactions between TFs, miRNAs and genes remains a big challenge for the 
future. Functionally, some of the 20 filtered miRNAs (e.g., members of the mir-29 family) are 
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associated with apoptosis and are involved in IFN signaling feedback loops. miRNA expression 
profiles in blood cells may provide biomarkers for monitoring the biological response to therapy to 
predict individual disease activity and progression. They may also help to better understand the 
pathogenetic mechanisms and to optimize the treatment of MS. Our results provide a rationale for 
subsequent studies in larger MS cohorts. 
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Supplementary Information  
Supplementary File 1 (TIFF image): Distribution of the raw Ct values measured with the TaqMan 
miRNA arrays. The data of the A-cards (A) and the B-cards (B) are shown for all six patients and all  
four time points. The detection limit was set at Ct = 38. 
Supplementary File 2 (XLS Excel spreadsheet): mRNA filtering result. This table provides the  
95 genes that were up-regulated or down-regulated in the PBMC of the patients two days, four days or 
one month after the initiation of subcutaneous IFN-beta-1b therapy. Different types of information are 
given for each gene, e.g., gene symbol, official full name, Entrez Gene identifier, and the MAID 
filtering results. 
Supplementary File 3 (XLS Excel spreadsheet): microRNA filtering result and validation. In 
comparison to pre-treatment levels, 20 miRNAs were found to be expressed at higher or lower levels 
in PBMC during IFN-beta treatment. The table provides, e.g., the TaqMan Detector identifiers, the 
MAID filtering outputs as well as the results from the validation analyses. 
Supplementary File 4 (XLS Excel spreadsheet): Clinical data and demographic data of the patients 
in the validation cohort. Twelve patients were recruited to confirm the observed expression changes of 
five selected miRNAs within the first month of IFN-beta-1b sc. treatment. 
Supplementary File 5 (XLS Excel spreadsheet): Validation real-time PCR data set. TaqMan  
single-tube assays were used to quantify the expression of five selected miRNAs before the start of  
IFN-beta therapy and after one month in PBMC of an independent cohort of 12 patients 
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(Supplementary File 4). This table contains the raw Ct values of these five miRNAs and the 
housekeeping miRNA hsa-miR-191-5p [33]. The measurements were done in triplicates. 
Supplementary File 6 (CYS Cytoscape session file): miRNA-mRNA interaction network. This 
Cytoscape file (http://www.cytoscape.org) [72] contains computationally predicted and experimentally 
determined interactions between IFN-beta-responsive miRNAs and mRNAs. The interactions were 
obtained from the databases miRWalk [56] and miRTarBase [57]. A visualization of the network is 
shown in Figure 4. 
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Abstract MicroRNAs (miRNAs) are small non-coding
RNAs which regulate many genes post-transcriptionally. In
various contexts of medical science, miRNAs gained in-
creasing attention over the last few years. Analyzing the
functions, interactions and cellular effects of miRNAs is a
very complex and challenging task. Many miRNA data-
bases with diverse data contents have been developed. Here,
we demonstrate how to integrate their information in a
reasonable way on a set of miRNAs that were found to be
dysregulated in the blood of patients with multiple sclerosis
(MS). Using the miR2Disease database, we retrieved 16
miRNAs associated with MS according to four different
studies. We studied the predicted and experimentally vali-
dated target genes of these miRNAs, their expression pro-
files in different blood cell types and brain tissues, the
pathways and biological processes affected by these miR-
NAs as well as their regulation by transcription factors.
Only miRNA–mRNA interactions that were predicted by
at least seven different prediction algorithms were
considered. This resulted in a network of 1,498 target genes.
In this network, the MS-associated miRNAs hsa-miR-20a-
5p and hsa-miR-20b-5p occurred as central hubs regulating
about 500 genes each. Strikingly, many of the putative target
genes play a role in T cell activation and signaling, and
many have transcription factor activity. The latter suggests
that miRNAs often act as regulators of regulators with many
secondary effects on gene expression. Our present work pro-
vides a guideline on how information of different databases
can be integrated in the analysis of miRNAs. Future inves-
tigations of miRNAs shall help to better understand the mech-
anisms underlying different diseases and their treatments.
Keywords Multiple sclerosis . MicroRNA . Databases .
Gene regulatory networks
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Introduction
Multiple sclerosis (MS) is a chronic, immune-mediated dis-
ease leading to demyelination and axonal loss in the central
nervous system (CNS). The inflammations are transient, but
post-inflammatory gliosis and neurodegeneration, causing
multifocal sclerotic plaques primarily in the white matter
of the CNS, can lead to functional deficits and permanent
disability. The course of this disease is unpredictable, and
relapsing forms are as well known as progressive courses.
The definite pathogenesis of MS remains unclear, but envi-
ronmental factors, immune dysregulation, and genetic pre-
dispositions play significant roles [1–3]. Many researchers
studied the genomics, transcriptomics, proteomics, and
metabolomics of this disorder to unravel potential patholog-
ical mechanisms. One experimental approach is the analysis
of the patients' individual gene expression in the course of
the disease and during therapy to reconstruct and better
understand the underlying molecular networks [4, 5]. In
1993, a new class of RNAs called microRNAs (miRNAs)
was detected in Caenorhabditis elegans [6] and also later in
humans [7]. Meanwhile, alterations in the cellular expression
levels of miRNAs were linked to the pathogenesis of a variety
of diseases [8, 9] and several groups have identified miRNAs
associated with MS [10–13].
miRNAs are small (~22 nt) RNA molecules that post-
transcriptionally regulate gene expression. They are tran-
scribed usually by RNA polymerase II with protein-coding
or non-coding genes [14]. It is assumed that approximately
35 % of mammalian miRNA loci overlap with annotated
protein-coding genes, with 90 % of these being located in
the introns [15]. The initial transcript, called the primary-
miRNA (pri-miRNA), can be thousands of nucleotides in
length and contains one or more stem-loop structures that
harbor the mature miRNAs. In the nucleus, the ribonuclease
III (RNaseIII) Drosha processes the pri-miRNAs to hairpin-
structured precursor-miRNAs (pre-miRNAs), which are
typically 70–110 nt in length. After a pre-miRNA is ac-
tively transported to the cytoplasm, the RNaseIII Dicer
develops a miRNA–miRNA* duplex (~20 bp) out of this
pre-miRNA and links one strand (the future mature
miRNA) to an RNA-induced silencing complex (RISC).
The other strand (miRNA*) either degrades or sometimes
becomes a second mature miRNA [14, 16–18]. Finally,
binding usually the 3′ UTR of a target mRNA, mature
miRNAs lead to the cleavage or to the translational repres-
sion of the mRNA, depending on the degree of sequence
complementary [14]. This post-transcriptional process con-
tributes to the regulation of many protein-coding genes
with diverse biological functions and thus has implications
for various diseases, [9].
It is assumed that one miRNA is able to regulate
hundreds of mRNA targets [19]. However, up to the present,
only few microRNA–mRNA interactions have been exper-
imentally validated, e.g., by luciferase reporter assays.
Hence, computational tools are commonly used to predict
putative target genes [20–22]. miRNAs contain a special
region (the seed region) located in the 5′ end of the strand
(2nd–8th nt) that plays an important role for target recogni-
tion. This fact is widely used in bioinformatic target predic-
tion algorithms. Other frequently used properties for target
prediction are the thermodynamics of the microRNA–
mRNA interaction and the evolutionary conservation of
the target sites [20–22]. In the last few years, due to the
growing interest in miRNAs, there has been a great devel-
opment of databases collecting, organizing, and providing
specific miRNA information. Several different types of
databases exist, e.g., databases with general information on
miRNAs (such as sequence and genome position), databases
with information on potential mRNA targets, and databases
associating miRNAs with specific diseases (Table 1)
[23–42].
In this review, we provide an insight into the different
existing miRNA databases and illustrate how to integrate
their information for examining (a) the network-like inter-
actions of miRNAs with mRNA targets, (b) the effects of
miRNAs on cellular functions, and (c) their regulation by
transcription factors (TFs) leading to tissue-specific expres-
sion. As a case study, we will focus on miRNAs that have
been mentioned in the context of MS.
MicroRNA Databases
One of the central public databases with general information
on miRNAs is miRBase. In version 18, miRBase contains
1,527 different human pre-miRNAs with 1,921 different
mature miRNA entries. It offers details about current miRNA
nomenclatures, sequences, genomic locations, precursor
forms, and literature references [28, 33]. Potential target genes
of miRNAs are not contained in miRBase, but other databases
have been implemented to provide such information (Table 1).
Some databases collect miRNA–mRNA interactions from the
current literature in PubMed and list them as experimentally
validated targets, e.g., miRTarBase [31] and TarBase [39].
miRTarBase version 2.5 contains 285 human miRNAs, hav-
ing 2,860 manually curated interactions with 1,721 different
genes. It has more entries and is updated more regularly than
TarBase.
Since the amount of validated targets is relatively small,
many other databases use computational algorithms for tar-
get prediction. Seed matches, conservation of the sequence
and thermodynamics of the miRNA–mRNA interaction are
widely used for predicting potential targets [20–22]. The
disadvantage of this approach is the enormous number of
possible targets, and therefore results may contain a lot of
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false positives. TargetScan [19, 36], DIANA-microT [38],
PicTar [29, 34, 35], MicroCosm [28], and microRNA.org
[24] are the most established and commonly used miRNA–
mRNA interaction databases. Of these, MicroCosm and
microRNA.org are based on the same algorithm called mi-
Randa [43]. There are also databases collecting and provid-
ing both, validated targets and predicted targets of other
databases, showing the differences between the predictions,
e.g., miRecords [42] and miRWalk [25]. miRWalk is a
database with its own target prediction algorithm, but also
allows to simply compare the results with nine other predic-
tion algorithms. Demanding a target to be predicted by
several algorithms can be very useful to reduce the high
number of putative and maybe false positive targets. Fur-
thermore, miRWalk is so far the only database offering
target predictions outside the 3′ UTR as well. This option
may be useful since recent studies have shown that miRNAs
in some cases regulate also via 5′ UTR regions, promoter
regions, or amino acid coding regions [44–46]. It is impor-
tant to note that the information of miRNA–mRNA interac-
tion databases can be used in two ways: (a) to retrieve
potential gene targets of miRNAs and (b) to identify for a
list of genes those miRNAs that are assumed to regulate
them. For the latter analysis, web tools such as FatiGO of
the Babelomics platform exist [47, 48].
Another way of investigating miRNAs is to look up
potential connections to human diseases. For this purpose,
databases such as miR2Disease [32] and PhenomiR [40]
deliver curated information from the literature in PubMed
about associations of miRNAs with disorders. Some other
databases provide tissue- and cell type-specific expression
profiles of miRNAs, which might be useful to elucidate
cellular functions of miRNAs. miRDB uses the miRNA
expression data set by Liang et al. [49] on 40 normal human
tissues and the results (miRNA copies per cell) can be
shown in a table, besides other general information [41].
Another expression profile providing database can be found
on the MirZ web server [30], which contains the expression
atlas smirnaDB that is based on the data by Landgraf et al.
[50]. In contrast to miRDB, smirnaDB even provides
miRNA expression levels of pathological tissues and cell
types [30]. miRGen 2.0 [23] is a database that also
Table 1 Overview of different types of microRNA databases
Content Database Reference Last update Web address
General information miRBase [28] Nov 2011 http://www.mirbase.org
Experimentally verified
mRNA targets
miRecords [42] Nov 2010 http://mirecords.biolead.org
miRTarBase [31] Oct 2011 http://mirtarbase.mbc.nctu.edu.tw
TarBase [39] Jun 2008 http://diana.cslab.ece.ntua.gr/tarbase/
Computationally
predicted mRNA targets
DIANA-microT [38] Jul 2009 http://diana.cslab.ece.ntua.gr/microT/
MicroCosm [28] Oct 2007 http://www.ebi.ac.uk/enright-srv/
microcosm/
microRNA.org [24] Aug 2010 http://www.microrna.org
miRWalk [25] Mar 2011 http://www.ma.uni-heidelberg.
de/apps/zmf/mirwalk/
PicTar [34, 35] Mar 2007 http://pictar.mdc-berlin.de
TargetScan [36] Mar 2012 http://www.targetscan.org
Transcription factor
binding sites
miRGen [23] Nov 2009 http://diana.cslab.ece.ntua.gr/mirgen/
CircuitsDB [26] Jan 2011 http://biocluster.di.unito.it/circuits/
Single nucleotide
polymorphisms
miRNASNP [27] Aug 2011 http://www.bioguo.org/miRNASNP/
Expression data sets miRDB [41] Jan 2012 http://www.mirdb.org/wiki/index.php5
smirnaDB [30] May 2009 http://www.mirz.unibas.
ch/cloningprofiles/
Association to diseases miR2Disease [32] Mar 2011 http://www.mir2disease.org
HMDD [37] Mar 2012 http://cmbi.bjmu.edu.cn/hmdd
PhenomiR [40] Feb 2011 http://mips.helmholtz-muenchen.
de/phenomir/
As of version 18, miRBase contains 1,921 distinct human mature miRNA entries. It is a central source of diverse types of general information
including miRNA nomenclatures, sequences, genomic locations and families. Numerous databases provide experimentally verified miRNA targets
and computational algorithms for target prediction. The table gives only selected examples of such databases. Further databases offer information
about miRNA expression in different tissues and cell types, literature-derived associations of miRNAs with diseases, and potential transcription
factor binding sites for investigating the transcriptional regulation of miRNAs. Databases that were used for the analyses presented in this review
are written in bold
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integrates the expression data of Landgraf et al. [50]. Fur-
thermore, miRGen 2.0 lists single nucleotide polymor-
phisms (SNPs) at the pre-miRNA locat ion and
transcription factor binding sites (TFBS) in the promoter
region of pri-miRNA transcripts. For the determination of
potential TFBS, miRGen 2.0 relies on the tool MatchTM
[51], utilizing the public library of TF position weight
matrices (PWMs) from the Transfac database (version 6.0)
[52]. By uncovering which TFs are likely involved in the
transcription process of miRNAs, miRGen 2.0 helps reveal-
ing the mutual regulatory relationships between miRNAs
and TFs. Finally, miRNASNP [27] provides a resource of
SNPs in pre-miRNAs and their flanking regions based on
the dbSNP database build 132. SNPs can affect the miRNA-
mediated regulatory functions and, as a consequence, can be
related to immune-mediated diseases such as MS.
MicroRNAs in Multiple Sclerosis
In miR2Disease (as of March 2012), 16 different miRNAs
are listed to be associated with MS according to four differ-
ent studies (Table 2) [53–57].
Keller et al. [56] examined the differences in the miRNA
expression profiles in peripheral blood cells between
relapsing-remitting MS (RRMS) patients and healthy controls
with the help of oligonucleotide microarrays. In their study,
ten miRNAs were found to be significantly dysregulated in
the MS group (hsa-miR-20b-5p, hsa-miR-142-3p, hsa-miR-
145-5p, hsa-miR-186-5p, hsa-miR-223-3p, hsa-miR-422a,
hsa-miR-491-5p, hsa-miR-584-5p, hsa-miR-664-3p, and
hsa-miR-1275). Five of these miRNAs have already been
associated with other diseases [55].
Otaegui et al. [57] focused on the relevance of miRNAs
in the relapse stage of MS patients. Peripheral blood mono-
nuclear cells (PBMC) were taken from patients during re-
lapse and during remission as well as from healthy subjects,
and the expression levels of miRNAs were measured with
the help of TaqMan real-time PCR arrays. Their data anal-
ysis revealed increased expression levels of hsa-miR-18b-5p
and hsa-miR-599 in the relapsing patient group compared to
the healthy group. Additionally, elevated levels of hsa-miR-
96-5p were described as characteristic of the remitting phase
of the disease [57].
Du et al. [54] analyzed peripheral blood leukocyte sam-
ples of RRMS patients with real-time PCR. They found
particularly in the CD4+ T cell population an increased
expression of hsa-miR-326 in relapsing patients, but not in
remitting patients. In the same study, they also investigated
this miRNA in mice with experimental autoimmune enceph-
alomyelitis (EAE), an animal model of MS. Overexpression
of hsa-miR-326 resulted in severe EAE with many T helper
17 (Th17) cells, while to the contrary, in vivo silencing of
hsa-miR-326 resulted in a milder form of EAE and less
Th17 cells. In this way, Du et al. [54] could show an
influence of hsa-miR-326 on Th17 cell differentiation with
a potential contribution to the pathogenesis of MS.
Cox et al. [53] analyzed about 700 miRNAs in whole
blood samples of therapy-naïve patients with different MS
subtypes and healthy controls with an Illumina Sentrix array
matrix. In all subtypes of MS, hsa-miR-17-5p and hsa-miR-
20a-5p were significantly underexpressed in comparison to
the healthy group. Additionally, Cox et al. [53] confirmed
these results with real-time PCR and provided evidence that
hsa-miR-17-5p and hsa-miR-20a-5p are regulators of genes
involved in T cell activation.
We analyzed the genomic location of the 16MS-associated
mature miRNAs with the help of miRBase and noticed that 5
of the 16 miRNAs are located intronically (hsa-miR-186-5p,
hsa-miR-326, hsa-miR-491-5p, hsa-miR-584-5p, hsa-miR-
664-3p). This reflects the fact that roughly one third of
miRNA loci overlaps with introns of protein-coding genes
[15]. The other 11 miRNAs are located in non-coding genes,
and none of the miRNAs has multiple genomic loci, i.e., each
miRNA is produced from only one pre-miRNA. The pri-
miRNA is known for only 8 of the 16 miRNAs (Table 2). pri-
miRNAs are often not well annotated because they are short-
lived and present only inside the nucleus, which makes it
difficult to characterize them experimentally [58]. Some of the
16 miRNAs are organized in clusters, which means that they
are transcribed with the same pri-miRNA. The two miRNAs,
hsa-miR-17-5p and hsa-miR-20a-5p, belong to the miR-17~92
cluster [59], and hsa-miR-18b-5p and hsa-miR-20b-5p belong
to the miR-106a~363 cluster [60]. Interestingly, the miR-106a
~363 cluster is highly homologous to the miR-17~92 cluster.
Both clusters contain similar and even identical miRNAs, which
are subsumed in miRBase as one family of miRNAs with
similar target genes and functions [59–61]. We found for 5 of
the 16 miRNAs at least one SNP in the genomic region of the
pre-miRNA in the miRNASNP database [27]. The SNP de-
scribed for hsa-miR-664-3p (rs113256801) is even in the region
of the mature miRNA (Table 2).
Although miR2Disease is useful for gaining an insight
into MS-associated miRNAs, it has to be mentioned that not
all current studies dealing with miRNAs in MS are already
included in this database. In particular, studies published
after the year 2010 are missing in miR2Disease. We shortly
introduce some of the additional miRNAs that have been
related to MS, although we excluded them from our further
investigations, focusing on the 16 miRNAs listed in miR2-
Disease. In the study by Junker et al. [62], miRNA profiles
of active and inactive CNS lesions of MS patients were
analyzed and compared to control specimens. This led to
the detection of different up-regulated miRNAs (e.g., hsa-
miR-34a-5p, hsa-miR-155-5p, and hsa-miR-326) in active
MS lesions. Recently, Noorbakhsh et al. [63] observed
Mol Neurobiol (2012) 45:520–535 523
  Manuscript - 3 
 
87 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
ab
le
2
D
et
ai
ls
of
m
iR
N
A
s
as
so
ci
at
ed
w
ith
M
S
ac
co
rd
in
g
to
m
iR
2D
is
ea
se
M
at
ur
e
m
iR
N
A
S
ym
bo
l
M
at
ur
e
m
iR
N
A
S
eq
ue
nc
e
R
ef
er
en
ce
P
at
te
rn
M
S
vs
C
tr
m
iR
N
A
fa
m
ily
pr
e-
m
iR
N
A
S
ym
bo
l
pr
i-
m
iR
N
A
S
ym
bo
l
C
at
eg
or
y
pr
e-
m
iR
N
A
S
N
P
s
hs
a-
m
iR
-1
7-
5p
C
A
A
A
G
U
G
C
U
U
A
C
A
G
U
G
C
A
G
G
U
A
G
C
ox
et
al
.
[5
3]
L
ow
er
m
ir
-1
7
M
IR
17
M
IR
17
H
G
R
N
A
ge
ne
hs
a-
m
iR
-1
8b
-5
p
U
A
A
G
G
U
G
C
A
U
C
U
A
G
U
G
C
A
G
U
U
A
G
O
ta
eg
ui
et
al
.
[5
7]
H
ig
he
r
m
ir
-1
7
M
IR
18
B
R
N
A
ge
ne
hs
a-
m
iR
-2
0a
-5
p
U
A
A
A
G
U
G
C
U
U
A
U
A
G
U
G
C
A
G
G
U
A
G
C
ox
et
al
.
[5
3]
L
ow
er
m
ir
-1
7
M
IR
20
A
M
IR
17
H
G
R
N
A
ge
ne
hs
a-
m
iR
-2
0b
-5
p
C
A
A
A
G
U
G
C
U
C
A
U
A
G
U
G
C
A
G
G
U
A
G
K
el
le
r
et
al
.
[5
5]
L
ow
er
m
ir
-1
7
M
IR
20
B
R
N
A
ge
ne
hs
a-
m
iR
-9
6-
5p
U
U
U
G
G
C
A
C
U
A
G
C
A
C
A
U
U
U
U
U
G
C
U
O
ta
eg
ui
et
al
.
[5
7]
H
ig
he
r
m
ir
-9
6
M
IR
96
R
N
A
ge
ne
rs
41
27
42
39
,
rs
73
15
96
62
hs
a-
m
iR
-1
42
-3
p
U
G
U
A
G
U
G
U
U
U
C
C
U
A
C
U
U
U
A
U
G
G
A
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-1
42
M
IR
14
2
R
N
A
ge
ne
hs
a-
m
iR
-1
45
-5
p
G
U
C
C
A
G
U
U
U
U
C
C
C
A
G
G
A
A
U
C
C
C
U
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-1
45
M
IR
14
5
L
O
C
72
82
64
R
N
A
ge
ne
hs
a-
m
iR
-1
86
-5
p
C
A
A
A
G
A
A
U
U
C
U
C
C
U
U
U
U
G
G
G
C
U
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-1
86
M
IR
18
6
Z
R
A
N
B
2
In
tr
on
ic
hs
a-
m
iR
-2
23
-3
p
U
G
U
C
A
G
U
U
U
G
U
C
A
A
A
U
A
C
C
C
C
A
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-2
23
M
IR
22
3
R
N
A
ge
ne
rs
34
95
23
29
hs
a-
m
iR
-3
26
C
C
U
C
U
G
G
G
C
C
C
U
U
C
C
U
C
C
A
G
D
u
et
al
.
[5
4]
H
ig
he
r
m
ir
-3
26
M
IR
32
6
A
R
R
B
1
In
tr
on
ic
rs
72
56
17
78
hs
a-
m
iR
-4
22
a
A
C
U
G
G
A
C
U
U
A
G
G
G
U
C
A
G
A
A
G
G
C
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-4
22
M
IR
42
2A
R
N
A
ge
ne
hs
a-
m
iR
-4
91
-5
p
A
G
U
G
G
G
G
A
A
C
C
C
U
U
C
C
A
U
G
A
G
G
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-4
91
M
IR
49
1
K
IA
A
17
97
In
tr
on
ic
hs
a-
m
iR
-5
84
-5
p
U
U
A
U
G
G
U
U
U
G
C
C
U
G
G
G
A
C
U
G
A
G
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-5
84
M
IR
58
4
S
H
3T
C
2
In
tr
on
ic
hs
a-
m
iR
-5
99
G
U
U
G
U
G
U
C
A
G
U
U
U
A
U
C
A
A
A
C
O
ta
eg
ui
et
al
.
[5
7]
H
ig
he
r
m
ir
-5
99
M
IR
59
9
R
N
A
ge
ne
hs
a-
m
iR
-6
64
-3
p
U
A
U
U
C
A
U
U
U
A
U
C
C
C
C
A
G
C
C
U
A
C
A
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-6
64
M
IR
66
4
R
A
B
3G
A
P
2
In
tr
on
ic
rs
11
32
56
80
1
hs
a-
m
iR
-1
27
5
G
U
G
G
G
G
G
A
G
A
G
G
C
U
G
U
C
K
el
le
r
et
al
.
[5
5]
H
ig
he
r
m
ir
-1
27
5
M
IR
12
75
R
N
A
ge
ne
rs
76
15
63
62
,
rs
77
82
16
59
A
s
of
M
ar
ch
20
12
,m
iR
2D
is
ea
se
lis
ts
4
di
ff
er
en
ts
tu
di
es
th
at
id
en
tif
ie
d
13
m
iR
N
A
s
as
hi
gh
er
ex
pr
es
se
d
an
d
3
m
iR
N
A
s
as
lo
w
er
ex
pr
es
se
d
in
bl
oo
d
ce
lls
of
M
S
pa
tie
nt
s
co
m
pa
re
d
to
co
nt
ro
ls
.E
ac
h
of
th
e
16
m
at
ur
e
m
iR
N
A
s
is
pr
oc
es
se
d
fr
om
on
e
si
ng
le
pr
ec
ur
so
r
m
iR
N
A
.F
iv
e
m
iR
N
A
s
ar
e
lo
ca
te
d
w
ith
in
in
tr
on
s
of
pr
ot
ei
n-
co
di
ng
ge
ne
s,
w
hi
le
th
e
re
m
ai
ni
ng
ar
e
lo
ca
te
d
w
ith
in
no
n-
co
di
ng
ge
ne
s.
F
or
8
m
iR
N
A
s,
th
e
pr
i-
m
iR
N
A
tr
an
sc
ri
pt
ha
s
no
tb
ee
n
an
no
ta
te
d.
F
iv
e
of
th
e
m
iR
N
A
s
ha
ve
at
le
as
to
ne
S
N
P
w
ith
in
th
e
ge
no
m
e
re
gi
on
of
th
e
pr
e-
m
iR
N
A
(a
s
of
db
S
N
P
bu
ild
13
2)
.h
sa
-m
iR
-1
7-
5p
an
d
hs
a-
m
iR
-2
0a
-5
p
be
lo
ng
to
th
e
m
iR
-1
7
~
92
cl
us
te
r
[5
9]
,a
nd
hs
a-
m
iR
-1
8b
-5
p
an
d
hs
a-
m
iR
-2
0b
-5
p
be
lo
ng
to
th
e
m
iR
-1
06
a~
36
3
cl
us
te
r
[6
0]
.C
tr
0
he
al
th
y
co
nt
ro
ls
,M
S
0
m
ul
tip
le
sc
le
ro
si
s,
SN
P
0
si
ng
le
nu
cl
eo
tid
e
po
ly
m
or
ph
is
m
524 Mol Neurobiol (2012) 45:520–535
  Manuscript - 3 
 
88 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
increased levels of hsa-miR-155-5p, hsa-miR-338-5p, and
hsa-miR-491-3p in the cerebral white matter of patients with
MS. Various other groups examined the miRNA expression
in peripheral blood from MS patients compared to healthy
controls and found further miRNAs being dysregulated in MS
patients, for instance miRNAs of the miR-106~25 cluster [64],
hsa-miR-1, hsa-miR-126-3p, hsa-miR-193a-3p and hsa-miR-
497-5p [65], hsa-miR-21-5p, hsa-miR-146a-5p and hsa-miR-
146b-5p [66], hsa-miR-15a-5p [67], hsa-miR-614 and hsa-miR-
572 [68], hsa-miR-155-5p [69], hsa-let-7g-5p and hsa-miR-150-
5p [70], hsa-miR-27b-3p, hsa-miR-128, and hsa-miR-340-5p
[71].Waschbisch et al. [72] confirmed the relevance of hsa-miR-
146a-5p and hsa-miR-155-5p in MS and its treatment. Three of
the 16 miRNAs listed in miR2Disease (hsa-miR-17-5p, hsa-
miR-142-3p, and hsa-miR-326) were independently verified to
be significantly modulated in expression in peripheral blood
cells of MS patients [65, 72].
Regulatory MicroRNA Interactions
We extracted potential mRNA targets of the 16 miRNAs
from the databases miRTarBase version 2.4 [31] and miR-
Walk [25] (August 2011). This information was then used to
visualize a network of miRNA–mRNA interactions in the
Cytoscape software [73]. For the target prediction with
miRWalk, we used the option of the web server to calculate
with all ten offered prediction algorithms. In total, 121,108
target predictions were obtained from miRWalk. To reduce
the huge number of predicted targets, we only used the
miRNA–mRNA interactions being predicted by at least 7
of the 10 algorithms. This resulted in 2,122 potential inter-
actions (Fig. 1). The overlap of predicted target genes be-
tween pairs of miRNAs is shown in Fig. 2. As our filtering
of interactions requested consistent results across 7 or more
algorithms, no interaction remained for 4 of the 16 miRNAs
(hsa-miR-17-5p, hsa-miR-491-5p, hsa-miR-664-3p, and
hsa-miR-1275). However, this does not mean that these four
miRNAs have no targets—it rather illustrates the trade-off
when analyzing predicted miRNA–mRNA interactions: a
more stringent filtering could result in the loss of useful
information, while a more tolerant filtering leads to in-
creased numbers of possibly false-positive predictions mak-
ing subsequent analyses more difficult. On the other hand,
limitations of the prediction programs might have lead to
inconsistent results for these four miRNAs. Many algorithms
miss organism-specific target sites when they demand se-
quence conservation [74], and it is usually neglected that
miRNA targeting requires structural accessibility [75],
involves also other molecules than RNAs, and is not always
restricted to 3′ UTR regions [44–46]. To otherwise increase
the accuracy of miRNA–mRNA interactions, one might favor
target genes having multiple predicted binding sites for the
same miRNA, and respective information is provided by, e.g.,
TargetScan, DIANA-microT, and miRDB. Besides, known
interactions from the literature and from curated databases of
experimentally verified targets should be integrated.
Using miRTarBase, we found several interactions for hsa-
miR-17-5p and hsa-miR-491-5p, for which there was no
predicted target gene in the filtered miRWalk result. In total,
miRTarBase contained 12 of the 16 MS-associated miRNAs
(all but hsa-miR-142-3p, hsa-miR-599, hsa-miR-664-3p,
and hsa-miR-1275), and we could retrieve 117 validated
miRNA–mRNA interactions for these miRNAs (Table 3).
Thirty of these interactions occurred also in the miRWalk-
derived interaction list. We finally ended up with 1,498
target genes that were connected to 14 different miRNAs
(hsa-miR-664-3p and hsa-miR-1275 were not existent in
miRTarBase and did not show relevant results in miRWalk)
by 2,239 predicted or validated interactions (Fig. 3, Online
Resource 1). The two most connected miRNAs in the net-
work are hsa-miR-20a-5p (525 interactions) and hsa-miR-
20b-5p (513 interactions). Both miRNAs share many
mRNA targets (n0434), hinting to similar functions.
In addition to the investigation of putative target genes,
we analyzed for the 16 miRNAs, which TF potentially bind
to the promoter regions of their corresponding pri-miRNA
transcripts, thus regulating their expression. Predicted TFBS
were derived from miRGen 2.0 [23]. This database com-
prises 9,322 TFBS predictions for the whole human ge-
nome. miRGen 2.0 contained 12 of the 16 miRNAs (all
but hsa-miR-18b-5p, hsa-miR-223-3p, hsa-miR-664-3p,
and hsa-miR-1275), and 221 TFBS predictions associated
with 74 Transfac PWMs were obtained for these 12 miRNAs.
To take into account the inherent redundancy of Transfac
entries, we consolidated very similar or identical sequence
motifs by using the web tool STAMP [76]. STAMP
Fig. 1 Number of miRNA–mRNA interactions consistently predicted
by multiple algorithms integrated within miRWalk. A total of 121,108
interactions determined by any of ten different algorithms could be
found in the miRWalk database for the 16 MS-associated miRNAs.
This number strongly decreases if we filter for interactions that are
consistently predicted by several programs. Only 8,209 interactions
were predicted by more than five different algorithms, and the inter-
section of all ten offered algorithms resulted in 19 miRNA–mRNA
interactions. This rather small overlap indicates the diversity of strat-
egies used by these prediction programs and the disparity of their
results
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computes a motif tree, which allows to group related
motifs. Nine of the 74 Transfac PWMs were removed a
priori since they do not belong to TFs in human, mouse,
or rat. The remaining 65 PWMs were reduced to 39 distinct
DNA-binding patterns (Online Resource 2). For instance,
TFBS predictions for OCT1 (POU2F1) exist for three differ-
ent PWMs (Transfac identifiers V$OCT1_02, V$OCT1_06,
and V$OCT1_Q6), and, therefore, they were pooled. We
integrated the condensed TFBS information into the Cyto-
scape network by adding 39 TF nodes that are connected to 12
miRNAs by 163 edges (Fig. 3, Online Resource 1). Interest-
ingly, 11 genes of these 39 TF nodes have been specified as
target genes by miRWalk or miRTarbase (e.g., FOXJ2 and
MYC), demonstrating the presence of regulatory feedback
loops.
Next, we took a closer look at the genes that are highly
connected in the network, since they may play crucial roles
in MS or related immune disorders. MS is characterized by
the involvement of a variety of immune cells like T helper 1
(Th1) cells, T helper 17 (Th17) cells, T regulatory (Treg)
cells and B cells [77]. We found that genes being targeted by
several MS-associated miRNAs are in many cases TFs or
key players involved in the regulation of these cells.
CDKN1A (p21) is the gene with the most interactions in
Fig. 2 Number and pairwise overlap of target genes of MS-associated
miRNAs predicted using miRWalk. Only 12 of the 16 MS-associated
miRNAs are listed, since four miRNAs (hsa-miR-17-5p, hsa-miR-491-
5p, hsa-miR-664-3p, and hsa-miR-1275) had no interactions that were
predicted by at least seven out of ten algorithms in miRWalk. The most
target genes were retrieved for hsa-miR-20a-5p and hsa-miR-20b-5p.
Since their mature sequences differ only in two bases, they have many
common mRNA targets (n0431). Therefore, they may play crucial and
similar roles as post-transcriptional regulators in MS
Table 3 Validated target genes of the 16 MS-associated miRNAs provided by miRTarBase
MicroRNA #Targets Target gene symbols
hsa-miR-17-5p 31 APP, BCL2, BCL2L11, BMPR2, CCL1, CCND1, CDKN1A, DNAJC27, E2F1, FBXO31,
GPR137B, JAK1, MAP3K12, MAPK9, MEF2D, MUC17, MYC, NCOA3, NPAT, OBFC2A,
PKD2, PTEN, PTPRO, RUNX1, SMAD4, TGFBR2, THBS1, TNFSF12, VEGFA, YES1, ZNFX1
hsa-miR-18b-5p 1 ESR1
hsa-miR-20a-5p 19 APP, BCL2, BMPR2, BNIP2, CCND1, CDKN1A, E2F1, HIF1A, MAP3K12, MEF2D, MUC17,
MYC, NRAS, PTEN, RUNX1, SMAD4, TGFBR2, THBS1, VEGFA
hsa-miR-20b-5p 12 ARID4B, BAMBI, CDKN1A, CRIM1, ESR1, HIF1A, HIPK3, MUC17, MYLIP, PPARG, STAT3, VEGFA
hsa-miR-96-5p 8 ADCY6, CDKN1A, FOXO1, FOXO3, HTR1B, KRAS, MITF, PRMT5
hsa-miR-145-5p 24 BNIP3, CBFB, CDKN1A, CLINT1, DFFA, FLI1, FSCN1, HOXA9, IFNB1, IGF1R, IRS1, KLF4,
KRT7, MUC1, MYC, MYO6, PARP8, POU5F1, PPP3CA, SOX2, STAT1, TIRAP, TMOD3, YES1
hsa-miR-186-5p 2 FOXO1, P2RX7
hsa-miR-223-3p 8 CHUK, E2F1, LMO2, MEF2C, NFIA, NFIX, RHOB, STMN1
hsa-miR-326 6 GLI1, MSH3, NOTCH1, NOTCH2, PKM2, SMO
hsa-miR-422a 2 CYP7A1, CYP8B1
hsa-miR-491-5p 3 BCL2L1, CHD4, TAF10
hsa-miR-584-5p 1 ROCK1
Twelve of the 16 MS-associated miRNAs were contained in miRTarBase version 2.4. Overall, 117 interactions have been extracted. Repeatedly
appearing genes are underlined, e.g., CDKN1A, which is targeted by five of these miRNAs. For 31 genes, there is experimental evidence in the
literature that they are regulated by hsa-miR-17-5p. Sixteen of these genes are also a target of hsa-miR-20a-5p
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our network. Five of the MS-associated miRNAs are pre-
dicted to regulate the expression of this gene, e.g., hsa-miR-
20a-5p and hsa-miR-20b-5p are linked to CDKN1A accord-
ing to both miRTarBase and miRWalk. CDKN1A is known
to block the S-phase induction of T cells, and dysregulation
of this gene can contribute to autoimmune processes [78].
Interestingly, de Santis et al. [64] showed that also hsa-miR-
25-3p and hsa-miR-106b-5p act on CDKN1A expression,
thereby modulating the TGFbeta pathway and influencing
maturation and differentiation of Treg cells in MS patients.
RUNX1, associated with four miRNAs in the network,
regulates the development and function of T cells. It is a
central factor in the differentiation of Th17 cells with a dual
effect on IL17 transcription. Inducing and building com-
plexes with RORgammaT, RUNX1 enhances IL17 tran-
scription. However, in the presence of FOXP3 in Th17
cells, it has a negative effect on RORgammaT-mediated
transcription, building complexes with FOXP3 [79, 80].
FOXO1 and FOXO3 (with five and three edges in the
network, respectively) belong to the forkhead family of
TFs. FOXO1 is a suppressor of T cell proliferation, activa-
tion, and differentiation. It was shown that the down-
regulation of FOXO1, for instance by hsa-miR-182-5p, is
necessary for the clonal expansion of T cells [81]. The
deletion of FOXO1 in mice results in inflammatory diseases
and reduced Treg cell differentiation and additional deletion
of FOXO3 exacerbates these effects [82]. The TF E2F1 is
targeted by four miRNAs in the network. It was reported
that E2F1 helps to regulate the threshold for antigen-
stimulated activation of T cells as well as their negative
selection in the thymus [83]. Iglesias et al. [84] observed
up-regulated E2F1-dependent genes in PBMC of RRMS
patients and showed that E2F1-deficient mice develop a less
disabling form of EAE. Another interesting target gene is
STAT3, which is regulated by two miRNAs in our network.
STAT3 influences the balance of Th17 and Treg cells. In
Th17 cells, it works downstream of pathways activated by
IL6, IL21, or IL23, thus mediating inflammatory responses.
On the other hand, STAT3 can bind to regulatory elements
of IL10 in Treg cells and enhance the expression of this anti-
inflammatory cytokine [85, 86]. Liu et al. [87] observed
resistance to EAE development in STAT3 knock-out mice.
A study by Frisullo et al. [88] showed evidence that in
patients with clinically isolated syndrome (CIS), higher
levels of phosphorylated STAT3 in CD4+ T cells favor an
early conversion to clinical definite MS.
We observed that some of the TFs, which are predicted to
regulate the transcription of the MS-associated miRNAs by
miRGen 2.0, play important roles in the immune system as
well. For instance, the TFs AP1 and NFkappaB are linked
to 4 and 6 of the 14 miRNAs in the network, respectively.
AP1, together with NFAT, NFkappaB, and OCT1, is in-
volved in T cell activation, particularly through enhancing
the expression of IL2, whose dysregulation may promote
autoimmunity [89–91]. NFkappaB and AP1 have overlap-
ping functions in the regulation of pro-inflammatory genes,
of which some, e.g., TNFalpha and MMP9, have been
previously associated with MS or EAE [92, 93]. Hilliard et
al. [94] reported that NFkappaB1-deficient mice show de-
creased T cell proliferation, reduced incidence, and a less
severe course of EAE. The importance of NFkappaB in the
differentiation of autoimmune T cells was confirmed by
various other groups [95–97]. Bonetti et al. [98] found
higher levels of AP1 and NFkappaB in oligodendrocytes
Fig. 3 Cytoscape network visualization of interactions between MS-
associated miRNAs, target genes and TFs. TF-miRNA interactions
were derived from the miRGen 2.0 database. Validated and predicted
miRNA–mRNA interactions were derived from miRTarBase and miR-
Walk, respectively. hsa-miR-20a-5p and hsa-miR-20b-5p are closely
related to each other and are predicted to regulate many target genes in
common. They are also in close vicinity to hsa-miR-17-5p, whose
targets were obtained from miRTarBase only and which belongs to
the same miRNA cluster as hsa-miR-20a-5p. There are several feed-
back loops in the network, e.g., SOX9 is both a transcriptional regu-
lator and a target of hsa-miR-145-5p. The network visualization is
available as a Cytoscape session file as Online Resource 1. TF0
transcription factor
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of MS lesions in the CNS, further emphasizing the roles of
both TFs in the pathology of MS. OCT1, another highly
connected TF in the network, belongs to the octamer TF
proteins and is linked to 12 miRNAs. OCT1 stimulates the
expression of IL2 in tight association with AP1 [91, 99].
Additionally, OCT1 can enhance IL3 transcription [100]
and is suggested to be involved in the inhibition of IL4, IL5,
and IL8 transcription [101, 102]. In a recent work by Riveros
et al. [103], OCT1 was counted to the 25 most important
MS-associated TFs, regulating genes involved in T cell
specification.
Expression and Function of the MicroRNAs
MS is driven by different immune cells (Th1, Th17, Treg,
and B cells) [77], which circulate in the peripheral blood and
enter the brain when the blood–brain barrier is damaged. To
investigate the expression of the MS-associated miRNAs in
different peripheral blood cell types and brain regions, we
used the smirnaDB database, which provides expression
levels of 692 human miRNAs for 170 different cell types
and tissues [30]. For the 16miRNAs that have been identified
as potentially MS-specific markers in the blood (Table 2),
there was data for 19 blood cell populations and 4 brain
regions (Fig. 4). hsa-miR-142-3p was the highest expressed
miRNA in all cell populations of the peripheral blood. An-
other miRNA, hsa-miR-223-3p, was highly expressed in
dendritic cells, monocytes, and granulocytes but was
expressed at relatively low levels in other cell types of the
blood and brain. In brain tissues, the expression of all 16 MS-
associated miRNAs seemed to be very low, although hsa-
miR-186-5p was somewhat higher expressed than the others.
Some miRNAs like hsa-miR-599 were not detected at all,
likely because of the limited sensitivity of the measurement
technique that was used to generate these data (cloning and
sequencing of small RNA libraries) [50]. Still, this analysis
demonstrates how the smirnaDB database can be applied to
link certain miRNAs to specific cell types. In release 18 of
miRBase, also useful links to miRNA expression data (deep
sequencing reads) are provided [33]. Another source of data
is, of course, the GEO database [104]. Here, e.g., the micro-
array data set of Cox et al. [53] on 733 microRNAs measured
in 96 samples including 59 whole blood samples of MS
patients (accession GSE21079) and the data set of Keller et
al. [56] on 863 microRNAs measured in 454 samples includ-
ing 23 whole blood samples of MS patients (accession
GSE31568) can be found. However, we did not use these
data for further analyses.
To investigate potential functions of miRNAs, one can
simply examine the functions of their target genes. Different
databases exist that define functional groups of genes. For
instance, KEGG [105] and Gene Ontology (GO) [106]
provide an assignment of genes to certain pathways and
biological processes. The idea to deduce the functions of
miRNAs from their targets has been implemented in the web
servers DIANA-miRPath [107] and MMIA [108]. These
tools facilitate, e.g., to identify the molecular pathways
being affected by miRNAs based on a KEGG enrichment
analysis, where it is tested whether genes of a particular
pathway are overrepresented (“enriched”) in the list of target
genes. To gain insights into the main functions of the 1,498
predicted and validated target genes and thus to reveal the
potential cellular roles of the MS-associated miRNAs, we
Fig. 4 Expression levels of 16
MS-associated miRNAs in
19 blood cell populations and 4
brain tissues. Cell type-specific
expression data were down-
loaded from smirnaDB and
visualized as a heatmap in
the R software environment.
hsa-miR-142-3p was highly
expressed in all cell populations
of the peripheral blood, but not
in brain sections. hsa-miR-223-
3p was expressed at high levels
primarily in dendritic cells,
monocytes, and granulocytes.
In brain sections, several
MS-associated miRNAs
were not detected with the
experimental methods that
were used to obtain these data
(clone count00) [50]
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performed a gene enrichment analysis with the KEGG path-
ways and the GO terms of the molecular function category.
We compared the functions of the target genes to the functions
of a reference gene list (all genes listed in the GeneCards
database version 3.04) using the R package GOstats [109].
The top 15 functional terms and pathways of this enrichment
analysis are shown in Table 4.
It was striking that many target genes seem to participate
in different T cell pathways, e.g., the MAPK signaling
pathway. In total, 54 of the miRNA targets belong to this
pathway, which is significantly more than was expected
from the reference gene list (p value01.5×10−10). The
MAPK pathway, mediated by the three different protein
kinases p38, ERK, and JNK [110], is involved in different
regulation processes of T cells and supports the production
of cytokines such as IFNgamma, IL10, IL17, and IL23. Due
to the regulation of specific genes in T cells, the MAPK
pathway may have also an influence on the pathogenesis of
MS and EAE, which was examined in different studies
[111–113]. Another central pathway in T cell differentiation
is the TGFbeta signaling pathway. Genes of this pathway
were significantly overrepresented in the target gene list as
well (p value02.5×10−8). TGFbeta has a dual effect on
naïve T cells, depending on the presence of different cyto-
kines. In the absence of IL6, TGFbeta promotes Treg cell
development and inhibits Th1/Th2 responses, supporting
anti-inflammatory processes. On the other hand, in the pres-
ence of IL6, it favors the differentiation of Th17 cells,
leading to increased inflammatory responses [114, 115].
Consequently, evidence is accumulating that TGFbeta is a
crucial factor in the pathophysiology of MS [116, 117].
Besides, it was remarkable that the enrichment analysis
revealed that many mRNA targets code for proteins with
TF activity. Therefore, the MS-associated miRNAs can be
regarded as the regulators of the regulators. This means,
they post-transcriptionally regulate the expression of TFs,
which themselves enhance or inhibit gene expression, leading
to an additional and indirect effect of miRNAs on transcript
levels in cells. Zinc finger proteins, a major family of human
TFs, were also significantly enriched in the list of predicted
and validated target genes (GO:0008270, p value00.0003, not
shown in Table 4). Zinc finger genes typically contain se-
quence repeats in their coding regions, and it was recently
shown that some miRNAs bind to target sites in these regions
outside the 3′ UTR, effectively regulating the expression of
these TFs [46].
While the presented way of analyzing the functions and
pathways affected by miRNAs is quiet simple, several open
issues should be realized. Firstly, the accuracy of the gene
enrichment analysis depends on the accuracy of miRNA–
mRNA interactions. Results will be distorted if the predic-
tions of interactions contain many false-positives. Secondly,
the effect of miRNAs on the expression of a particular gene
is sometimes difficult to estimate. If a miRNA regulates a
gene's expression through degradation, increased levels of
the miRNA can lead to decreased levels of the target
mRNA. However, in our example, some miRNAs were
described as higher and some as lower expressed in MS
Table 4 Enrichment analysis of target gene functions using KEGG pathways and the GO molecular function ontology
GO term/KEGG pathway Accession Expected count Count Odds ratio P value
Protein binding GO:0005515 598 821 2.16 6.4×10−39
Binding GO:0005488 1,011 1,149 2.36 1.5×10−25
Nucleic acid binding TF activity GO:0001071 82 160 2.31 2.3×10−17
Sequence-specific DNA binding TF activity GO:0003700 82 159 2.29 4.9×10−17
Enzyme binding GO:0019899 61 128 2.48 2.2×10−16
TF binding GO:0008134 25 63 2.98 8.0×10−12
MAPK signaling pathway KEGG:04010 21 54 3.00 1.5×10−10
Protein kinase activity GO:0004672 50 97 2.20 1.6×10−10
Protein serine/threonine kinase activity GO:0004674 36 76 2.42 3.5×10−10
Sequence-specific DNA binding GO:0043565 57 104 2.08 5.6×10−10
Pathways in cancer KEGG:05200 26 60 2.65 1.0×10−9
Transcription activator activity GO:0016563 27 60 2.58 2.8×10−9
Axon guidance KEGG:04360 10 31 3.71 1.9×10−8
TGF-beta signaling pathway KEGG:04350 7 24 4.64 2.5×10−8
Protein domain specific binding GO:0019904 37 71 2.18 4.6×10−8
Shown are the top 15 overrepresented terms of the GO molecular function ontology and KEGG pathways with odds ratio>2. The functional terms
and pathways are sorted according to the p values of the hypergeometric test calculated by GOstats [109]. As an example, 160 of the 1,498 target
genes belong to the category “nucleic acid binding TF activity”, which is significantly more than expected by chance (expected count082). GO0
Gene Ontology, TF0 transcription factor
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(Table 2). In that case, opposing effects exist if a mRNA is
simultaneously targeted by down- and up-regulated miRNAs.
Thirdly, the net effect of dysregulated miRNAs on a particu-
lar pathway is hard to quantify for the same reason. Note that
the function of a gene within a pathway is critical as well,
since it might be an activator or inhibitor. Finally, the mutual
regulatory interactions (including feedback loops) over time
lead to diverse secondary effects, which makes it difficult to
unravel causes and effects. All this hampers the study of
miRNAs. A separate functional analysis of up- and down-
regulated miRNAs might be helpful but should be interpreted
with caution. The association of the levels of miRNAs and
mRNAs to the functions of cells remains largely a challenge
for the future.
Concluding Remarks
A major topic in miRNA studies is the investigation of
miRNA gene targets. Several different computational algo-
rithms have been developed and implemented in public
databases to predict interactions between miRNAs and tar-
get mRNAs with perfect or imperfect sequence complemen-
tarity (Table 1). The databases differ in their information
content and up-to-dateness. The huge amount of potential
target genes is associated with a considerable number of
possibly false positive predictions, making it difficult to
interpret the results. Therefore, it is reasonable to utilize
target genes that have been described in experimental studies
and that are listed in databases like miRTarBase [31]. How-
ever, validated interactions are usually integrated in such data-
bases with some delay, and their quantity is still relatively low,
even though high-throughput techniques such as CLIP-Seq
and Degradome-Seq promise to fill this gap in the future
[118]. Another way to reduce the enormous number of pre-
dicted target genes to ease further analysis and interpretation is
to use multiple algorithms of different databases and to focus
on miRNA–mRNA interactions being consistently predicted
by several algorithms (ensemble strategy). We showed in this
review how this can be done using meta-resources like miR-
Walk [25]. Further interaction information can be obtained by
a non-curated literature search with text mining tools. Such
information is delivered by, e.g., the “validated targets mod-
ule” of the miRWalk database and more elaborated commer-
cial software products like Pathway Studio [119]. Finally, the
mutual interactions between miRNAs and genes can be visu-
alized in networks using software platforms like Cytoscape
[73]. The architecture of such networks can then be further
analyzed, e.g., to identify network modules or regulatory
feedback loops.
Some databases like miR2Disease provide insights into
studies of miRNAs associated with human disorders. This
can be very useful, but it has to be considered that the
information in such databases is not complete, and the latest
studies can be missing. So far, 13 different studies have
associated miRNA expression patterns in blood with MS
[53–57, 64–72]. hsa-miR-142-3p, hsa-miR-146a-5p,
hsa-miR-155-5p, and hsa-miR-326 have been repeatedly
described as higher expressed in the blood, while two inde-
pendent studies found elevated levels of hsa-miR-155-5p
also in brain tissues of MS patients [62, 63, 120]. Several
other miRNAs have been proposed as further potential
disease biomarkers. Differences in the results can be as-
cribed to differences of the studies in the analyzed cell
populations, measurement technology [10], and data analy-
sis as well as in the clinical and demographic characteristics
of the patients and their treatment status. Additional confir-
mation is needed to assess the specificity and clinical value
of these so far nominated miRNAs. Certainly, future studies
will examine specific issues in more detail, e.g., compare
miRNA expression profiles in blood or brain cells between
different subtypes of MS (CIS, RRMS, secondary progres-
sive MS) or between different phases of disease activity
(remission vs. relapse). To date, only few groups like
Waschbisch et al. [72] have investigated the effects of
immune-modulating MS therapies on miRNAs. Such studies
are needed to analyze whether a therapy can influence the
dysregulation of miRNAs and to better understand the thera-
peutic mechanisms of action in a miRNA-gene network con-
text. miRNAs may improve the diagnosis, monitoring, and
management of MS and could lead to new therapies which
specifically target miRNAs and the biological processes they
control. They may even serve as prognostic biomarkers for
MS, helping to predict individual courses of the disease and to
distinguish between therapy responders and non-responders.
Although this is a very active field of research, we still just
begin to anticipate the biological significance and therapeutic
potential of miRNAs.
Enrichment analyses with KEGG pathways and GO
functional terms allow to reveal the different molecular
processes affected by miRNAs. In our study, we found that
many target genes of the MS-associated miRNAs participate
in T cell activation and differentiation, which has also been
described by Junker [11]. Our results support the hypothesis
that miRNAs dysregulated in MS favor the development of
pro-inflammatory T cell phenotypes and potentially regulate
Treg functions. Due to their modulating role in both neuro-
nal and immune system processes, miRNAs are likely im-
portant players in the pathogenesis of neurological,
immune-mediated disorders [121]. Moreover, it was striking
that the miRNAs seem to play a crucial role in regulating
TFs, hence having an additional indirect influence on gene
regulation. This may be a general phenomenon since previ-
ous studies have also found that TFs prevail among miRNA
targets [122]. A work flow how to analyze the primary and
secondary targets of microRNAs (with secondary targets
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being target genes of miRNA-regulated TFs) was presented
in the study by Tu et al. [122]. They obtained the secondary
targets using TFBS predictions provided by the tfbsCons-
Sites track of the UCSC genome browser. This track is
based on PWMs from the public version of the Transfac
database. A drawback of this approach is that for many TFs
no well-defined PWMs exists. Nevertheless, an analysis of
the secondary targets can be very meaningful, because while
miRNAs often act by reducing the mRNA level of its targets
through destabilization [123], they can also act through
translational repression [14]. Therefore, even if the target
gene expression is not necessarily affected, a miRNA might
still have significant influences on the expression of genes
downstream of a TF or pathway it is targeting.
The more researchers are sharing their miRNA data in
public databases like GEO and ArrayExpress, the more
important it is to make use of this rich source of information.
For instance, one can compare the expression levels of
specific miRNAs between different cell types, tissues, and
disease conditions. In the last few years, many different
experimental platforms have been developed to generate
miRNA data sets [10]. New techniques allow the measure-
ment of a greater variety of miRNAs with higher sensitivity.
This enables researchers to investigate specific cell types
and specimens where miRNAs are present at very low
amounts, e.g., microparticles in plasma [124–127]. The era
of next generation sequencing (NGS) will deliver new
results regarding the expression of miRNAs and their target
genes. An RNA-seq analysis with NGS provides the oppor-
tunity to sequence all RNA transcripts in a sample simulta-
neously without specific assays and prior knowledge, and
may help, e.g., to find new transcript variants, detect miRNA
modifications [127], and investigate SNPs in miRNAs. Despite
difficulties in handling the generated data, such technologies
bear the potential to better elucidate the complex processes of
cellular gene regulation and with that the pathomechanisms of
diseases such as MS.
In this review, we presented different kinds of databases
in the context of miRNAs, their contents, and utility. We
showed how to use various miRNA databases and how to
integrate the heterogeneous information to investigate
functions and interactions of miRNAs. This may serve
as a guideline for similar studies on different issues or
diseases.
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MicroRNA (miRNA) are small non-coding RNA molecules about 21–25 nucleotides long. They control gene
regulation by translational repression and cleavage. Several studies have shown that many miRNA are
associated with the etiology of different diseases. Recent developments in diverse miRNA profiling platforms
like microarray and quantitative real-time PCR may enable the identification of specific miRNA as novel
diagnostic and predictive markers for various diseases. MiRNAs could even be used as therapeutic drug
targets. Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
Dysregulated immune system processes result in demyelination of neurons and consequently, electrical
impulses that travel along the nerves are disrupted resulting in the impairment of organs. In the past three
years, there has been an increased interest in establishing miRNA-based biomarkers for MS. So far, there are
six studies on miRNA expression in MS patients in which first miRNAs were discovered as potential disease
markers. For instance, one study showed that blood levels of miR-145 can discriminate MS patients from
healthy controls, and another showed that active lesions in the brain are characterized by a strong up-
regulation of miR-155. Studies on experimental autoimmune encephalomyelitis (EAE), the animal model of
MS, further support the significance of miRNA as e.g. mice with miR-155 deletion are highly resistant to EAE.
Such investigations help to understand the molecular processes involved in the disease. The identification of
miRNA markers that are associated with type of MS, individual disease activity or clinical progression under
treatment may open new avenues for early diagnosis and optimized therapy of MS.
© 2011 Elsevier B.V. All rights reserved.
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1. Introduction
MicroRNAs (miRNA) are small endogenous non-coding RNA
molecules ~21–25 nucleotides in length. They regulate gene expres-
sion of target genes in a sequence-specific manner [1]. Down-
regulation of RNA transcript targets is facilitated either by transla-
tional repression (imperfect sequence match) or by mRNA cleavage
(perfect match). MiRNAs have emerged as one of the key players in
regulation of gene expression in various cell types.
Although the first miRNA was identified over fifteen years ago, we
just started to appreciate their involvement in various disease
pathogenesis. Recently numerous, expression profiling studies have
detected specific miRNA ‘signatures’ for a variety of diseases,
including multiple sclerosis (MS) (see Section 6). MiRNA genes are
often located at genomic regions associated with pathogenesis, which
suggests that miRNA molecules may be involved in crucial cellular
changes [2]. There are about 1100 miRNAs reported in humans and
most of them have predicted targets from various databases (Table 1).
lin-4 in C. elegans was the first miRNA to be discovered by Lee,
Feinbaum and Ambros in the year 1993 [3]. The lin-4 gene did not
code for a protein but instead for a short RNA transcript which
regulates the timing of the larvae development. The mechanism
involved was that lin-4 miRNAs translationally represses lin-14
mRNAs, which codes for a nuclear protein [3].
MS is primarily an inflammatory disorder of the central nervous
system (CNS). It is characterized by the infiltration of lymphocytes
into the CNS leading to axonal demyelination of neurons [4]. MS
is heterogeneous with respect to clinical manifestations and res-
ponses to therapy. It is widely considered that MS is related to
environmental factors in individuals with complex genetic-risk
profiles [4,5]. MS leads to chronic disability through deficits of sen-
sation and of motor, autonomic and neurocognitive function. There
are several studies conforming the presence of inflammatory cells
and their products in the brain lesions of MS patients, in addition
to reports from animal models experiments. These studies led to
the generally accepted hypothesis that MS is mediated by pathogenic
T-cell responses against myelin antigens, followed by a more complex
neurodegenerative process [4]. The auto-reactive T-cells migrate
across the blood-brain barrier (BBB) and mediate damage against
the neurons and their protective myelin sheaths and axons. This
leads to a signal conduction block or decrease at the site of demyeli-
nation [6]. The development of high-throughput functional geno-
mics platforms has made it possible to identify novel relationships
between various molecular mechanisms and the pathogenesis of MS
[7]. There is growing evidence that the differential down-regulation
and up-regulation of selective miRNAs may be an important me-
chanism for maintaining disease progression (Table 2). Identification
of biomarkers appears desirable for an improved diagnosis of MS
as well as for monitoring disease activity and individual treatment
responses.
2. Biogenesis of miRNAs
First, RNA polymerase II transcribes the primary miRNA (pri-
miRNA) transcripts in human and animals [8]. The following miRNA
maturation is a two-step process involving two enzymes with
ribonuclease III (RNase III) activity, Drosha and Dicer. Drosha and its
partner protein DGCR8 (DiGeorge syndrome critical region 8) process
the nuclear pri-miRNA into a ~70 nucleotide precursor miRNA (pre-
miRNA) [9]. The pre-miRNA is then exported from the nucleus to the
cytoplasm by Exportin-5/RanGTP which specifically recognizes the
structure of pre-miRNA molecules [10]. In the cytoplasm, Dicer
together with its partner protein TRBP (trans-activator RNA binding
protein) digests the pre-miRNA into a 21–25 nucleotide miRNA
duplex. In a complex process that is not yet clearly understood one
strand of this duplex is recruited to be loaded into the RNA-induced
silencing complex (RISC) [11]. RISC will bind to its target mRNA in the
3′ UTR resulting in degradation or translational repression. The
translational repression process may adapt several mechanisms
including co-translational protein degradation, inhibition of transla-
tional elongation, premature termination of translation, and inhibi-
tion of translation initiation [12] (Fig. 1).
Table 1
MiRNA target prediction databases.
MicroRNA target
prediction database
Uniform resource locator
MicroCosm http://www.ebi.ac.uk/enright-srv/microcosm/
htdocs/targets/v5/
miR2Disease Base http://www.mir2disease.org/
miRBase http://mirbase.org/
miRecords http://mirecords.biolead.org/
PMRD: plant
microRNA database
http://bioinformatics.cau.edu.cn/PMRD/
TargetScan http://www.targetscan.org/
microRNA http://www.microrna.org/microrna/home.do
TarBase http://diana.cslab.ece.ntua.gr/tarbase/
miRBD http://mirdb.org/miRDB/
miRGator http://genome.ewha.ac.kr/miRGator/miRGator.html
miRGen http://www.diana.pcbi.upenn.edu/miRGen.html
miRNAMap http://mirnamap.mbc.nctu.edu.tw/
Vir-Mir http://alk.ibms.sinica.edu.tw/
cgi-bin/miRNA/miRNA.cgi
ViTa http://vita.mbc.nctu.edu.tw/
DIANA MicroTest http://www.diana.pcbi.upenn.edu/
cgi-bin/micro_t.cgi
microInspector http://bioinfo.uni-plovdiv.bg/microinspector/
NBmiRTar http://wotan.wistar.upenn.edu/NBmiRTar/login.php
PicTar http://pictar.mdc-berlin.de/
PITA http://genie.weizmann.ac.il/
RNA22 http://cbcsrv.watson.ibm.com/rna22.html
RNAhybrid http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/
miRWalk http://www.umm.uni-heidelberg.de/
apps/zmf/mirwalk/
Table 2
MiRNA involved in multiple sclerosis. Gene loci refer to chromosome position.
MiRNA Gene loci Cell type Statement Reference
miR-106b 7q22.1 CD4+CD25+ modulates the TGF-β signaling pathway De Santis et al. [38]
miR-17 13q31.3 CD4+, CD8+, B upregulated in CD4+ cells from MS patients Lindberg et al. [7]
miR-18b Xq26.2 PBMC maybe involved in remission in MS patients Otaegui et al. [32]
miR-20a 13q31.4 CD4+ significantly under-expressed in MS compared to controls Cox et al. [33]
miR-25 7q22.2 CD4+CD25+ modulates the TGF-β signaling pathway De Santis et al. [38]
miR-326 11q13.4 PBMC regulates Th-17 differentiation and is associated with the pathogenesis of MS Du et al. [40]
miR-34a 1p36.22 Brain tissue significantly expressed in lesions of MS patients and astrocytes of EAE mice Junker et al. [37]
miR-497 17p13.1 CD4+, CD8+, B down-regulated in CD4+ cells of patients with MS Lindberg et al. [7]
miR-599 8q22.2 PBMC higher expressed in patients experiencing a relapse versus controls Otaegui et al. [30]
miR-96 7q32.2 PBMC highly expressed in remitting and less in relapse status Otaegui et al. [30]
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3. MiRNA profiling platforms
Patterns of differentially expressed genes detected by high-
throughput platforms provide insights into a disease's physiology
and can also be used as biomarkers [13,14]. MiRNA microarrays
enable the study of miRNA expression dynamics in various biological
samples. RNA samples used for miRNA microarray hybridization need
to be enriched for small RNAs. The first step of a miRNA microarray
experiment is therefore the isolation of total RNA and the enrichment
or direct isolation of small RNAs. In the next step, miRNAs are labelled
and cleaned-up, followed by miRNA hybridization to arrays spotted
with miRNA probes. Then the matrix is washed and scanned.
Subsequent bioinformatic analysis may identify miRNAs differentially
expressed between the samples (e.g. disease versus healthy). miRNA
microarray results can be validated by, northern blot, quantitative
reverse transcription-polymerase chain reaction (RT-PCR), or other
analytical methods. Recent advancements of highly efficient labelling
and novel microarray probe design enable direct labelling as low as
120 ng of total RNA using Cy3 or Cy5, without fractionation or
amplification, to produce accurate measurements that span a linear
dynamic range from 0.2 amol to 2 fmol of input miRNA [15].
4. MiRNAs and the immune system
It is widely accepted that miRNAs are involved in immune system
development and regulation (Table 3). T-cell specific deletion of Dicer
results in a reduced number of T-cells in the thymus and periphery
[16,17]. Dicer deficiency in B-lymphocytes diminishes B-cell survival and
as consequence of that reduces antibodyproduction [18].MiR-155 plays a
role in immune system responses to infections. The importance of a
proper regulation of miR-155 expression is also apparent by its much
higher expression in several types of hematopoietic malignancies [19].
Microarray analysis of miR-146a targets after miR-146a over-expression
in Akata B-cell line has demonstrated miR-146a-mediated inhibition of a
group of interferon-responsive genes [20]. MiR-150 has a dynamic
Fig. 1.MicroRNA biogenesis and mode of action. The microRNA pathway steps in mammalian cells are shown: A miRNA gene is transcribed into a primary miRNA transcript called
the pri-miRNA. Pri-miRNA is cleaved by drosha to a hairpin pre-miRNA. Pre-miRNA is transported out of the nucleus by Exportin-5. Pre-miRNA is cleaved by dicer to form a short
double-stranded mature miRNA duplex. MiRNA duplex separates into two single-stranded mature miRNAs and complexes with a RISC-like structure. The miRNA/RISC complex
binds to mRNA, which is translationally repressed and cleaved.
Table 3
MiRNA in the context of immunoregulation.
MicroRNA Cell type Statement Reference
miR-150 B cell Critical for B-cell differentiation Zhou et al. [50]
miR-181b B cell Involved in class switch
recombination in
activated B-cells
de Yébenes et al. [49]
miR-23a B cell miR-23a family members
can inhibit B-cell
development
Kong et al. [51]
miR-146a T cell Controls T-reg cell-mediated
regulation of Th1 responses
Lu et al. [47]
miR-146a T cell Expressed in interleukin-17
producing T-cells in rheumatoid
arthritis patients
Niimoto et al. [48]
miR-155 T cell Promotes autoimmune
inflammation by enhancing
inflammatory
T-cell development
O'Connell et al. [41]
miR-181a T cell Intrinsic modulator of T-cell
sensitivity and selection
Li et al. [45]
miR-182 T cell Induced by IL-2, promotes clonal
expansion of activated helper
T lymphocytes
Stittrich et al. [46]
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expression profile during lymphocyte development, it is highly expressed
in matured B-cells and T-cells but not in their progenitors [21]. The
proposed role of miR-150 in B-cell development involves the transcrip-
tional regulation of transcription factor c-Myb [21]. In vivo studies have
shown that decreased expression of c-Myb results in fewer matured
B-cells and can block the transition from pro-B-cell to pre-B-cell, which
can be observed in miR-150 transgenic mice as well [21].
MiR-181a is mostly expressed in bone marrow, spleen and
thymus. B-cells have the highest expression of miR-181a. When
miR-181a was over-expressed in vitro it induced a two to three fold
increase in CD19+ B-cell populations. Moreover, miR-181a is involved
in T-cell differentiation and function [22,23], and is assumed to
regulate T-cell receptor (TCR) signal strength by down-regulating
expression of several protein tyrosine phosphatases and by activation
of two TCR signalling molecules, lymphocyte-specific protein tyrosine
kinase (Lck) and extracellular signal-regulated kinase (Erk).
Mice with miR-17-92 cluster deletion die within minutes of birth,
most likely because of the underdevelopment of the heart and lungs
[24]. BCL-2-interacting mediator of cell death (Bim), a pro-apoptotic
member of the anti-apoptotic BCL-2 family, has been identified as a
target of miR-17–92 cluster members. MiR-17–92 mediates regula-
tion of the expression of tumour suppressor PTEN [25]. Another
miRNA, miR-223 is expressed specifically in cells of the granulocytic
lineage. Its expression changes during maturation, becoming incre-
mentally higher as granulocytes mature [26]. MiR-223 mutant mice
spontaneously develop inflammatory lung pathology and exhibit
exaggerated tissue destruction after endotoxin challenge [26].
5. MiRNA and the nervous system
MiRNAs are abundant in the brain and are essential for efficient
brain function. For instance, miR-134 has been shown to inhibit the
translation of an mRNA encoding a protein kinase, LIM domain kinase
1 (Limk1), which controls spine development. Exposure of neurons to
extracellular stimuli such as brain-derived neurotrophic factor re-
lieves miR-134 inhibition of Limk1 translation and in this way may
contribute to synaptic development, maturation and plasticity [27].
Expression of miRNA gene cluster miR379–410, which comprises
up to 50 microRNA genes, is induced by neuronal depolarization and
has an important function in dendritic development in cultured
neurons [28]. MiR-134, a member of this cluster, was earlier shown to
be localized to dendrites of cultured hippocampal neurons, where it
regulates dendritic spine morphology by its reversible inhibitory
effect on Limk1 mRNA in response to brain-derived neurotrophic
factor [28].
MiR-124a is a non-neuronal cell-specific miRNA, which decreases
the levels of hundreds of non-neuronal transcripts. The transcrip-
tional repressor RE1 silencing transcription factor (REST) has a
reciprocal activity, inhibiting the expression of neuronal genes in
non-neuronal cells [29]. REST regulates the expression of a family of
miRNAs, including brain-specific miR-124a. In non-neuronal cells and
neural progenitors, REST inhibits miR-124a expression, allowing the
persistence of non-neuronal transcripts. As progenitors differentiate
into mature neurons, REST leaves the miR-124a gene loci, and non-
neuronal transcripts are degraded selectively [29].
6. MiRNAs in multiple sclerosis
MS is a complex genetic disease associated with inflammation in
the CNS white matter mediated by auto-reactive T-cells. Many mRNA
expression profiling data sets have been generated to better
understand the disorder and the effects of particular treatments. For
instance, in peripheral blood mononuclear cells (PBMC) from MS
patients distinct expression patterns have been identified between
relapse and remission disease state [30,31]. As of November 2010, six
studies exist that investigated miRNAs in the context of MS. They are
summarized in the following.
In the first study [32], PBMC were obtained from MS patients in
relapse status (n=4) and in remission status (n=9) as well as from
healthy controls (n=8). RT-PCR with Taqman low-density array was
used to profile the expression levels of 364 different miRNAs. The
authors could show differential expression of three miRNA (hsa-mir-
18b, hsa-mir-493 and hsa-mir-599) between MS patients experienc-
ing a relapse and healthy controls.
In the second study [33], the miRNA transcriptome in whole blood
samples from 59 treatment-naïve MS patients were analyzed: 18
patients were diagnosed with primary progressive multiple sclerosis
(PPMS), 17 were diagnosed with secondary progressive multiple
sclerosis (SPMS) and 24 patients had relapsing–remitting multiple
sclerosis (RRMS). For comparison, expression levels were examined in
37 healthy controls. The platform used here was the Illumina Sentrix
array matrix. In this study miR-17 and miR-20a were significantly
down-regulated in all types of MS. miR-17 and miR-20a are known to
regulate various genes involved in T-cell activation.
In the third study [34], whole blood from 20 RRMS patients and 19
healthy controls was analyzed using the Geniom real-time analyzer
platform. This enabled the measurement of 866 miRNAs. The
best single disease-specific miRNA marker was miR-145. According
to this study, higher levels of miR-145 clearly discriminate MS pa-
tients from controls with a specificity of 89.5% and a sensitivity of
90.0%.
In the fourth study [7], 365 miRNAs were analyzed in lymphocytes
of RRMS patients. The study showed the first evidence for distinct
miRNA expression profiles in CD4, CD8 and B-cells of MS patients
(n=8) compared with those of healthy volunteers (n=10). MiR-17-
5p, which is involved in auto-immunity, was up-regulated in CD4 cells
of MS patients. This correlated with alterations in the expression of
potential target genes of miR-17-5p, phosphatase and tensin
homology and phosphatidyl-inositol-3-kinase regulatory subunit 1,
whichwere down-regulated upon stimulation of CD41 cells with anti-
CD3/CD28 in vitro.
Recently, the same group started two different studies. In one
study, they analyzed miRNA expression patterns in serum samples
from RRMS, SPMS and PPMS patients and healthy volunteers, five
from each group. They found 46, 26 and 48 differentially expressed
miRNAs in RRMS, SPMS and PPMS compared to the healthy
volunteers. Nine miRNAs were redundant in all the three compari-
sons. MiR-21 andmiR-106bwere up-regulated in all MS courses. MiR-
106b belongs to the miR-17–92 cluster [35]. In the other study,
B-lymphocytes were isolated from peripheral blood of 19 RRMS
patients in remission (11 untreated 8 treated with natalizumab) and
10 healthy volunteers. The miR-17–92 cluster members (miR-17-
5p, 19a/b, 20a, 92a) were found to be down-regulated in the
B-lymphocytes of the MS patients. Moreover, natalizumab seems to
have some unique effects on miRNA expression in B-lymphocytes of
RRMS patients [36].
In the fifth study [37], miRNAs in MS lesions were profiled. Three
microRNAs, miR-34a,miR-155 andmiR-326, were found up-regulated
in active compared to inactive MS lesions. These miRNAs target the 3′
UTR of CD47. The study therefore suggests that deregulated miRNAs
in MS lesions reduce CD47 in brain resident cells, this leads to the
release of macrophages from inhibitory controls. Ten microRNAs that
were most strongly up-regulated in active multiple sclerosis lesions,
were also found in astrocytes. One of those, miR-155, is known to
modulate immune responses in different ways but so far had not been
assigned to CNS resident cells.
In the sixth study [38], CD4+CD25high T-cells from12RRMSpatients
in stable condition and 14 healthy controls were analyzed. The platform
used here was the Agilent human miRNA microarray v.2 (#G4470B,
Agilent technologies). A total of 723 humanmiRNAswere detected and
23 of themwere identified as differentially expressed in CD4+ CD25high
177M. Thamilarasan et al. / Autoimmunity Reviews 11 (2012) 174–179
  Manuscript - 4 
 
104 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cells from MS samples compared to healthy controls. This was the first
study that investigated miRNA expression profiles in CD4+ CD25high
T-regulatory cells (T-regs) isolated from peripheral blood of MS
patients. In a preliminary sub-study, the authors compared
CD4+CD25highCD127low T-regs and CD4+ CD25highCD127+ T-effector
cells, and found a significantly highermiR-19b T-reg/T-effector cell ratio
in MS versus HV. The respective ratio of miR-106b and miR-25 at least
tended to be higher in MS. Over-expression of themiR-106b-25 cluster,
in particular miR-25 andmiR-106b, can silence two important effectors
of the TGF-β (transforming growth factor beta) signalling pathway:
CDKN1A/p21 (cyclin-dependent kinase inhibitor 1A) and BCL2L11/Bim.
TGF-β is involved in differentiation and maturation of T-reg cells.
Therefore, the dysregulation of this miRNA cluster may alter T-reg cell
activity in the course of MS, by altering TGF-β functions.
7. MiRNAs in experimental autoimmune encephalomyelitis (EAE)
Experimental autoimmune encephalomyelitis (EAE) is an animal
model of brain inflammation. EAE induced in rodents is widely used as
a model of MS. The disease appears in exacerbation and remission and
is characterized by loss of nerve conduction and chronic progression
of disability. The two main components involved are macrophages
and T-lymphocytes mediating the destruction of myelin sheaths
surrounding the nerves. Several studies have shown that actively
induced EAEmodels can reproduce the typical temporal maturation of
MS lesions from inflammation with or without deposition of
immunoglobulin through demyelination and axonal damage to gliosis
and partial remyelination [39].
There are growing evidences that interleukin 17 (IL-17) producing
T helper cells (Th-17 cells) are key players in various autoimmune
diseases, including MS. In a recent study, miR-326 expression was
shown to correlate with disease severity in patients withMS andmice
with EAE [40]. In vivo silencing of miR-326 resulted in fewer Th-17
cells and a milder EAE, while in contrast over-expression resulted in
more Th-17 cells and a severe EAE. Mice with miR-155 deletions
(Mir155−/−) where highly resistant to EAE.
The function of miR-155 is to promote inflammatory properties
of T-cells including Th-17 and Th-1 cell subsets [41]. MiR-155 is one
of the first miRNAs connected to inflammation just because of its
potent up-regulation in multiple immune cell lineages by toll-like
receptor (TLR) ligands, inflammatory cytokines, and specific antigens
[42–44].
8. Conclusion and perspectives
Since their discovery, the field of miRNA research has grown
tremendously, and we presently know that these molecules are
important regulators of gene expression and can influence immune
system development. The relatively small number of miRNAs as well
as the possibility of using standardized, fast, and inexpensive
detection methods suitable for high-throughput analysis, make
miRNAs promising candidates for ex vivo detection biomarkers for
MS. Recent studies have shown that microRNAsmay play a key role in
many aspects of MS pathogenesis and that alteration of their
expression can have profound effects on MS phenotypes. The
translation of these findings to in vivo models and clinical studies
will unquestionably lead to greater insights into their utility in clinical
settings. MiRNA expression profiles introduce a newly appreciated
layer of complexity to the diverse physiology and pathology of MS.
Regarding existence of several hundred mammalian miRNAs along
with many other putative noncoding RNAs, it is likely that the results
reviewed here are just the tip of the iceberg in terms of the
involvement of regulatory RNAs in orchestrating development and
function of the immune system regarding to MS.
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Take-home messages
• MiRNAs are one of the key regulators of the gene expression.
• MiRNAs can significantly alter the response of the immune system.
• MiRNAs play a critical role in the biogenesis of MS.
• MiRNAs can evolve as potential drug targets for the treatment of MS.
• Studies so far have proved the importance of miRNAs as a worthy
biomarker candidate.
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Recent clinical trials suggest that tacrolimus is safe and effective as an induction or maintenance therapy of lupus nephritis
Tacrolimus is a potent immunosuppressive and immunomodulatory agent used to prevent rejection in organ transplantation, which has
been recently proposed as effective for the treatment of nephritis in SLE patients. The article by Lee et al. (Lupus 2011;20:636-40) is a
systematic review of the literature reporting the results of clinical trials on the efficacy and safety of tacrolimus as an induction or
maintenance therapy for lupus nephritis (LN). Up to July 2010, seven clinical trials, which met the review inclusion criteria, were considered,
examining a total of 115 patients with biopsy-proven LN and 54 controls, during a follow-up period of 6-24 months. Both case-control and
open-label studies were evaluated. Unpublished reports or retrospective studies were not included. Tacrolimus was compared with placebo
or standard treatments, i.e. glucocorticoids and/or cyclophosphamide or azatioprine, in case-control studies, or evaluated as a single
therapeutic regimen in open-label prospective studies.
In general, tacrolimus therapy was well tolerated and did not produced serious adverse effects in all the studies.
Although the evaluated studies were few and clinically heterogeneous with respect to study design, LN class, tacrolimus dosage and follow-
up duration, they were almost concordant in assessing the efficacy and safety of tacrolimus for induction and maintenance therapy of LN,
thus suggesting tacrolimus as a promising alternative to conventional immunosuppressive agents.
Anna Ghirardello
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